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 Due to advances in screening and therapy design, cancer patients are living longer while on 
or following therapy. Therapy-related adverse events (AEs) are an unintended, but not 
infrequent, outcome of these treatments. AEs can impact quality of life, adherence to therapy, 
economic status, and treatment decision-making. This novel qualitative study is the first to 
undertake a multi-stakeholder evaluation of the impact of AE information on informing cancer 
patient care in the context of extended survival. The evaluation focuses on a growing subset of 
cancer patients – those receiving adjuvant therapy.  
Adjuvant therapies, used to manage many common cancers, lower the risk that the cancer 
will return. In this setting, mediating the impact of potential acute or delayed adjuvant treatment-
related AEs relative to an uncertain potential for tumor recurrence presents important challenges 
in balancing risks versus benefits.  
Stakeholder perspectives on generating, disseminating, and/or adjuvant treatment-related AE 
information were elicited via key informant interviews with patient advocacy, clinical care, 
regulatory, drug development, and healthcare payer representatives. The stakeholders identified 
future needs in four key areas: 1) information resources, 2) information integration and 
implementation, 3) value systems and culture, and 4) alignment and ownership of collective 
efforts to improve the use of AE information in the adjuvant setting. 
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  This study revealed the following novel insights: 1) there is cross-stakeholder agreement 
that change is needed to improve the use of AE information in the adjuvant setting to improve 
patient outcome, 2) the directionality of needed changes are similar across stakeholders, although 
specific priorities varied, and 3) the potential to realize broad systemic progress in the use of 
adjuvant-related AE information is a challenge that lacks clear ownership. This lack of 
ownership has adversely impacted resourcing, efficiency, and collective progress and is likely to 
be a progress-limiting factor in realizing transformational change.  
To address the system-limiting challenges identified in this research, a proposed approach 
to incentivize and support stakeholders in forward action is offered. The proposal offers an 
infrastructure to promote collaborative and independent efforts in fulfillment of the many 
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Life with cancer and its treatment—whether as a patient, survivor, or supporter—is an almost 
universal experience. Per the U.S. National Cancer Institute (NCI), 40% of the population will be 
diagnosed with cancer in their lifetime and many others are friends or family members of cancer 
patients (Howlader et al., 2016). Fortunately, the last decade has seen tremendous advances in 
cancer therapy design and delivery and thus an increase in survival rates for many cancer types 
(Edwards et al., 2014). This increasing efficacy means that patients are living longer while on 
therapy or following their primary course of therapy. 
Unfortunately, therapy-related adverse health events are an unintended, but not infrequent, 
outcome of these life-saving therapies (Berridge, Pettit, & Sarazan, 2014; Cleeland et al., 2012; 
Pettit et al., 2016). At their most severe or persistent, cancer treatment-related adverse events 
(AEs) can be lethal (e.g., cardiac failure or severe immune response) (Armstrong et al., 2014; 
Emens, Butterfield, Hodi, Marincola, & Kaufman, 2016). They can also inhibit the curative 
value of the therapy if the side effects impede a patient’s ability to continue therapy (Castellanos, 
Chen, Drexler, & Horn, 2015). Oncologic therapies may also cause less dire but still debilitating 
systemic events, including fatigue, gastrointestinal issues, skin inflammation, and neuropathy 
(Bennett et al., 2016; de Golian, Kwong, Swetter, & Pugliese, 2016; Kumar et al., 2017; 
Macdonald et al., 2015; Ocean & Vahdat, 2004; Santoni et al., 2014; Speck et al., 2013). These 
events may occur acutely during treatment or may be delayed and/or persist months or years 
after a therapy is complete. 
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Before an oncology drug moves into clinical practice in the United States, the balance between 
acceptable AEs (risk) and efficacy (benefit) is influenced and assessed by pharmacologic drug 
design, nonclinical testing, clinical trials, and regulatory review, all of which are major investments 
spread across the private and public sectors. The average cost of development of a drug has been 
estimated at approximately $2.5 billion (Dimasi, Hansen, & Grabowski, 2003). During this 
process, the risk:benefit ratio for the therapy is calibrated (by the drug developer and regulatory 
reviewers) against the lethality of the target cancer (Kuderer & Wolff, 2014). Broadly speaking, 
these approaches provide an accepted and protective means of balancing anticipated AEs with 
efficacy in the patient population (Eichler, Pignatti, Flamion, Leufkens, & Breckenridge, 2008). In 
practice, the significant effort and investment in nonclinical oncology safety studies and clinical 
trials generates data that are more highly focused on and predictive of some outcomes (e.g., acute 
organ toxicities) than others (e.g., chronic pain or delayed-onset events) (Dambach et al., 2016; 
Woolf, 2010). Interindividual variability in response to treatment, heterogenous tumor types, and 
limited study durations remain challenges in the generation of highly nuanced predictions of 
population-level biological outcomes (Mak, Evaniew, & Ghert, 2014). However, investment in 
enhancing preclinical predictivity is a significant area of growth. The biomedical research 
community is pursuing the adoption of novel preclinical experimental platforms, innovative 
preclinical and clinical trial designs, the use of comparative effectiveness methods, and enhanced 
collection of patient-reported AE data to enhance the predictive relevance of premarket safety and 
efficacy data (Basch et al., 2016; Dambach et al., 2016; Fiore & Lavori, 2016; Redig & Jänne, 
2015; Woodcock et al., 2016). Because of these public-private development and evaluation efforts, 
the oncologic therapy options currently available in the United States are more varied and effective 
than ever before (Buffery, 2016). 
 
3 
The practical impacts of treatment-related AEs and their associated supportive care 
requirements may not be fully characterized until the oncology drug is in broad clinical use 
(Pettit et al., 2016). These impacts can include a broad range of direct financial costs as well as 
emotional, social, logistical, and physical tolls. Observational studies and health record analyses 
demonstrate that cancer treatment-related events can degrade patients’ or survivors’ overall 
health status, cause financial strain, and limit their ability to meet family obligations, work, or 
pursue fitness or hobbies (Cleeland et al., 2012; Fitzner, Oteng-Mensah, Donley, & Heckinger, 
2017). Modulatory factors such as variable treatment adherence rates, drug-drug interactions, 
access to care, and patient comorbidities result in a range of patient experiences and healthcare 
system demands (Fitzner et al., 2017). For the purposes of this analysis, this will be referred to as 
the “postmarket” setting. Supportive care to ameliorate AEs may require patients to procure a 
broad range of pharmacologic treatments, undergo monitoring and testing, change diet and 
exercise practices, or pursue “alternative” approaches like acupuncture (Kottschade et al., 2016; 
Lee et al., 2017; Wallner, Köck-Hódi, Booze, White, & Mayer, 2016). Even for a specific 
treatment-related AE (e.g., aromatase inhibitor–induced chronic pain), the nature of the 
supportive approaches that are adopted may vary considerably from site to site (Yang et al., 
2017). Collectively, the cost of purchasing and administering therapy, monitoring health while 
on therapy or after, and managing AE detection and care represents a major societal 
investment—as much as $120 billion and growing annually (Fitzner et al., 2017; Yabroff, Lund, 
Kepka, & Mariotto, 2011).  
Despite this investment, one notable mode of evaluation that is not routinely applied in the 
U.S. drug approval process is cost-effectiveness. The U.S. Food and Drug Administration (FDA) 
is not mandated to consider financial impacts when making regulatory approval decisions for 
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oncologics and thus does not consider cost factors in its decision making (McKee, Farrell, 
Pazdur, & Woodcock, 2010; Siddiqui & Rajkumar, 2012). Even if costs are not directly 
considered in drug design or approval, there can be no question that economic considerations 
(among other factors) materialize once the drug moves into clinical practice. As illustrated in 
Figure 1, a range of influences (e.g., cost of drug, access to clinical facilities, quality of life 
[QoL] impacts of treatment and disease, impact on familial support systems, etc.) affect overall 
patient experience and outcome. 
FIGURE 1: Schematic pathway linking cancer treatment, survivorship,  




Adverse Events, Patient-Centered Care, and Patient Preferences 
Given the potential impact of AEs on patient outcome (health, QoL, and financial), the 
relevance of AE data as inputs to inform decision making by patients and clinicians seems 
evident. Foundational documents such as the World Health Organization (2003) report on 
adherence to long-term therapies and the movement toward “patient-centered care” and “shared 
decision making” clearly establish the need for patient access to understandable information 
about the benefits, risks, costs, and logistics of their treatment (Advisory Board Company, 2015; 
Atherton et al., 2013; Barry & Edgman-Levitan, 2012; Hare et al., 2017; National Institute for 
Health and Care Excellence, 2009; Zucca, Sanson-Fisher, Waller, & Carey, 2014). Patient-
centered care, introduced in 1988 by the Picker Institute and later adopted by the Institute of 
Medicine report Crossing the Quality Chasm, promotes the following: consideration of physical 
comfort; emotional support; respect for patients’ preferences and values; care integration and 
coordination; involvement of family and friends; and the provision of information, 
communication, and education that supports patients’ ability to make informed decisions about 
their care (Institute of Medicine, 2001; Zucca et al., 2014). Although the concept of patient-
centered care is widely embraced, the way in which these elements are pragmatically 
incorporated into practical care decisions or data generation incentives remains fluid (Barry & 
Edgman-Levitan, 2012). Not unexpectedly, preferences for balance of QoL versus length of life 
vary from patient to patient (and can vary during the course of therapy) (Meropol et al., 2008; 
Singh, Butow, Charles, & Tattersall, 2010). Further, the measurable impact of new patient-
centered interventions is an area of active study with regard to the impact of patient satisfaction 
on therapeutic adherence and health outcome (Hoerger et al., 2013; Shingler et al., 2014). 
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Similarly, patient preference also plays an important role in understanding how AE or QoL 
information is incorporated into treatment and decision making. A 2014 in-depth literature 
analysis explored the published correlations between cancer treatment preferences (e.g., 
preference for a specific balance of toxicity, QoL, potential for “progression-free survival,” 
logistics, cost, etc.) and potential adherence to therapy and patient outcome (Shingler et al., 
2014). “Progression-free survival” is defined by the NCI (2018) as “The length of time during 
and after the treatment of a disease, such as cancer, that a patient lives with the disease but it 
does not get worse.” Although no quantitative relationships could be established, the study 
recommends a “greater focus on the importance of patient preference in improving adherence 
levels to medication” and asserts that in oncology, “patient preference is a driver of adherence” 
(Shingler et al., 2014). As illustrated in Figure 2 below, Shingler et al. propose a range of 
influencing factors that may impact such adherence.  
FIGURE 2: Conceptual model for relationships between  




As summarized below, the authors specify three categories of factors (external, cognitive, 
and behavioral) that are theorized to influence adherence and are closely related to the patient 
experience of AEs.  
External Factors Influencing Adherence to Therapy 
• “Information (spoken/written/other) that the patient has with their healthcare provider, 
friend or relatives regarding likely treatment benefits, side effects and related burden.” 
• “Characteristics (of the treatment regimen) such as possible symptoms control etc. that 
patients may or may not perceive as a burden.” 
Cognitive Factors Influencing Adherence to Therapy 
• “Beliefs regarding their disease and prognosis which they arrive with… the value they 
place on maintaining QoL versus perhaps maximizing their chance of survival…” 
Behavioral Factors Influencing Adherence to Therapy 
• “…[The] views or values that patients have regarding what they want from their 
treatment… e.g., wanting to maximize their survival… or …not wishing to undergo 
further rounds of chemotherapy.” 
Given the many levels at which AE information is anticipated to influence patient preference 
in this model, the incorporation (or absence) of a particular AE data type is again highlighted as a 
critical element with influence on clinical care and patient outcome. 
Value Frameworks: New Tools for Cancer Care Decision Making 
Although patient-centered care is not a new concept, the means of implementing this 
approach in a way that supports improved patient outcomes and knowledge generation, with 
regard to oncology treatment-related AEs and QoL impacts, has remained challenging. Over the 
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last 10 years, quantitative efforts to capture the impact of treatment-related AEs have often taken 
the form of economic studies and quality-adjusted life-year (QALY) models and projections 
(Pearce, Haas, & Viney, 2013). These efforts are largely aimed at economic, regulatory, and/or 
policy audiences. Beginning in 2016, the field took a significant conceptual step forward with the 
release of five major “value frameworks.” These approaches are intended to inform policy 
decisions as well as pragmatic therapy choices by clinicians and patients. Value frameworks 
seek to fulfill some of the patient-centered care objectives by providing a means to integrate data 
on efficacy, safety (AEs), patient QoL, and, in some cases, cost for specific therapeutic 
modalities (ESMO, 2017; ICER, 2017; MSKCC, 2017; NCCN, 2017b; Schnipper et al., 2016). 
The 2016 frameworks and their self-proclaimed objectives are as follows: 
• American Society of Clinical Oncology (ASCO) Value Framework: “A framework 
that would enable a physician and patient to assess the value of a particular cancer 
treatment regimen given the patient’s individual preferences and circumstances” 
(Schnipper et al., 2016). 
• European Society for Medical Oncology’s (ESMO) Magnitude of Clinical Benefit 
Scale (MCBS): “The ESMO-MCBS is an important first step to the critical public 
policy issue of value in cancer care, helping to frame the appropriate use of limited 
public and personal resources to deliver cost effective and affordable cancer care” 
(ESMO, 2017).  
• Institute for Clinical and Economic Review (ICER) Value Assessment Framework: 
“Ultimately, the purpose of the value framework is to form the backbone of rigorous, 
transparent evidence reports that, within a broader mechanism of stakeholder and 
public engagement, will help the United States evolve toward a health care system 
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that provides sustainable access to high-value care for all patients” (ICER, 2017). 
• Memorial Sloan Kettering Cancer Center’s (MSKCC) DrugAbacus: “DrugAbacus 
provides a way of thinking about how to price drugs. This interactive tool takes more 
than 50 cancer drugs and lets you compare the company’s price to one based on 
value” (MSKCC, 2017).  
• National Comprehensive Cancer Center Network (NCCN) Evidence Blocks: “The 
goal is to provide the health care provider and the patient information to make 
informed choices when selecting systemic therapies based upon measures related to 
treatment, supporting data, and cost” (NCCN, 2017a).  
The construct of these five frameworks and their inputs, outputs, weighting, and intended 
audiences all vary considerably. However, all speak to a movement toward a more nuanced and 
inclusive evaluation of the impacts of therapeutic choice in the cancer care arena. The relative 
constructs of these five frameworks have been qualitatively compared and contrasted in the 
literature (Allen, Stewart, Roberts, & Sigal, 2017; Basch, 2016; Chandra, Shafrin, & Dhawan, 
2016; Schnipper & Bastian, 2016; Subramanian & Schorr, 2016) and thus a comprehensive 
structural comparison will not be repeated here. 
A synthesis of key elements of these frameworks with respect to incorporation of AE and 
QoL evaluation follows in Table 1. Note that some of the frameworks differentiate between 
adjuvant therapy (defined by the NCI as “treatment given after the primary treatment to lower 
the risk that the cancer will come back”) and therapies given as primary treatment (NCI, 2017a). 
As highlighted in Table 1, AE/toxicity data (typically from published clinical trial data) are 




TABLE 1: Comparison of five major value frameworks regarding the  
use of toxicity and adverse event approaches1 










Clinical trials • Generates a single 
composite scored 
called the NHB 
• Uses different 
algorithms for 
advanced disease vs. 
adjuvant setting 
• Uses AE data drawn 
from clinical trials 
• Can incorporate 





• Can score for DFS 









Clinical trials • Semiquantitative 
process results in 
assignment of letter 
score (A–C) for 
adjuvant setting 
• Semiquantitative 
process results in 
assignment of 




• Can score for DFS 
(cure) or PFS  
• “Toxicity” and QoL 
rating incorporated 








• Assigns a series of 
Evidence Block 
Scores (5-point high 
score, 1-point low 
score) for categories 
such as toxicity, 
efficacy, cost, etc.  
 
• Incorporates a range 
of both qualitative 
and quantitative 





                                                 
1Table 1 was modified from tables previously published in Chandra et al. (2016), Cohen, Anderson, & Neumann 
(2017), and Schnipper & Bastian (2016). AE, adverse event; ASCO, American Society of Clinical Oncology; DFS, 
disease-free survival; ESMO, European Society for Medical Oncology; FDA, U.S. Food and Drug Administration; 
ICER, Institute for Clinical and Economic Review; NCCN, National Comprehensive Cancer Network; NHB, net 
health benefit; PFS, progression-free survival; QALY, quality-adjusted life-year; QoL, quality of life; R&D, 


















term costs and 
longer-term 
healthcare system 
burdens and benefits 
• Includes QALY 
scoring factors  
• Serious AEs are 
factored into scoring 
• Ability to work while 











• Factors benefits and 
burdens of treatment 
into a new “price” 
based on the Abacus 
algorithm relative to 
industry-specified 
price 
• Scores improved 
survival rate  
• Serious AEs (e.g., 
grade 3 or greater) 
incorporated into 
scoring 
• The probability that a 
patient discontinues 
treatment because of 
toxicity is considered 
in scoring 
• Treatment novelty, 
R&D cost, health 
burden, and treatment 
duration 
The Development of Patient-Relevant Data 
Novel opportunities to synthesize information from patient experience with a marketed drug, 
clinical trials, medical surveillance studies, electronic health records, and/or clinician expertise 
are the focus of recent calls to enhance the use of “real-world evidence” (RWE) to promote a 
“learning healthcare system” (LHS) in the United States (Califf et al., 2016; Sherman et al., 
2016; Sherman, Davies, Robb, Hunter, & Califf, 2017). RWE is defined as “information on 
health care that is derived from multiple sources outside typical clinical research settings, 
including electronic health records (EHRs), claims and billing data, product and disease 
registries, and data gathered through personal devices and health applications” (Sherman et al., 
2016). The concept of an LHS initiated from a series of workshops on healthcare improvement 
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as convened by the Institute of Medicine in the early 2000s. The LHS concept promotes the 
generation of “the best evidence and to apply that evidence to the healthcare choices that each 
patient and provider make in collaboration; to drive the process of discovery as a natural 
outgrowth of patient care; and to ensure innovation, quality, safety, and value in health care” 
(Institute of Medicine, 2007). Not surprisingly, the elements incorporated into the value 
frameworks above closely parallel the tenets of the LHS model. The generation of more RWE 
has been proposed as a means of realizing a more iterative and interconnected healthcare system.  
The feasibility of RWE as a complement to regulatory safety evaluation via randomized 
controlled trials (RCTs) and/or as a means of generating novel efficacy, safety, or use 
information for marketed drugs is under active consideration but remains uncertain (Califf et al., 
2016; Sherman et al., 2016, 2017). Novel clinical trial designs and settings (e.g., the National 
Institutes of Health Collaboratory), large-scale health record analysis (e.g., Million Veterans 
Program), and new patient-engaged networks (e.g., PCORnet) have been cited as potential 
opportunities to generate RWE (PCORnet, 2017; U.S. Department of Veterans Affairs, 2017; 
Weinfurt et al., 2017). As these are all relatively new programs (less than 3 years), their impacts 
are not yet defined. Ultimately, the success and novelty of any RWE approach to informing 
healthcare will rely upon the generation of credible, fit for purpose, and otherwise unavailable 
information as well as viable channels to disseminate and use this information. Sherman et al. 
(2017) cite the potential for RWE (e.g., postmarket surveillance or postmarket trials) to help 
refine dose-setting, subpopulation identification, and long-term safety considerations for novel 
cancer therapeutics that receive expedited initial approval. The model they describe, however, 
does not truly expand the traditional approach to drug evaluation and retains the longstanding 
emphasis on standard safety/efficacy endpoint collection and regulator-mediated evaluation and 
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decision making. If indeed RWE is intended to enhance the value of health data (AE-driven or 
otherwise) to a range of stakeholders, it seems clear that more nuanced and diverse evaluation of 
stakeholder need must be clarified.  
Real-world patient experience is also being pursued via efforts to enhance patient 
engagement in regulatory approval considerations. In 2012, the U.S. Congress approved the 
Food and Drug Administration Safety and Innovation Act, which requires the FDA “to develop 
and implement strategies to solicit the views of patients during the medical product development 
process and consider the perspectives of patients during regulatory discussions.” This directive, 
in combination with resources and programs defined via the Prescription Drug User Fee Act 
reauthorizations, led to the launch of the FDA’s Patient Center Drug Development (PCDD) 
initiative. A primary outcome of the PCDD has been disease-focused meetings, convened by the 
FDA, that actively involve patients in providing perspective on risk:benefit considerations of 
relevance for the specific disease and associated therapies. Although these meetings have been 
an important step forward in integrating patient perspectives in selected settings, their impact on 
the overall approach to evaluating and conveying information on a therapy’s impact on patient 
QoL and outcome is still evolving.  
An Unmet Need for Systems-Level Evaluation 
This introduction provides an overview of the plethora of AE data sources (e.g., drug safety 
and drug development, medical surveillance and patient reporting, clinical studies and clinician 
experience, RWE efforts, and regulatory science and trials) and AE-related decision frameworks 
(e.g., value frameworks, cost frameworks, patient-centered care frameworks, LHS models) 
inhabiting the cancer care landscape. On the one hand, this breadth can be viewed as a signal of 
the public health and cancer care communities’ commitment to and investment in these issues. 
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On the other hand, the continued development and reinvention of these approaches suggests that 
the complement of current efforts may not be adequately synergistic or fit for purpose. 
A systems-level assessment of whether the biomedical and public health communities are 
generating AE-related information and frameworks that are suited to the needs of contemporary 
cancer treatment decision makers is lacking. This study will address the question of whether the 
existing “puzzle pieces” fit together to provide the types of information most needed by patients 
and other key stakeholder groups to make informed decisions around cancer treatment (see 
Figure 3). By evaluating relevant information networks and network interactions, this study will 
develop new insights toward the goal of understanding the following question: How can AE 
information be used to more effectively inform cancer patient care? 
FIGURE 3: Data sources and approaches intended to “inform”  





CHAPTER 2: LITERATURE REVIEW 
As a first step in addressing the question of how AE information can be used to more 
effectively inform patient care, it is necessary to first define how AE information has been used 
historically, how it is being used currently, and how it has been proposed for future use. 
Comprehensive literature reviews were conducted using published, peer-reviewed manuscripts as 
the informational bases for this evaluation. Specifically, two foundational questions were 
evaluated: 
• Review 1: How have economic models been designed and populated to measure the 
impact of treatment-related AEs on cancer patients and the healthcare system? 
• Review 2: What recommendations have been promoted to improve the quality and/or 
relevance of AE-related input data for cancer care value frameworks? 
The first review focuses on economic impact models of treatment-related AEs in cancer 
patients and the healthcare system. A review of economic modeling approaches was deemed 
critical, as these methods were the primary format for “valuation” of treatment-related AEs prior 
to the publication of integrated value frameworks in 2016. The second literature review builds 
forward by defining the ways in which 2016/2017 integrative value frameworks have (or have 
not) modulated these prior approaches. Specific attention was given to published 
recommendations on the use of AE data to inform value framework–driven decision making. 
Two distinct literature search strategies (described below) were conducted, although the results 
are integrated here to define common approaches, key strengths and limitations, and consensus 
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recommendations for future needs. The methodological flow of this parallel approach is 
diagramed below in Figure 4. 
FIGURE 4: Multistage process for structured literature reviews 
 
Literature Review Part 1: Cost Models and Valuation of Adverse Events 
An informal review of the literature reveals multiple recent publications that calculate the 
costs/burdens of managing a broad range of cancer treatment-related toxicities. To date, there has 
not been a structured evaluation of the variance in these methodologies with a specific emphasis 
on their underlying assumptions and data sources, the diversity of AEs and costs evaluated, 
and/or the range of populations studied. A 2013 review covered some of these topics as they 
related to studies between 1999 and 2009 with a primary focus on whether QoL, multiple dose 
administration, and multiple AEs were considered in the cost assessment (Pearce et al., 2013). 
This review builds on prior evaluations by incorporating material from the years 2007–2017, 
enhancing the focus on the source of AE data and AE terminology (ontology), characterizing the 
target patient population to whom the cost/risk predictions apply, and exploring assumptions 
around the cost of AEs and related supportive services. Specifically, this review addresses the 
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following question: How have economic models been designed to measure the impact of 
treatment-related AEs on cancer patients and the healthcare system? 
A structured search was conducted using the following databases: PubMed, Web of Science, 
CINAHL Plus with Full Text, and EconLit. The selection of biomedical, nursing/allied 
healthcare, and economics databases for inclusion in this review reflects the multidisciplinary 
nature of the issues and stakeholders under study. Additional studies were identified through a 
manual search of references in relevant articles (snowballing) and evaluation of resources from 
leading organizations in the cancer care arena in the United States (e.g., ASCO). The search 
terms used in this effort are described below (Table 2). Because the databases that were searched 
span multiple disciplines, the subset of terms utilized for that database varied slightly from 
database to database. 
TABLE 2: Search terms for literature review 
Date limitations: 2007 to present 
Concept Key words, search terms 
Cancer focus “cancer” or “oncology”  
AND 
Treatment “therapy” or “treatment” or “therapies” or “drugs” or “medication” 
  AND 
Adverse effects from 
therapy 
“safety” or “toxicity” or “adverse effect” or “adverse event” or 
“toxicities” or “harm” 
  AND 
Cost and/or burden 
evaluation 
“value of treatment” or “cost of toxicity” or “cost of toxicities” or 
“cost of adverse effects” or “burden of toxicity” or “burden of 
toxicities” or “burden of adverse effect” or "toxicity management" 




Inclusion and Exclusion Criteria 
The focus of this research is on those studies that specifically seek to characterize the costs 
(economic, social, logistical) of managing and treating adverse effects of oncologic therapy. To 
ensure the contemporary relevance of the methodologies and underlying economic, healthcare, 
and treatment assumptions, only those studies published in the last 10 years were reviewed. The 
term “comparative effectiveness” is intentionally excluded in order to exclude the “comparative 
effectiveness research” literature. Although these studies do sometimes include cost estimates of 
AEs, their focus is exclusively on the differential/comparator between two similar therapies, and 
thus the total cost of AEs (the focus of this review) is rarely measured (Pearce et al., 2013). Prior 
systematic reviews of AE effect cost assessments have noted this limitation in the use of 
comparative effectiveness studies and thus they were excluded from this search. Radiological or 
surgical interventions were excluded, as the focus of this research is drug-induced AEs, not those 
initiated by radiotherapy or surgical intervention. Proposed inclusion and exclusion criteria are 
included in Table 3. 
 
19 
TABLE 3: Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Qualitative and quantitative studies • Focus of study is exclusively or primarily on 
healthcare delivery outside of the United 
States 
• Descriptive and analytical studies • Studies that do not substantively evaluate 
cost or treatment burdens associated with 
adverse consequences of cancer treatment 
• Methodological and meta-analyses that 
employ primary analysis of data 
• Article is older than 2007 
• Focused primarily on the U.S. healthcare 
system. Studies that included non-U.S. 
system evaluation were also included as 
long as U.S. healthcare evaluation was 
also incorporated  
• Studies focused on the cost of “best 
supportive care” defined as provision of 
palliative care in the absence of an 
antineoplastic regimen (Zafar, Currow, & 
Abernethy, 2008) 
• Studies that measure adverse events 
associated with a prescribed 
pharmacologic intervention to treat cancer 
• Studies not in English 
 • Chemoprevention or homeopathic studies 
 • Studies for which the intervention is surgical 
or radiological 
 • Summary reports or reviews unless they 
include novel analyses 
 
The proposed search strategy was as follows: a) search databases as specified above; b) 
include all references identified in direct as well as snowballing search into reference manager 
and remove duplicates; c) review all manuscript abstracts and date of publications against 
inclusion/exclusion criteria and restrict reference list accordingly; d) conduct a full text review of 
all remaining manuscripts; and e) for those manuscripts meeting all inclusion criteria, populate 
the extraction table accordingly. The articles remaining after all exclusion criteria had been 
applied were reviewed in full. This literature evaluation and data collection allows for 
comparison approaches for estimating the cost of AEs with a unique emphasis on the source of 
the AE data, cost data, population assumptions, and the ontologies used to describe them. 
Uniquely, this review will focus on U.S.-based assessments, whereas prior reviews have been 
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heavily weighted to evaluations outside of the United States. This study is limited to the United 
States, as other countries have different means for setting reimbursement levels and may have 
differential access to drugs and therapies. As such, cost estimation values and approaches are not 
meaningful across national boundaries. 
The structured literature search yielded 631 unique citations after deduplication. Following a 
review of the abstracts of all 631articles, 49 were deemed eligible for full text review. After full 
text review, an additional 21 studies were excluded for failing to meet the study search criteria. A 
total of 28 studies were then utilized in the final review. The flow chart of study selection 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] diagram) is 
included here as Figure 5. 
FIGURE 5: PRISMA diagram demonstrating the part I literature evaluation  





The results of this structured review (2007–2017) provide insight into both the procedural 
means and situational assumptions driving estimation of the costs of AEs associated with 
oncologic therapy. The studies reviewed here employed one of two general approaches: 
estimation of the total cost of a therapeutic regime (drug costs, clinical visit costs, adverse effect 
costs, etc.) or assessment of the cost of one or more specific AEs associated with a designated 
cancer therapy. These studies used a variety of approaches to calculate costs, including 
probabilistic models representing transition between different treatment/health states, 
retrospective cost estimations, and/or prospective data collection and cost estimation. The studies 
covered a broad range of therapeutic drug classes, cancer types, and patient populations. Per the 
inclusion criteria, all studies included cost estimates and assumptions that were designed to be 
reflective of a U.S.-based patient population and U.S. medical and insurance practices. This 
review will not compare the absolute value of reported costs across studies because of the 
variable drugs, study designs, timescales, and patient populations assessed. 
With the exception of one prospective cohort study (Haiderali, Menditto, Good, Teitelbaum, 
& Wegner, 2011), all studies reviewed here relied upon previously published clinical 
trials/published reports or EHR data as sources of information on cancer patient experience with 
oncologic therapy. Despite the varied nature of these studies, their many shared approaches 
provide valuable insight into the utility and limitations of efforts to quantify the impact of 
treatment-related AEs on cancer patients and the healthcare system. Three key areas were 
identified for cross-study comparison purposes: 1) assumptions around the cost of AEs and 
related supportive services, 2) source of AE data and impact of AE terminology usage, and 3) 
characterization of the target patient population to whom the cost/risk predictions apply. A 
 
22 
synthesis of the treatment of these issues across the literature follows below and in Tables 4A–
4E. Collectively, these three data elements create a picture of their approaches to assessing the 
economic impact of cancer treatment-related AEs. 
Cost Assessment Methodologies and Data Sources 
A review of the cost assessment methodologies and data sources is included here as Table 
4A. Although all articles included in this review incorporated cost assessment of treatment-
related AEs, the primary objective of the studies varied. Some sought to model or predict the 
total cost burden associated with a specific oncologic therapy, while others focused primarily on 
characterizing the frequency and cost of one or more treatment-related AEs. There was an almost 
even split (43%/46%) between the 26 articles that employed mathematical modeling approaches, 
primarily Markov models, and those that conducted retrospective total cost estimations based on 
published data from clinical trials and the literature. Markov models are stochastic or 
probabilistic models that characterize relationships between different states (e.g., disease state 1, 
disease state 2, disease free, dead) based on the probability of moving from one state to another. 
Of the remaining 2 of 28 papers, one employed a prospective cost assessment involving real-time 
data on incidence and costs and the other was a meta-analysis of published cost studies 
(Haiderali et al., 2011; Niraula et al., 2014). 
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Studies utilizing Markov models to 
estimate cost 
(Note: Markov models are widely 
used for health economic analyses 
to evaluate potential outcomes of a 
disease process. The model reflects 
movement across different health 
states that are predefined by the 
modeler.) 
12 (43%) Ayvaci, Shi, Alagoz, & Lubner, 2013; 
Burudpakdee et al., 2012; Chu, Schulman, 
Zelt, & Song, 2009; Dalton et al., 2012; 
Goulart & Ramsey, 2011; Havrilesky, 
Secord, Kulasingam, & Myers, 2007; Hess 
et al., 2015; Kurian et al., 2007; Twelves et 
al., 2006; Usmani et al., 2016; Y. N. Wong 
et al., 2009; Xie, Diener, Sorg, Wu, & 
Namjoshi, 2012 
Studies conducting retrospective 
cost estimation based on analysis 




Ayvaci et al., 2013; Burudpakdee et al., 
2012; Chu et al., 2009; Dalton et al., 2012; 
Goulart & Ramsey, 2011; Havrilesky et al., 
2007; Hess et al., 2015; Kurian et al., 2007; 
Niraula et al., 2014; Twelves et al., 2006; 
Usmani et al., 2016; Wong et al., 2009; Xie 
et al., 2012 
Studies conducting prospective 
data collection and cost estimation 
1 (3%) Haiderali et al., 2011 
Meta-analyses across published 
cost studies  
1 (3%) Niraula et al., 2014 
 
The data used to inform these cost studies varied in both source and content (Table 4B). 
More than a third of the articles (39%, n=11) utilized cost estimates from the U.S. Centers for 
Medicare and Medicaid Services (CMS) as their sole source of data on the cost of treating AEs 
associated with therapy. The CMS database includes data on Medicare-insured patients aged 65 
years and older, people younger than 65 with certain disabilities, and those with end-stage renal 
disease (CMS, 2014). Another 25% of the articles (n=6) drew data from commercial, regional, or 
proprietary healthcare databases and another 15% (n=4) from the public Healthcare Cost and 
Utilization Project (HCUP). HCUP is a compilation of databases that include encounter-level 
hospital data drawn from Medicare, Medicaid, private insurance, and the uninsured but does not 
include outpatient data. Among these, a few articles highlighted the distinction between the fees 
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recorded in the HCUP database and the actual cost to the hospital or physician (and in one case, 
discounted to reflect the differential between the cost to the hospital and the amount billed to the 
insurer) (Havrilesky et al., 2007). The remaining seven articles (26%) drew data on cost from 
other published studies. The underlying source of data in these cited studies was not assessed for 
purposes of this review but is anticipated to have come from the sources above. 
TABLE 4B: Defining costs 




“indirect” costs such as time 
off work, caregiver costs, or 
lost employment potential 
6 (25%) Ayvaci et al., 2013; Bristow et al., 2007; 
Haiderali et al., 2011; Kurian et al., 2007; 
Sorensen et al., 2012; Tina Shih, Xu, & 
Elting, 2007;  
Studies utilizing Medicare 
as a proxy for cost data for 
drugs and services required 
to treat an adverse event 
11 (41%) Ayvaci et al., 2013; Bajaj, Veenstra, Goertz, 
& Carlson, 2014; Bilir et al., 2016; Goldstein 
et al., 2014, 2016; Goulart & Ramsey, 2011; 
Haiderali et al., 2011; Hess et al., 2015; 
Rajan, Carpenter, Stearns, & Lyman, 2013; 
Wong et al., 2009; Xie et al., 2012 
Studies utilizing prior peer-
reviewed studies as a proxy 
for cost data for drugs and 
services required to treat an 
adverse event 
6 (22%) Dalton et al., 2012; Kurian et al., 2007; 
Niraula et al., 2014; Ting et al., 2015; 
Twelves et al., 2006; Usmani et al., 2016 
Studies utilizing private 
healthcare or state 
healthcare costs to estimate 
fees regarding adverse 
events 
7 (26%) Bristow et al., 2007; Burke, Wisniewski, & 
Ernst, 2011; Chu et al., 2009; Craver et al., 
2011; Sorensen et al., 2012; Stopeck et al., 
2012; Tina Shih et al., 2007 
Studies using the Healthcare 
Cost and Utilization Project 
to estimate costs associated 
with adverse events 
4 (15%) Burudpakdee et al., 2012; Delea, Amdahl, 
Diaz, Nakhaipour, & Hackshaw, 2015; 
Havrilesky, Chino, & Myers, 2013; Kowal-
Podmore, Munakata, Tencer, & Smith, 2008 
 
The majority of studies (~75%, n=21) identified in this review incorporated only direct costs 
(defined as cost of a hospital visit associated with an AE and/or cost of a physician visit) into 
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their modeled or cumulative cost assessments. Ninety-five percent of these studies (20 of 21) 
also included the cost of prescribed drugs (to treat the AE) in their estimation and/or the cost of 
over-the-counter drugs. Only one of these 21 studies (~5%) limited their analysis to direct 
hospital/physician fees (Burke et al., 2011). A significantly smaller percentage of the studies 
(25%, n=6) also included a valuation of “indirect” costs such as lost wages for time off work, 
caregiver costs, lost future employment potential, and so forth. The assumptions around the 
impact of the AE on lost worktime were variable but hourly wage rates and compensation data 
were consistently drawn from the U.S. Bureau of Labor Statistics. 
The representation of the cost assessment varied across the studies and included calculation 
of additional QALYs relative to total treatment cost, incremental cost to avoid a particular AE, 
total accumulated costs during a given treatment period (primary treatment costs and AE-related 
costs), total accumulated costs to treat AE only, and costs per progression-free life-year (PFLY). 
Defining and Quantifying Adverse Events 
In the context of clinical trials reported in the United States (and Europe), AEs are typically 
described with a grading system developed in the 1980s by the Cancer Therapy Evaluation 
Program (CTEP) of the NCI. This system, called the Consensus Toxicity Criteria (CTC), 
includes a standardized list of outcomes and symptoms in oncology trials and also includes a 
severity grading scale associated with these effects (Thanarajasingam, Hubbard, Sloan, & 
Grothey, 2015). Grade 1 is the least severe and can include outcomes like fatigue. Grade 4 
indicates very severe toxicities (like liver failure), and grade 5 denotes death associated with an 
adverse treatment effect. The source and nature of AE data included in the reviewed studies is 
summarized in Table 4C. 
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TABLE 4C: Nature/frequency of treatment-related adverse events 
Topic Number of 
articles 
References 
Studies using postmarket databases to 
support adverse event type and 
incidence; includes electronic health 
records, surveillance studies, cohort 
studies, etc. 
5 (18%) Burke et al., 2011; Chu et al., 2009; 
Craver et al., 2011; Rajan et al., 2013; 
Tina Shih et al., 2007 
Studies citing other sources of data on 
adverse event type and incidence  
2 (7%) • Direct patient survey and case reports: 
Haiderali et al., 2011 
• Drug label data: Sorensen et al., 2012 
Studies referencing Common 
Terminology Criteria for Adverse 
Events (CTCAE) or other formal 
adverse event reporting standards 
1 (3%) Ayvaci et al., 2013 
 
RCTs from Phase II, III, and/or IV were the predominant source of data (75%, n=21) on the 
frequency and nature of the AEs incorporated into these cost evaluation studies. Of those studies 
utilizing clinical trials, 76% (n=21) incorporated only those AEs that were reported as a grade 3 or 
grade 4. Only 1 of 29 studies identified in this review made any direct reference to the specific 
ontological criteria used to define the grading in their studies (e.g., Common Terminology Criteria 
for Adverse Effects [CTCAE]) (Ayvaci, Shi, Alagoz, & Lubner, 2013). The CTCAE was initially 
developed by the NCI CTEP in 1983 and has been continually updated to include additional AE 
ontologies and severity grades (Chen & Setser, 2008). The remaining studies that referenced 
RCTs either did not fully specify the AE inclusion criteria or incorporated all reported AEs. 
A significantly smaller percentage of the studies (18%, n=5) utilized “postmarket” databases 
(e.g., Premier Perspective Database with data from 600 U.S. hospitals) as a resource to identify 
the frequency and nature of AEs requiring clinical care. These data sources used International 
Classification of Diseases (ICD) codes to delineate patient symptoms and treatment. (Note: 
Outside of the clinical trial setting, clinicians do not routinely utilize the CTCAE to delineate 
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AEs in clinical practice.) ICD codes were also used to classify adverse effects in the one study 
that collected prospective data for the evaluation of treatment-related AEs via direct reporting 
from participating clinicians and patient surveys (Haiderali et al., 2011). One study utilized 
treatment label data as the source of information for adverse effect frequency and type (Sorensen 
et al., 2012). In addition to incorporation of AEs as measured by CTCAE or ICD reports, the 
impact of treatment-related AEs on patient QoL may also be considered in the risk:benefit 
assessment of therapeutic approaches. The evaluation of QoL impacts can be a complicated and 
subjective process. Existing and rapidly evolving survey tools include Patient-Reported Outcome 
Common Terminology Criteria for Adverse Events (PRO-CTCAE) and EuroQol-5D surveys 
(EuroQol, 2017; NCI, 2017b). These tools seek to incorporate patient perspective on the impact 
of therapy on endpoints such as pain, self-care, mobility, and so forth. Per Table 4D, only one of 
the 28 studies identified in this review incorporated direct measures of QoL into the cost 
assessment (Haiderali et al., 2011) via surveys of participating patients. However, 39% of the 
studies (n=11) included “utility factors” in their Markov models. These utility factors incorporate 
QoL-related adjustments relative to the different health conditions in the models. These 
adjustment factors appear to have been based primarily on EuroQol 5D surveys and time trade-
off (TTO) surveys conducted in prior clinical trials—most of which were conducted in the early 
2000s. Specific discussion of the assumptions or relevance of the utility factors selected was 
minimal to absent. 
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Studies incorporating quality 
of life via the use of “utility 
factors” derived from prior 
literature 
11 (33%) Ayvaci et al., 2013; Bristow et al., 2007; Delea 
et al., 2015; Goldstein et al., 2014; Goulart & 
Ramsey, 2011; Havrilesky et al., 2007; Kurian 
et al., 2007; Manolio et al., 2013; Stopeck et al., 
2012; Ting et al., 2015; Usmani et al., 2016 
Studies incorporating measures 
of quality of life based on de 
novo measures by investigator 
1 (3%) Haiderali et al., 2011 
Defining Patient Populations 
The utility of the study predictions to inform future treatment decisions requires a clear 
definition of not only the cancer type and therapy but also the patient population demographics. 
In the reviewed studies, 21% (n=6) focused their cost and AE predictions on populations older 
than age 60 years, 46% reported results of relevance to patients older than age 18, and 32% did 
not specify the age demographic of the study predictions (Table 4E).  




Defines target population 
of the model/analysis as 
a patients age 60 or older 
6 (21%) Ayvaci et al., 2013; Chu et al., 2009; Goulart & 
Ramsey, 2011; Havrilesky et al., 2007; Rajan et al., 
2013; Ting et al., 2015 
Studies 
modeling/describing 
patient populations of 
various ages 
13 (46%) Bajaj et al., 2014; Bilir et al., 2016; Burke et al., 
2011; Craver et al., 2011; Goldstein et al., 2014, 
2016; Haiderali et al., 2011; Hess et al., 2015; Kurian 
et al., 2007; Niraula et al., 2014; Sorensen et al., 
2012; Tina Shih et al., 2007; Twelves et al., 2006 
Studies in which study 
population/relevant 
population ages are not 
described  
9 (32%) Bristow et al., 2007; Burudpakdee et al., 2012; 
Dalton et al., 2012; Delea et al., 2015; Kowal-
Podmore et al., 2008; Stopeck et al., 2012; Usmani et 




Limitations of This Review 
This review has a number of limitations. Because this review sought to assess impact in a 
U.S. healthcare context, economically based health technology assessments (HTAs) as required 
in Europe and several other regions to assess the cost-benefit of novel therapies were not 
incorporated. HTA studies are numerous and relatively standardized in their approaches and 
assumptions. Although HTAs relate only to single-payer healthcare systems that do not match 
the current U.S. multipayer profile, they could provide potentially useful sources for 
methodological comparisons. Because selected HTAs also include QoL (QALY) assessment in 
their economic evaluation of the cost-benefit of the therapy, they can also provide a resource in 
this regard for financial valuation-focused queries. The breadth of U.S.-based studies in this 
review provides an opportunity to characterize a diverse range of methods, but it also means that 
comparison across studies at a granular level is limited. Future studies might focus on a single 
drug class or cost assessment approach to allow for more focused cross-study comparison of 
input data and conclusions. Additionally, more comprehensive insights into methodological and 
data input assumptions across these studies could be gleaned by review of key underlying studies 
cited by the studies reviewed here. Finally, the use of cost as a means of capturing the totality of 
treatment-related AEs on patients is an approach subject to considerable debate in economic, 
clinical, patient, and medical ethics communities (Danis, 2017; Kumar & Moy, 2013). Beyond 
the technical challenges of obtaining relevant data (as described above), the distillation of a 
broad range of physical, emotional, financial, and logistical challenges into a “dollar” figure is 
distasteful and dismissive to some. This review is offered without judgement on this point, but 
with recognition that the exercise of estimating cost allows for thoughtful examination of a range 
of clinical, lifestyle, financial, social, and temporal elements that extend well beyond the scope 
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of the typical U.S.-based drug safety assessment. Further discussion of the linkages between 
economic-driven AE value approaches and integrative value frameworks for informing cancer 
care will follow in the discussion section below. 
Literature Review 2: Current Practice in and Expert Perspectives on the Use of Adverse 
Events in Value Frameworks 
Since the publication of the ASCO Value Framework, the ESMO Magnitude of Clinical 
Benefit Scale, the ICER Value Assessment Framework, the MSKCC DrugAbacus, and the 
NCCN Evidence Blocks (ESMO, 2017; ICER, 2017; MSKCC, 2017; NCCN, 2017b; Schnipper 
et al., 2016), multiple organizations and experts have published commentaries on or critiques of 
the frameworks. These comparisons have focused primarily on a) the construct of the 
framework, b) the ease of use of the framework, and/or c) the utility and relevance of the output. 
This review builds on prior evaluations with a collective synthesis of recommendations for future 
improvement of the frameworks as they relate to sourcing and interpreting framework input 
data—particularly AE and/or patient-reported outcome (PRO) data. This review addresses the 
following question: What recommendations have been promoted to improve the quality and/or 
relevance of AE-related input data for value frameworks? 
A structured literature search was conducted using the following databases: PubMed, Web of 
Science, and CINAHL Plus with Full Text. The selection of biomedical and nursing/allied 
healthcare databases included in this review reflects the broad base of stakeholders involved in 
evaluating value to patients during cancer care. Additional studies were identified through a 
manual search of references in relevant articles (snowballing). The proposed search terms used in 
this effort are described below (Table 5). 
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TABLE 5: Search strategy 
No date limitations: search conducted July 2, 2017 
Concept Key words, search terms 
Cancer focus “Cancer” or “oncology”  
AND 
Value frameworks “value framework” 
  AND 
Adverse effects from 
therapy 
“safety” or “toxicity” or “adverse effect” or “adverse event” or 
“toxicities”  
 
The inclusion and exclusion criteria are described in Table 6. The search strategy parallels 
that of the prior review. 
TABLE 6: Inclusion/exclusion criteria 
Inclusion criteria Exclusion criteria 
• Studies that provide analysis or 
assessment of one or more 
comprehensive “value framework(s)” or 
an equivalent approach to integrate 
adverse event evaluation into an overall 
pharmacologic intervention to treat 
cancer 
• Primary/seminal framework references were 
excluded 
• Qualitative and quantitative studies • Studies not using adverse event and/or safety 
data to assess cancer treatment interventions 
and decision making 
• Descriptive and analytical studies • Article is older than 2012 
• Peer-reviewed studies • Studies not in English 
 • Studies relating to frameworks for assessing 
risk to environmental carcinogens or exposures 
 • Meeting reports and non–peer-reviewed studies 
  
The results of this literature search are summarized in the PRISMA diagram in Figure 6. 
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FIGURE 6: PRISMA diagram demonstrating the part II literature  
evaluation and exclusion process 
 
This review captures recommendations and perspectives from a total of 17 peer-reviewed 
publications. The reviewed studies were almost evenly split between those including a 
narrative/qualitative comparison of different frameworks and those incorporating case 
study/quantitative comparisons across different value frameworks. As detailed in Table 7, 47% 
(n=8) included a narrative comparison across two or more different frameworks and 35% (n=6) 
conducted quantitative or semiquantitative case study comparisons across two or more 
frameworks. Of those conducting quantitative comparisons, three of six studies prospectively 
applied the frameworks using either novel data sets or by challenging a novel expert group to 
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reapply the data and rerun the framework (Cohen, Anderson, & Neumann, 2017; Del Paggio, 
2017; Shah-Manek, Galanto, Nguyen, & Ignoffo, 2017). The remaining four publications 
addressed either a single framework or a single element of the frameworks (e.g., use of toxicity 
data) (Jim & McLeod, 2017; Miller et al., 2017; Waldeck, Botteman, White, & van Hout, 2017; 
Yu, 2016). With limited exceptions, all studies provided perspectives on opportunities to 
improve either the construct of the framework or some aspect of the input data. The most 
common identified areas for improvement, in relation to the nature and quality of input data used 
to populate these frameworks, fell into eight categories described in Table 8. 
TABLE 7: Study designs 
Study design Number of 
articles 
References 
Publications with narrative 
comparisons of different 
frameworks 
8 of 17 (47%) Allen et al., 2017; Basch, 2016; Chandra et 
al., 2016; Evans, Cheung, & Chan, 2017; 
Mandelblatt, Ramsey, Lieu, & Phelps, 2017; 
Neugut et al., 2016; Schnipper & Bastian, 
2016; Subramanian & Schorr, 2016  




6 of 17 (35%) 
 
Bentley et al., 2017; Booth & Del Paggio, 
2017; Cohen et al., 2017; Del Paggio, 2017; 
Shah-Manek et al., 2017; Westrich, Buelt, & 
Dubois, 2017 
Studies that reran analyses 
prospectively using 
published data to populate 
value frameworks 
3 of 6 (50%) Cohen et al., 2017; Del Paggio, 2017; Shah-
Manek et al., 2017 
Studies that addressed 
either a single framework 
or a single element of 
framework inputs 
4 of 17 (18%) Jim & McLeod, 2017; Miller & Aplenc, 




TABLE 8: Proposals for improvement of inputs to existing framework  
Suggested improvement Number of 
articles 
References 
Need improvements to clinical 
trial design to obtain more 
patient-relevant data 
5 of 17 Allen et al., 2017; Bentley et al., 2017; 
Booth & Del Paggio, 2017; Del Paggio 
et al., 2017; Jim & McLeod, 2017 
Need cost data that reflect full 
cost of care/treatment (not just 
drug costs) 
5 of 17 Chandra et al., 2016; Del Paggio, 2017; 
Mandelblatt et al., 2017; Miller & 
Aplenc, 2017; Waldeck et al., 2017 
Frameworks should incorporate 
patient-reported outcome data (via 
inclusion of patient-reported 
outcomes in clinical trials) 
4 of 17 Basch, 2016; Bentley et al., 2017; Del 
Paggio, 2017; Jim & McLeod, 2017 
Frameworks should incorporate 
data from sources other than 
clinical trials (e.g., observational 
studies) 
3 Allen et al., 2017; Basch, 2016; Chandra 
et al., 2016 
Frameworks should incorporate 
more robust and/or detailed safety 
and/or toxicity data 
6 Basch, 2016; Chandra et al., 2016; Del 
Paggio, 2017; Jim & McLeod, 2017; 
Mandelblatt et al., 2017; Miller & 
Aplenc, 2017 
Frameworks should use integrated 
quality of life measures in lieu of 
safety data 
1 Waldeck et al., 2017 
Frameworks should incorporate 
more longitudinal data 
2 Allen et al., 2017; Basch, 2016 
Frameworks should engage 
patients in the data evaluation and 
input process 
3 Allen et al., 2017; Basch, 2016; Booth & 
Del Paggio, 2017 
 
As clarified in Table 8, no one recommendation or modification to improve the relevance of 
the frameworks for informing patient QoL was cited by all the publications. The need for more 
robust and/or detailed safety and toxicity data inclusion in frameworks was, however, the most 
common recommendation identified. This recommendation manifests in two general directions, 
as illustrated in Figure 7. 
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FIGURE 7: Summary of recommendations from literature review for  
improving adverse event data relevance in value frameworks 
 
Additionally, several studies called for more overarching changes to clinical trial design with 
regard to patient inclusion criteria, duration, outcomes measures, and so forth (Allen et al., 2017; 
Bentley et al., 2017; Booth & Del Paggio, 2017; Del Paggio et al., 2017; Jim & McLeod, 2017). 
The details of such modifications were not thoroughly addressed in these publications and are the 
subject of much discussion elsewhere, but they could have significant impact on the type of AE 
data generated in the future (Bhatt & Mehta, 2016). 
Although not the focus of this review, it is important to note that many of the publications 
also called for broad-based improvements in the design or use of the frameworks themselves. 
Specifically, enhanced clarity and transparency as to the intended audience for the framework 
outputs (Basch, 2016; Booth & Del Paggio, 2017; Chandra et al., 2016; Cohen et al., 2017; 
Waldeck et al., 2017) and improved guidance to enhance reproducibility were common 
recommendations (Bentley et al., 2017; Cohen et al., 2017; Evans et al., 2017; Mandelblatt et al., 
2017; Shah-Manek et al., 2017; Westrich et al., 2017). 
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Synthesis of Results of Literature Evaluations 
Characterizing the risk:benefit profile of an antineoplastic therapy requires integration of a 
complex and heterogenous mix of pharmacologic, economic, actuarial, ethical, and sociologic 
factors. The complementary literature searches described here illustrate progress toward this 
integration. However, with respect to use and integration of AE information, several common 
themes and areas for improvement were identified. These areas of commonality are discussed in 
detail below and will be used to inform the subsequent research aims of this study. 
Challenges in Use of Clinician-Reported Adverse Event Data Derived From Randomized 
Controlled Trials 
In both the purely economic and integrated value framework approaches reviewed here, 
Phase II–III RCTs serve as the primary source of data on the incidence of treatment-related 
adverse effects. Almost 80% of the cost studies and/or value framework approaches currently 
rely heavily or exclusively on RCT data to inform toxicity/safety. RCTs are accepted, well-
controlled studies with defined inclusion criteria and dosing and monitoring strategies. However, 
many of the studies reviewed here noted the limitations of RCTs for purposes of providing 
pragmatic patient decision support (i.e., high internal validity but low external validity). These 
limitations include the following: 
• Populations engaged in RCTs tend to be “healthier” and with fewer comorbidities 
than the average patient population on the therapy (Martin et al., 2004). The 
frequency and severity of AEs in the clinical trial population may be under-
representative of AE incidence and severity in the broader patient population and may 
thus lead to an underestimation of overall cost burden (Mitchell et al., 2014). 
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• The type of AEs recorded in Phase II/III trials specifically have been reported to skew 
toward a focus on only high-grade (grade 3 or 4) toxicities, pool toxicities of varying 
severity, include both quantitative and qualitative evaluations, and/or misgrade 
toxicities (Peron, Maillet, Gan, Chen, & You, 2013; Zhang et al., 2016b). Thus, it is 
possible that a significant pool of AE data could have been systematically excluded 
from these evaluations. Even when lower-grade toxicities are reported in RCTs, this 
review demonstrates an almost exclusive (~80%) use of the high-grade AE data for 
purposes of cost modeling or in value frameworks. The ASCO framework was 
recently revised to allow for incorporation of grade 1 and 2 AEs if they occur at 
sufficient frequency (Lowell E Schnipper et al., 2016). Given the tendency to under-
report low-grade AEs in trials and published concerns about “unclear reporting of 
lower-grade toxicities,” the potential for these endpoints to usefully inform 
patient/clinician choice via integrative tools is limited at present (Miller et al., 2016; 
Shah-Manek et al., 2017; Zhang et al., 2016a). 
• The timeframe of study in an RCT provides a limited window (months to ~4 years) 
for capture of treatment-related effects. Some AEs do not manifest for many years 
after the closure of therapy and/or persist for many years after therapy has been 
completed. As such, RCTs may provide an incomplete picture of impact. 
• The evolving nature of the CTCAE ontology used to record and grade creates a 
“moving target.” The number of terms has expanded by a factor of 4 in the last 20 
years. Thus, the version of CTCAE (or other ontology) can have a significant impact 
on the nature, naming, and overall reported incidence of AEs used in cost evaluation 
studies. Several clinical specialty areas that address common antineoplastic treatment-
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related AEs (e.g., rheumatology) have developed their own AE ontologies and grades 
to reflect the more nuanced perspective of a specialist (Calabrese, Kirchner, Kontzias, 
Velcheti, & Calabrese, 2017). Future AE incidence burden evaluations would benefit 
from a thorough characterization of the ontological and inclusion/exclusion 
framework that guided the capture of their core input data and its potential impact on 
outcomes. 
• RCTs are designed for evaluation by regulatory scientists for purposes of drug 
approval decision making. These studies have not been designed to generate 
information to be used by clinicians or patients with regard to individual therapeutic 
or supportive care pathways. 
Alternatives to the Use of Clinician-Reported Adverse Event Data Derived From Randomized 
Controlled Trials 
Although of many of the studies reviewed here identified one or more shortcomings of RCT-
derived AE data, only three (17%) of the reviewed publications on value frameworks proposed 
the future incorporation of data from sources outside of an RCT setting (Allen et al., 2017; 
Basch, 2016; Chandra et al., 2016). Similarly, only 18% of the cost models used data sources 
outside of RCTs for AEs (Burke et al., 2011; Chu et al., 2009; Craver et al., 2011; Rajan et al., 
2013; Tina Shih et al., 2007). This trend points to a simple fact: while it is relatively easy to 
identify weaknesses in the RCT as a data source for informing patient value-choices, the 
identification of viable alternatives or complements is quite challenging. 
As described in Figure 7, recommended alternatives fell into two general and not mutually 
exclusive categories: 1) increased use of PRO measures and 2) increased use of 
observational/surveillance/EHR data sets. 
 
39 
Patient-Reported Outcomes and Quality of Life Metrics 
As patients and clinicians seek both enhanced progression-free survival as well as positive 
QoL, the inclusion of PRO data and/or QoL metrics into the valuation (economic or otherwise) 
of antineoplastic therapy regimes has gained prominence in recent years. The sources of data on 
QoL in the studies in this review included Markov model-based utility factors derived from 
EuroQol 5-D surveys, direct patient surveys that collected data on quality metrics, and clinician 
judgement on impact of patient QoL. The ICER and ESMO frameworks include QoL through 
incorporation of a QALY metric. ASCO uses palliation of symptoms and treatment-free intervals 
as a proxy for QoL measures. The quality of these input data are uncertain, as some of the QoL 
adjustment factors used in these economic evaluations were derived from assessments conducted 
as many as 20 years ago and some included undocumented “value judgements” based on 
clinician experience (Delea et al., 2015; Havrilesky et al., 2009; NCCN, 2017b; Stopeck et al., 
2012). Additionally, the way in which these data were integrated into the value assessments 
described in this review varied from probabilistic modeling approaches to awarding of ad hoc 
“bonus points.” It is beyond the scope of this review to assess the relative strengths and 
weaknesses of each of these approaches. However, this review does reveal that the practice of 
including PRO or QoL metrics into integrated value assessments relating AEs and treatment 
choice is neither systematic nor standardized. 
Undoubtedly, this is a challenging space. The tools and perspectives on the extent to which 
QoL or PROs can or should be leveraged routinely in trials or clinical practice are evolving 
rapidly (NCI, n.d.). The disparity between patient and clinical perspectives on AE burden is well 
established (Basch et al., 2015). Thus, the future use of tools to assess AEs from the perspective 
of the patient may provide novel insights into the overall physical, logistical, and financial 
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burden of antineoplastic therapy. This is likely to hold true in both the clinical trial and the 
standard clinical setting. 
Increased Use of Observational/Surveillance/Electronic Health Record Data Sets 
Collectively, the publications reviewed here offered very limited recommendations for or 
examples of incorporating AE data from sources other than RCTs. The few prospective or 
patient database–driven economic evaluation studies in this review appear to provide a clearer 
picture of the frequency and nature of AEs, although the less controlled setting can make an 
estimation of treatment-attributable costs more challenging (Burke et al., 2011; Chu et al., 2009; 
Craver et al., 2011; Rajan et al., 2013; Tina Shih et al., 2007). None of the value frameworks 
utilize such data at this time. This phenomenon reflects the “gold standard” status of RCTs for 
driving drug safety and efficacy decisions and lack of standards for use of other data sources. 
Increasingly, the potential for observational studies and large-scale healthcare databases to 
provide reliable data on a broad range of patient adherence practices, outcomes measures, and 
polypharmacy/comorbidity situations has been recognized (Balicer & Afek, 2017; Fiore et al., 
2017; Mahajan, 2015). Future developments in this arena will require a thoughtful confrontation 
of the tension between uncontrolled data derived directly from patient care settings and the value 
of nuanced and realistic representation of patient experiences. 
The Costs 
A detailed discussion of cost estimation models is not the focus of this review. However, the 
link between value decisions, cost calculations, and AE-related impacts is an important 
component of this discussion. Some economic evaluation studies reviewed here attempted to 
include all treatment-related costs that the author could identify (drug cost, hospital cost, doctor 
visits, monitoring and testing, over-the-counter drugs, administration fees, lost work cost, 
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caregiver costs, future employment potential costs, etc.; e.g., Sorensen et al., 2012), whereas 
others addressed only the primary cost of treating the AE in a hospital setting (Burke et al., 
2011). Exact cost metrics used within the current value framework structures were equally 
variable but are largely restricted to cost of the drug and/or primary treatment visits. Many of the 
analyses reviewed here specifically recommended that future iterations of the model should 
incorporate the full cost of care including AEs (Chandra et al., 2016; Del Paggio, 2017; 
Mandelblatt et al., 2017; Miller et al., 2017; Waldeck et al., 2017) This recommendation, while 
sound on its face, begs the questions of what constitutes the burden of antineoplastic therapy-
related AEs, who carries these burdens, and thus how broadly should costs be captured? It also 
speaks to the importance of transparent discussion regarding the stakeholders to whom the value 
assessment is intended to apply. 
The Patients 
At the core of all of the value discussions and treatment choices described here are the 
patients. Somewhat surprisingly, nearly a third of the economic valuation studies reviewed here 
failed to provide clear demographic information on either the patient population that constituted 
their input data or the patient population to whom their model/valuation was intended to 
characterize or both (Bristow et al., 2007; Burudpakdee et al., 2012; Dalton et al., 2012; Delea et 
al., 2015; Kowal-Podmore et al., 2008; Stopeck et al., 2012; Usmani et al., 2016; Wong et al., 
2013; Xie et al., 2012). In fact, none of the primary value frameworks described in Table 1 or 
any of the publications about these frameworks (as reviewed here) included a discussion of 
patient demographics other than a focus on patients with a specific disease. Even for those 
studies where the patient population was clearly defined, there were sometimes disconnects 
between the target population and the patient group that served as primary data on AEs, QoL 
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metrics, and/or cost estimations. For example, ~40% of the studies reviewed here utilized cost 
data from Medicare, although only ~20% characterized their study population as older than age 
60. Such disconnects may be inevitable given the limited availability of data in this space. 
However, the relevance of frameworks for information on patient choice and treatment decisions 
could be enhanced with greater clarity around these limitations and their potential impacts on the 
way in which AE-related impacts are synthesized and subsequently interpreted. 
Summary of Opportunities to Improve the Use of Adverse Events to Inform Care 
Decisions2 
Patients, payers, clinicians, regulators, and drug developers all have a vested interest in the 
development of approaches that allow for informed choice around the use of antineoplastic 
therapies that enhance progression-free survival with minimal impact on overall QoL. Recent 
efforts to characterize the impact of AEs associated with antineoplastic therapy reveal that many 
therapeutic classes are associated with significant financial, logistical, and health burdens for the 
patients who receive these treatments. However, the review above illustrates that our current 
means to assess and synthesize the scale and impact of this burden on patients and the system at 
large are insufficient. Much of the input data used in current efforts to describe AE incidence and 
severity may be of limited relevance for a diverse and comorbid patient population. Personal 
experience and preferences are challenging topics to integrate into a standardized decision 
framework, but this review clarifies that incorporation of PROs, QoL, and patient preference is a 
significant deficit. Similarly, presentation of the overall impact of AE on patient experience can 
be challenged by uncertainty around the extent (chronological as well as functional) of the costs 
                                                 
2Note: The literature reviews conducted for Chapters 1−3 served as the basis for a publication in August 2018 in 
Cardio-Oncology (Pettit & Kirch, 2018). 
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and attributes that should be incorporated into these assessments. In summary, the collective 
literature review and analyses conducted here support the following: 
• Future initiatives seeking to provide integrated information to patients and clinicians 
relating to therapeutic choice in cancer settings would benefit from incorporation of AE 
data of greater relevance to the “real-world” patient experience (i.e., “more patient-
relevant information”); 
• There is a need for enhanced transparency around the strengths and limitations (i.e., 
fitness for purpose) of different AE data types to be used to inform cancer care and 
therapy development/support decisions; and 
• There is an overall lack of clarity around how to best use AE data to inform cancer 




CHAPTER 3: RESEARCH AIM AND METHODS 
As evidenced by the literature evaluation conducted in Chapters 1 and 2, there are significant 
challenges associated with contemporary processes and incentives for AE and QoL data generation, 
dissemination, and use for cancer care decision making. However, “cancer care” is an incredibly 
broad and heterogenous arena. We know that the specific timescales, networks, and incentives for 
developing or using therapy-related AE or QoL information can vary significantly depending on a 
patient’s overall prognosis (e.g., metastatic versus adjuvant) and anticipated duration of therapy 
(Allen et al., 2017). Patient preferences, clinician recommendations, and regulatory requirements for 
information around trade-offs between length of life and QoL also vary in different cancer treatment 
settings (Meropol et al., 2008). An evaluation of systemic opportunities for improved AE data 
utilization must both acknowledge critical contextual distinctions and recognize that some elements 
of systemic change could benefit a broad range of settings.  
This study recognizes the importance of context by conducting a focused exploration of the 
roles, expectations, and information flows across stakeholders involved in the adjuvant therapy 
setting. Adjuvant therapies are defined by the NCI as “treatment given after the primary 
treatment to lower the risk that the cancer will come back. Adjuvant therapy may include 
chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy” and 
is used in managing many of the most common cancer types, including breast, lung, and prostate 
cancer (NCI, 2017a). Adjuvants may be administered over extended time periods, often when the 
patient is putatively “cancer free” and there is a significant likelihood of extended patient 
survival. In this setting, mediating the impact of potential acute or delayed adjuvant treatment-
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related AEs relative to an uncertain potential for tumor recurrence can be extremely challenging. 
Information about adjuvant-related AE frequency, scope, control, and support options can be 
reasonably expected to have a real impact on outcomes such as the decision to initiate or 
maintain adjuvant treatment, therapeutic adherence, patient health, QoL, and/or ability to fulfill 
tasks during daily living (Meropol et al., 2008). Because of these important impacts, a study of 
the incentives and barriers to generating and using AE information linked to adjuvant therapy 
was selected as the focus for this research. This study does not specifically explore differences 
between different cancer types treated with adjuvant therapy, or different therapeutic classes of 
adjuvants. For purposes of this exploratory study, perspectives on the integration of evidence 
around treatment benefits and risks that are common across the adjuvant setting at large are 
informative. As discussed in Chapter 5 (“Cross-Stakeholder Results and Discussion”), some 
observations from this study of the adjuvant arena also have relevance in the acute treatment 
setting and the long-term survivorship arena.  
Specifically, this study explored the following aims: 
• Primary aim: Utilize qualitative interviews to understand and integrate key 
stakeholder perspectives on current and future roles as developers and/or users of 
adjuvant therapy-related AE information for cancer care decision making. 
• Sub-aim 1: Understand the perceived roles that therapy developers, 
regulators, clinicians (oncologists and non-oncologists), patient advocates, and 
payers (“the stakeholders”) play in adjuvant therapy-related data generation, 
dissemination, and use, and how these stakeholders are affected by incentives 
and available resources. 
• Sub-aim 2: Learn what the stakeholders feel is most important for them to be 
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better supported in their role as generators, disseminators, or users of adjuvant 
therapy-related AE information and why they have identified these needs. 
• Sub-aim 3: Evaluate systemwide alignment across the stakeholders with 
respect to roles, incentives, and barriers that impact their generation or use of 
AE information to inform cancer care via adjuvant therapy. 
• Sub-aim 4: Identify systemic gaps that could be leveraged into opportunities 
for improving the use of AE information to improve cancer care for patients 
on adjuvant therapy. 
Methods 
Semistructured key informant interviews (KIIs) were identified as the preferred means to 
elicit qualitative information from critical stakeholders that serve as the basis for this study. KIIs 
are an established approach for eliciting nuanced and in-depth stakeholder input from established 
experts. Such interviews are recognized means to elicit perspectives relative to programmatic, 
social, and cultural issues as well as insights around stakeholder motivations and behaviors 
(Creswell, 2014; University of Washington, n.d.; USAID, 1996). The validity of the KII 
approach for this specific study is further supported by prior research in which KIIs were used as 
a key data source for similar healthcare-focused studies. For example, KIIs have been used to 
elucidate challenges and opportunities in collaboration across different clinical communities 
seeking to collectively improve patient care and to characterize the potential to adapt clinical 
care guidelines to facilitate shared decision making across clinicians and patients (Barker, Bosco, 
& Oandasan, 2005; Van Der Weijden et al., 2013). 
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The structure and focus of the KIIs for this study was guided by an implementation science–
derived conceptual model. Implementation science frameworks have been used previously to 
characterize inter-relationships between stakeholders and health/program outcomes in complex 
healthcare ecosystems, including cancer care (Burke et al., 2015; Chambers, Feero, & Khoury, 
2016; Hassmiller Lich, Urban, Frerichs, & Dave, 2017; Mitchell & Chambers, 2017; Price, 
2016). For this study, an existing implementation framework was modified to generate a novel 
conceptual model with enhanced relevance to the adjuvant therapy-related AE setting (see 
below).  
Development of the Conceptual Model Guiding the Interview Design 
Process models are employed in implementation science studies to provide “practical 
guidance in the planning and execution of implementation endeavors and/or implementation 
strategies” (Nilsen, 2015). The process model known as the Knowledge to Action Framework 
(Figure 8) describes an idealized process for the movement of information to action across 
stakeholders (Graham et al., 2006). This model was developed based on Graham’s review of 
dozens of process of change models and has remained a highly cited framework since its 
publication (Burke et al., 2015). Although the Knowledge to Action Framework does not specify 
cancer care or oncologic research, the knowledge generation and usage pathways it describes are 
directly relevant to the systems and issues identified as central in the literature review for this 
study (see Chapters 1 and 2). The Knowledge to Action Framework was thus selected as a 
seminal resource from which to build a more tailored conceptual model for this investigation. 
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FIGURE 8: Graham’s Knowledge to Action Framework3 
 
The Graham framework provides a sound foundation against which to anchor the following 
general themes that are central to the primary and supporting aims of this study: 
• Which party (or parties) is responsible for problem formulation and thus directing 
related knowledge creation? How is this initiated, sustained, and/or realigned? 
• Which party (or parties) is responsible for adapting knowledge to the local context 
and evaluating barriers to access or use? How is this initiated, sustained, and/or 
realigned? 
                                                 
3Source: Graham et al. (2006).  
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• Which party (or parties) is responsible for evaluating whether the information is 
achieving its desired outcomes/reaching its intended user base? How is this initiated, 
sustained, and/or realigned? 
Based on the literature review and the investigator’s professional knowledge, the Graham 
model was modified to enhance its direct relevance to the therapy-related AE and QoL 
knowledge generation and usage setting (Figure 9). This new conceptual model, named 
the “Roles, Evidence, Action, and Leadership Cycle” (REAL Cycle), traces the movement of 
AE and QoL information needs to information generation to information adaptation to 
information use for cancer care decision making and back to information needs. The REAL 
Cycle provides a frame for integrating diverse stakeholders’ self-perceived roles (and their 
perceptions of the role of others) with respect to AE-related data for cancer treatment and care 
decision making. The flow of information in this model is shown to be modulated by facilitating 
and inhibiting factors as well as the presence of information disseminators. This study utilized 
the REAL Cycle to build a line of inquiry and data collection in support of the study aims. 
The REAL model anticipates that when AE and QoL information is used to meaningfully 
inform cancer patient care in the adjuvant setting, it can lead to improved outcomes for cancer 
patients (green box in Figure 9). Per Chapters 1 and 2, these outcomes could take the form of 
enhanced adherence to and efficacy of therapy, enhanced awareness or use of supportive care 
options, reduced therapy-related AEs, greater patient understanding about the impacts of their 
therapy, and so forth. However, a direct assessment of the link between AE and QoL information 
and specific patient outcomes was beyond the scope of this study.  
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FIGURE 9: REAL Cycle: Roles, Evidence, Action, and Leadership toward improved  
use of adverse events information in cancer care4 
 
Translating the Conceptual Model Into Qualitative Research Plans  
The translation of the REAL Cycle into a qualitative research plan per the primary aim 
comprised two elements: a) definition of critical stakeholder groups and b) design of qualitative 
KIIs. A discussion of the methods for each approach follows below. 
Definition of Key Stakeholders for Study 
This study sought to build understanding of systems-level interactions within and across 
stakeholders who are engaged in generating, disseminating, using, and/or requesting adjuvant 
treatment-related AE information of relevance to cancer patient care. The stakeholder categories 
were defined per evaluation of the literature (Chapters 1 and 2) and professional experience. The 
                                                 
4This is an original conceptual model generated by the investigator. 
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specific stakeholder categories and number of stakeholders interviewed for this study were as 
follows: 
• Patient advocacy. Representatives interviewed from this category are organizational 
leaders of patient advocacy organizations. The representatives interviewed for this 
study are employed by organizations that are focused on cancer exclusively or have 
dedicated patient-focused programs in the cancer arena. All of the patient advocates 
who were interviewed had some direct involvement with patients receiving adjuvant 
therapy. Although individual patient interviews could also provide important 
perspectives, they were excluded as a primary data source for this study, as the 
research was focused on the interactions between structured or semistructured 
elements of the cancer care information network. However, all patient advocates 
interviewed for this study were also cancer survivors themselves and thus provided 
both personal and organizational perspectives. Four of the five individuals 
interviewed are the senior operating officer/executive director/founder of the 
nonprofit patient advocacy group that they represent. A total of four interviews in this 
category were completed and evaluated, at which point saturation of themes was 
reached. 
• Clinical care. Representatives interviewed from this category are MD-level clinicians 
working in major academic and private medical centers in the United States. All 
interviewees are involved in the care of cancer patients undergoing active cancer 
therapy or as part of post-therapy supportive care. Specifically, this study included 
oncologists with experience in adjuvant therapy delivery as well as rheumatologists 
and cardiologists involved in monitoring and treating adjuvant therapy-related AEs. A 
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total of five interviews in this category were completed and evaluated, at which point 
saturation of themes was reached. 
• Regulatory science. Representatives interviewed from this category are U.S. or 
European5 government-employed regulatory scientists and regulatory policy makers 
who hold a PhD (n=3) or MD (n=2). All regulators interviewed for this study are 
directly or indirectly involved in the evaluation of nonclinical and/or clinical drug 
safety information associated with the regulatory approval and ongoing safety 
monitoring processes for adjuvant and other cancer therapies. All of the regulators 
interviewed are also actively engaged in the development of new and revised 
regulatory standards and practices for cancer therapy evaluation at the national and 
international level. A total of five interviews in this category were completed and 
evaluated, at which point saturation of themes was reached.6 
• Cancer therapy research and development. Representatives interviewed from this 
category are business-sector pharmaceutical scientists who are involved with the 
development of nonclinical and/or clinical data and methods associated with the 
safety and efficacy assessment of new or existing cancer therapies. Each of the five 
interviewees is employed by a different pharmaceutical company and all of the 
companies operate as multinationals. All of the individuals are senior leaders in their 
organizations (80% with more than 25 years of experience in the field) and are 
                                                 
5Although the recommendations from this research will be primarily U.S. based, both U.S. and E.U. regulators work 
under a set of guidelines for pharmaceutical safety assessment through the International Council on Harmonization. 
As such, perspectives from both U.S. and European regulators were engaged to provide a greater breadth of 
perspective on current approaches and opportunities. 
6Saturation was assessed by the investigator as the point at which no new major themes, insights, or properties were 
revealed during the interview process (Creswell, 2014). 
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responsible for scientific, managerial, and strategic oversight over their domain of 
expertise (e.g., nonclinical safety, translational safety, clinical trials, PROs, etc.). A 
total of five interviews in this category were completed and evaluated, at which point 
saturation of themes was reached. 
• Healthcare plans. Representatives interviewed from this category are employed by a 
U.S. public payer (CMS) or by a private-sector healthcare insurer. All representatives 
were personally familiar with treatment and supportive care coverage policies and 
programs for cancer patients receiving adjuvant therapy. Four of the interviewees’ job 
roles included senior leadership and program design responsibilities for their 
employer and one was responsible primarily for program evaluation of novel payment 
and coverage models for his employer. A total of five interviews in this category were 
completed and evaluated, at which point saturation of themes was reached (three 
private payers and two government payers, although one respondent had worked in 
both sectors and some insights in both aspects). 
Stakeholder Recruitment 
Specific interviewees were selected based on their anticipated fulfillment of five criteria for 
key informant interviewees as delineated by Tremblay (1957): role, knowledge, willingness, 
communicability, and impartiality. Individuals in these categories were deemed to be either 
generators, disseminators, and/or utilizers of therapy-related AE information for cancer treatment 
decisions. Sampling blended an informant sample emphasis (those selected for their specific 
expertise) with a maximum variation sample emphasis (those selected to represent diverse 
experience) (Marshall, 1996). As breadth was a necessary component of the sampling design, the 
investigator used a purposeful sampling technique for selection of interviewees.  
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An informational e-mail was used to recruit potential interviewees and explain the study 
rationale, time expectations, and voluntary nature of their participation and to request feedback 
on participation interest. A one-page project description was also provided (Appendix E). 
Sample recruitment scripts for e-mail and phone outreach are included as Appendix A. All 
interviews were conducted via telephone or web-based audio conference.  
Once an interviewee agreed to participate, a formal communication was sent via e-mail to 
confirm the objectives for the interview, to provide the institutional review board (IRB) approval 
number, data recording policy, and phone number/web link for connecting to the interview 
session, and to thank the individual in advance for his or her voluntary involvement. Consent to 
interview and consent to record were both confirmed via verbal agreement at the start of the 
interview and as part of the digitally recorded and subsequently transcribed interview (see 
Appendix B). Details on data confidentiality and storage follow below.  
Telephone interviews (n=24) were conducted between August 1, 2018 and October 31, 2018.  
Design and Focus of Qualitative Key Informant Interview Questions 
The REAL Cycle was used to develop question themes and subthemes for the KIIs. The 
interview guide is included here as Appendix C and reflects the final guide after initial 
modification following conduct of two cognitive interviews prior to the formal launch of the 
study. A mapping of each KII question to the overall study aims is included in Table 9 below. 
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TABLE 9: Relationship between key informant interview questions and study aims 
Note: See the Key Informant Interview Guide (Appendix C) for detailed probes that were also be 
used by the Interviewer. 
KII question Information elicited via 
prompts during discussion 
Relationship between KII 
response and study aims 
1. INTRODUCTORY 
QUESTION: “Please tell me 
about your organization and 
its mission with regard to 
cancer therapy and cancer 
care. What is your role in this 
organization?” 
• General contextual 
information 
Provides context as to the 
roles and responsibilities of 
the respondents and informs 
the alignment of and 
relationship between 
stakeholders (Sub-aim 1) 
2. ROLE: “Please describe 
your role in balancing the 
beneficial and negative effects 
associated with the provision 
of adjuvant therapy to cancer 
patients.” 
• Scope of a stakeholder’s 
role as characterized from 
their own perspective 
• Input on facilitators and 
barriers to fulfilling 
stakeholder’s role 
Provides insight to key 
facilitators and barriers to the 
roles identified by each 
stakeholder (Sub-aim 2) 
3. RESOURCES:  
3A. “In the context of the 
roles you have described, can 
you tell me about the 
resources you rely upon to 
support these roles (e.g., data, 
experts, studies, funding, 
medical records, invoices, 
etc.)?”  
3B. “Do these resources meet 
your needs? Why or why 
not?” 
• The nature of specific 
information and resource 
flows within the system  
• Perceptions of the quality, 
relevance, and ease of 
access of AE information 
and resources cited by the 
stakeholders 
• Perspective on what it 
would take for stakeholders 
to be better supported in 
their roles 
Elicits information on specific 
resources, accessibility and 
implementation, and systemic 
strengths and weaknesses 




4. FUTURE NEEDS: SELF 
“Are there other types or 
sources of information or 
resources that you wish your 
organization had to help with 
respect to helping patients 
balance the beneficial and 
negative effects of adjuvant 
therapy?”  
• Barriers to current roles that 
are revealed upon suggestion 
of why something 
new/different needed 
• Potential future directions of 
value to stakeholder 
respondent  
• Barriers or facilitators to 
procuring the additional 
information or resourcing 
identified by the respondents 
• Perspectives on how 
new/different information 
would change or improve the 
stakeholder’s ability to fulfill 
their role (or support others in 
theirs) 
Elicits stakeholder 
recommendations on gaps in 
the system and opportunities 
for improved support in 
their role  
(Sub-aims 2 and 4) 
5. FUTURE NEEDS: 
SYSTEM “Moving forward, 
is there anything you would 
you like to see change (either 
in your own organization or 
others) to improve our overall 
approach to balancing 
treatment-related risks and 
benefits related to adjuvant 
therapy?”  
• Stakeholder perspectives on 
how they might better relate to 
or inform other stakeholders 
in the future  
• Perspectives on what other 
stakeholders could or should 
do to improve this system  
Facilitators and barriers 
associated with the change 
they recommend  
Elicits stakeholder 
recommendations on gaps in 
the system and opportunities 
for improved systemic 
functionality 
(Sub-aims 3 and 4) 
6. OPEN: “Are there 
additional comments or 
thoughts you’d like to offer?” 
• Opportunity for stakeholder to 




Review of the study design was finalized by the University of North Carolina (UNC) IRB 
(IRB-17-2590) on February 20, 2018. At that time, it was determined to not be human subjects 
research and was thus exempt from IRB oversight requirements. Per personal communication 
from legal counsel at her employing institution, the investigator (Syril Pettit) did not require an 
IRB from her employer, as they do not issue IRBs. The research conducted was not a condition 
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of the investigator’s professional employment and was exclusively part of her independent 
professional development as a student at the UNC Gillings School of Global Public Health. No 
data or human resources from her primary employer were used in the dissertation research. None 
of the individuals or organizations engaged via this research are or were employed by the 
investigator’s employer or received any compensation for services from that employer, nor did 
they receive any compensation for their participation in this research. 
Data Collection and Management 
With permission of the interviewee (obtained prior to the start of each interview), KIIs were 
recorded as digital audio files using GoToMeetingTM software and saved with an encoded file 
name on a password-protected network drive location. A digital file linking the interviewee name 
to the encoded file name was kept in a password-protected location accessible only to the 
principal investigator. The original audio files will be deleted following approval of this 
dissertation and completion of an associated publication. 
All audio files were transcribed (again with a coded file name on a password-protected 
network drive location) from their audio format into a text document transcript format. 
Transcriptions were contracted to Rev.com, a professional fee-for-service transcription service. 
The investigator reviewed all text transcriptions for accuracy by comparison against the primary 
audio recording.  
Data Analysis and Coding 
Coding Software  
Text transcripts of all interviews were evaluated via the encrypted, password-protected, web-
based qualitative evaluation tool, Dedoose version 8.0.42 (www.dedoose.com).  
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Coding Support  
Dual coding on all interviews, and finalization of the code book, was achieved in 
collaboration with Mr. Randall Teal, Qualitative Research Specialist, UNC Communication for 
Health Applications and Interventions Core Center. Further details on the code book 
development and secondary coding and reconciliation processes are included in Table 10. In 
summary, after initial coding and reconciliation, Mr. Teal and the investigator reached 100% 
consensus on coding of all sections of all interviews conducted for this study. A copy of the final 
code book and coding guide is included as Appendix D.  
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TABLE 10: Code book development and secondary coding process  
Action Participant(s) Process/outcome 
REAL framework used 
to deductively define 
key themes and codes  
Principal 
investigator 
Initial draft code book 
Sample coding of two 




Code book modified with the addition of novel 
inductive codes, to simplify and clarify other 
codes, to link codes to specific interview 
questions, and to provide descriptive text to guide 
coders in application of the codes. Production of 
revised draft code book 
Coding of two KIIs with 





Meeting held to compare coding assignments 
between the primary and secondary coders. 
Minor modifications to code book to clarify 
application of different codes and to eliminate 
codes deemed unnecessary. Code book and key 
finalized (Appendix D). For those limited areas 
of disparity in code assignment, coders discussed 
variances and agreed on a final consensus code 
assignment for all segments of text  
Coding of 11 KIIs with 





Meeting held to compare coding assignments 
between the primary and secondary coders. For 
those limited areas of disparity in code 
assignment, coders discussed variances and 
agreed on a final consensus code assignment for 
all segments of text  
Coding of final 11 KIIs 





Meeting held to compare coding assignments 
between primary and secondary coder. For those 
limited areas of disparity in code assignment, 
coders discussed variances and agreed on a final 
consensus code assignment for all segments of 
text 
 
Limitations/Boundaries of Research 
The major delimitations of this proposed study are as follows: 
• Scope. This study’s focus on adjuvant therapy was deemed appropriate in order to 
adequately delimit stakeholder feedback and provide a basis for cross-stakeholder 
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comparison. The focus on adjuvants was also deemed appropriate because of the 
unique risk:benefit questions that relate to that setting. However, future research 
efforts might add to this study by either narrowing the focus to a particular adjuvant 
class or patient subpopulation or by expanding to additional or alternative treatment 
settings.  
• Stakeholders. The stakeholder base proposed for evaluation in this study is limited to 
stakeholders from the regulatory, clinical care, patient advocacy, drug research and 
development, and healthcare payer perspectives, as they are considered of primary 
relevance to the questions to be addressed relating to scientific information on AE 
type and frequency. However, future studies might incorporate perspectives from 
additional stakeholders that have been intentionally excluded from this study, such as 
legislators, individual patients, academic researchers, grantors, and so forth.  
• Depth versus breadth. The study is delimited to a sampling of informants who can 
provide input from diverse sectors (e.g., patient advocacy, regulatory)—with 
recognition that they are unable to speak on behalf of their sector as a whole and that 
their personal and professional experiences shape their replies. In each sector 
included in this study, there are potentially many ways to subdivide that sector and 
thus elicit further granularity and specificity of replies. Although general saturation of 
themes was reached with five individuals per informant category, it is possible that 
subsequent studies could further subdivide the stakeholder groups and explore intra-
stakeholder variance more extensively.  
• Geography. This study is focused on multiple stakeholder groups in the cancer care 
arena but is primarily delimited to the United States. Although many of the 
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recommendations and comments will be relevant and applicable across geographic 
lines, it is recognized that the regulatory approval, cultural norms and expectations, 
and healthcare payment/access systems vary from country to country. 
• Qualitative focus. This study is restricted to qualitative approaches and perspectives. 
With additional time and resources, this study could be augmented with quantitative 
survey data and/or quantitative case analyses relating the impact of specific AE 
information to specific patient health outcomes or other decision endpoints. 
Approach to Information Synthesis 
A synthesis of the stakeholder feedback was conducted by the primary investigator with 
scientific advice and support from her dissertation committee members and Mr. Randall Teal. A 
synthesis of stakeholder-specific perspectives on roles, challenges, and future opportunities for 
the use of information around adjuvant therapy-related AE information to improve cancer care 
decision making (Sub-aims 1 and 2) is included here as Chapter 4. An evaluation of cross-
stakeholder alignment in perspectives on current status and future needs (Sub-aims 3 and 4) is 
addressed in Chapter 5. A proposed “Plan for Change” that translates the findings from Chapters 




CHAPTER 4: INTRA-STAKEHOLDER RESULTS AND DISCUSSION OF TRENDS 
Introduction 
This chapter provides a synthesis and discussion of intra-stakeholder group perspectives on 
the use of adjuvant therapy-related AE information to improve cancer care patient care (Sub-
aims 1 and 2). After dual coding of all interviews, the Dedoose qualitative analysis software was 
used to visualize major trends in code usage within and across stakeholders and to coalesce 
excerpts of text relevant to each of the codes as applied to the KIIs (see Chapter 3 for 
methodological details).  
This chapter begins with a detailed synthesis of intra-stakeholder themes with respect to 
current roles, challenges, and future needs. A summary this feedback, along with a discussion of 
their perspectives on alignment and ownership of future efforts, is also included. The chapter 
concludes with a further exploration of differences in stakeholder roles and needs identified in 
this study as elucidated by trends in code application across stakeholders. Discussion of broad, 
inter-stakeholder themes stakeholder is reserved for Chapter 5. 
Overall, the codes applied with the most significant frequency across all interviews were as 
follows (scale is approximate) (Figure 10): 
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FIGURE 10: Visual Representation of Coding Frequency 
 
Those codes used with less frequency were as follows: “Participant Job and Personal 
Background,” “Motivators to Generating or Using Data,” “Roles in Data or Information 
Sharing,” “Roles in Data or Information Generation,” “Job Role Changes Over Time,” “Specific 
Data Resources,” and “Role in Adjuvant Therapy.”7 Because of the respondents’ predominant 
focus on “roles,” “barriers,” and ‘future needs,” this chapter will provide a synthesis of responses 
for each stakeholder group in relation to these three general categories of feedback.  
Responses Summarized by Stakeholder Category 
Drug Developers  
Roles  
Although the specific job categories of the respondents in the drug development arena varied, 
all of the stakeholders interviewed in this category characterized their primary role as supporting 
the movement of safe and effective drugs into the marketplace so that those therapies can be 
available to patients. Specific roles included the development of data toward risk 
                                                 
7Although the majority of the interview content specifically addressed adjuvant therapy, the code “Roles in 
Adjuvant Therapy” was intentionally applied only for very specific comments about the participant’s role in 
supporting adjuvant therapy relative to other therapy types. As such, the lack of frequency of the code application 
does not reflect a lack of overall focus on adjuvant therapy-related issues in the interviews.    
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(toxicity):benefit (efficacy) profiles for nonclinical drug development,8 translational drug 
development,9 clinical safety, and PRO evaluation. Respondents emphasized that a significant 
focus of their role is to develop data with the most robust possible translational relevance for 
predicting and optimizing likely outcomes (adverse and therapeutic) in the patient populations 
for whom the therapy is targeted.  
We are trying really hard with a lot of ambition to move towards chronic therapies 
or even curative therapies. So, having a side effect profile where we cure the 
cancer but get the individuals some other difficult to manage, potentially even life 
changing debilitation is not acceptable to us if we can avoid it.  
This stakeholder group consistently characterized their role as data generators. When queried 
about the direct consumers of the information that they generate about a therapy’s risk:benefit 
profile, the majority of those interviewed specified that their current job roles are heavily focused 
on generating information for one of two primary objectives:  
• Generating data on a novel therapeutic’s safety or efficacy to colleagues within their 
company to facilitate internal decision making; and/or 
• Generating information necessary for fulfillment of regulatory requirements 
necessary to achieve approval.  
Roles in Adjuvant Therapy  
All of the interviewees noted that their direct experience in developing data for adjuvant 
therapies was less extensive than their experience with those designed for treatment of metastatic 
                                                 
8Nonclinical drug development includes the use of animal models, computer-based simulation and prediction 
models, and cellular or other in vitro systems to predict safety and efficacy in patients prior to entry into clinical 
trials.  
9Translational drug development focuses on bridging information from nonclinical models and clinical experience to 
optimize efficacy via appropriate dosing and safety considerations.  
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cancer. Respondents noted that many of the therapies approved for adjuvant use were developed 
initially for primary therapeutic treatment and only later shifted to adjuvant settings. Therapies 
that receive secondary approval for use in adjuvant treatment, after primary approval for 
treatment in the metastatic setting, may require significant, minimal, or no novel data generation 
(as data on the safety of these are often derived from patient experience in the primary treatment 
setting) as directed by the regulatory authority (ICH, 2009).  
Current Challenges  
With respect to their role in informing adjuvant therapy development and use, the most 
commonly cited limitations were as follows.  
Difficult to replicate the timescale of treatment. Many of the respondents cited challenges 
in replicating the timescale of treatment in the adjuvant setting. Specifically, they noted the 
difficulty in generating timely and relevant safety data that can meaningfully inform patients 
taking an adjuvant therapy for months to years in duration. These limitations were cited in both 
the nonclinical (animal/in vitro model) context and clinical context. In the nonclinical context, 
the primary concern was as follows: 
We can’t do studies for 5 years. Not just because it’s costly, but because, simply, 
the life span of either an in vitro model or an animal model is not going to allow 
for that type of work.  
In the clinical arena, the feasibility and utility of conducting long-term clinical trials to define 
the balance of AEs relative to increases in overall survival for patients on extended adjuvant 
treatment was also cited as a limitation. Several respondents noted that as the time scale of 
dosing extends, in either a clinical trial setting or in a standard clinical setting, the number of 
variables impacting patient response to the therapy (both beneficial and adverse) are increased. 
Thus, this can make it difficult to meaningfully assess causality of potential AEs experienced by 
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patients on adjuvant therapy (e.g., whether those events are a result of the therapy, the disease, 
other medical or environmental conditions, etc.). Respondents expressed a variety of views as to 
whether existing postmarketing studies on patient experience in the adjuvant arena provide 
sufficient information to inform patients and clinicians about adjuvant treatment-related AEs. For 
example, some felt that such studies were adequately robust and met current needs, some felt 
their relevance for longer-term treatment was insufficient, and some were unable to comment on 
their level of rigor and relevance.  
Difficulties in measuring and/or detecting relevant safety endpoints. Respondents in this 
category also placed significant emphasis on the challenge of predictively, reproducibly, and 
rigorously measuring AEs of relevance to patients who will be receiving adjuvant therapy. For 
safety evaluation via animal models, some toxicities or AEs may not manifest until after the 
study period (e.g., delayed cardiotoxicity) and thus would be missed by even an extended 
nonclinical study evaluation. Additionally, some of the most frequent AEs associated with 
adjuvant therapies (e.g., chronic pain, chronic fatigue, memory impairment, etc.) were cited as 
difficult if not impossible to reliably induce and/or measure in animal models. The majority of 
respondents also noted that with the increasing using of immunotherapies and other novel 
treatment modalities applied to adjuvant settings, the modeling challenges are likely to increase 
rather than decrease in the near term.  
One thing I think we’re always a little bit on the back foot around is really 
understanding intrinsic toxicity concerns around new modalities. 
Respondents also noted that predicting patient experience with a high degree of specificity, 
particularly within patient populations with variable comorbidities, polypharmacy, and so forth, 




New metrics on patient experience lack standardized use. Those respondents most 
familiar with the use of PRO measures in clinical trials asserted that the tools for measuring 
patient experience in trials are robust and available. However, they lamented what they perceived 
to be a lack of routine uptake and utilization by regulators and the cancer research community at 
large.  
I think we need to align around analytic techniques and optimal vehicles for 
patient communication of these results, but I don’t think we need new methods. I 
think we need alignment around the approaches we have now in a more 
systematic way. 
These respondents felt that this lack of uptake has hindered their potential to benefit patient 
and clinician education. 
Regulatory data generation requirements focus on efficacy more than chronic safety for 
oncologic therapies. Several participants noted that regulatory requirements for the approval of 
oncologic therapies for metastatic cancer appropriately focus on expeditiously (but safely) 
bringing new therapies to patients. These regulatory standards place significantly less emphasis 
on evaluation of the potential long-term (chronic) toxicity of the therapy. The guidelines for 
approval of oncologic therapies as developed by United States, European Union, and Japanese 
regulatory authorities state that  
In the development of anticancer drugs, clinical studies often involve cancer 
patients whose disease condition is progressive and fatal. In addition, the dose 
levels in these clinical studies often are close to or at the adverse effect dose 
levels. For these reasons, the type, timing, and flexibility called for in the design 
of nonclinical studies of anticancer pharmaceuticals can differ from those 
elements in nonclinical studies for other pharmaceuticals. (ICH, 2009)  
Put simply, chronic toxicity studies (e.g., 2-year rodent carcinogenicity studies) and extended 
reproductive toxicity studies in animal models are typically not conducted for approval of an 
oncologic therapy used for metastatic cancer. Even when seeking approval for use of a therapy in 
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the adjuvant setting, the respondents noted that a regulatory incentive/requirement to conduct 
such studies is not always present. As clarified in a June 2018 “Question and Answer” document 
published by the FDA, the regulatory guidance used for metastatic cancer therapy data 
development should be used as a “starting point” for therapies intended for the adjuvant setting 
as well (FDA, 2018). The FDA notes that adjuvant therapy approvals may in some cases require 
the conduct of additional chronic nonclinical studies, reproductive or other toxicology studies, or 
clinical trials. However, the FDA (2018) further states that “When the anticancer pharmaceutical 
is shown to extend survival of patients, no additional general toxicology studies are usually 
warranted,” and existing clinical data from the initial approved use in the metastatic setting is 
often considered most appropriate for informing a subsequent adjuvant approval (FDA, 2018). 
Many of the respondents linked their uncertainties around the biological relevance of longer-term 
studies on adjuvant-related AEs to a lack of regulatory incentive to conduct such evaluations. 
One respondent offered the following very pointed observation around when or whether 
pharmaceutical companies would conduct extensive nonclinical chronic safety studies: 
I think we won’t do it until health authorities request that… it’s expensive and I 
don’t think that chronic is going to go there unless it has to. 
Future Needs  
The most common recommendations for future development were as follows.  
Increase connectivity between clinical and nonclinical research teams within a given 
pharmaceutical company. All but one of the respondents noted that information collected on 
AEs in patients (during trials or postmarketing) was not routinely shared with nonclinical safety 
groups, unless that toxicity was robust enough to bring a regulatory safety stop to the therapy 
development program. Thus, they felt there was a missed opportunity to consider the nature, 
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prevalence, and patient perspective on specific AEs in future nonclinical or translational studies 
or monitoring approaches. Improved data sharing and collective analysis within a company was 
cited as an area ripe for improvement. 
Improve approaches to data generation and sharing around safety across companies 
and researchers. The opportunity to promote/improve data sharing and collaborative data 
development across the pharmaceutical sector was also a common theme. Specifically, 
respondents cited opportunities to work together as a research community to develop better 
nonclinical models of and biomarkers for AEs. If realized, this could enhance understanding of 
the biological mechanisms associated with AEs nonclinically and improve clinical prediction or 
control of AEs. This recommendation was cited as a need in the adjuvant arena in general. 
However, it was cited as an increasingly pressing need, given the rise of immunotherapy and 
other novel treatment modalities that lack established nonclinical safety models or long-term 
clinical data. Respondents called for a new cadre of predictive safety testing approaches that are 
aligned for monitoring near and long-term AEs associated with novel mechanisms of therapeutic 
action. The use of pooled AE information from clinical surveillance studies was also identified 
as a potential future resource for improving both study designs and the patient relevance of 
information delivered via drug labels and patient education materials.  
Better engage the “patient perspective.” The respondents consistently noted that more 
should be done to engage the patient’s viewpoint in drug development. Phrases such as “consider 
patient perspective,” “integrate patient experience,” and “consider patient stories” were used 
frequently. However, little was offered as to exactly how this information would or should be 
collected and integrated to achieve this objective. Overall the respondents seemed to envision a 
future in which patient tolerance for and experience of AEs more directly informs adjuvant drug 
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design, safety information development and delivery, and therapeutic dosing. However, their 
view of the path to achieve this objective was only vaguely defined.  
Promote and support a culture shift in drug development. In both explicit and implicit 
ways, the respondents called for shifts in thinking around risk:benefit evaluation and patient 
experience in both adjuvant and general oncology drug development. As one respondent noted,  
We are trying to be more long term in our thinking… I’d love to tell you that we 
were there… where we are is [long-term effects are] a significant consideration as 
we advance development candidates… not necessarily that we can always fix it.  
Within this stakeholder group, there were frequent calls for a future where drug development 
and evaluation programs increasingly and, with more precision, serve the needs of a growing 
population of long-term cancer survivors and patients on longer-term adjuvant therapy. Many of 
the participants noted specific examples of practice changes in their organizations aimed at 
moving toward this future state (e.g., novel conversations around optimal animal models, 
integration of PRO concepts into clinical tests and labels, etc.). However, many expressed 
uncertainties about how these smaller transitions would translate to consistent systemic changes 
in drug development practice. They noted a lack of clear drivers to support systemic change in 
drug development/safety evaluation practice and uncertainty around who would be responsible 
for leading such efforts.  
Link financial incentives to reduced AE profiles in adjuvants. Some of the respondents 
who focused on needed culture changes also noted that building an economic argument to 
support investments around reducing AEs associated with a given adjuvant therapy was an 
unmet need. This was well summarized by one of the respondents as follows: 
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So, if a drug company wants to make a drug that has as better safety profile, or 
even an adjuvant... I don't know who would take that on as a strategy and why. 
I’m not sure about the economic side of that… I think there needs to be more 
discussion about how the patient story can translate into the business case.  
Participants who offered this feedback felt that organizational culture change (as described in 
the above comments) would only be sustainable if the financial return on investment for new 
practices was also defined.  
Summary of Roles and Accountability  
Overall, respondents in this category were highly focused on their regulatory-defined role in 
generating experimental data to support safe and efficacious use of therapy, but they highlighted 
many predictive testing/modeling challenges in this arena as they relate to the adjuvant 
application context. Participants observed a broadening treatment and survival horizon for cancer 
therapy in general. Many observed a growing societal focus on therapy-related AEs relative to 
patient QoL but noted that this has not yet translated into novel financial or regulatory drivers. 
With respect to accountability for implementing future change, these stakeholders identified 
roles their sector could play in developing novel data or novel therapies. However, they also 
described uncertainties around what groups or forces would drive both the positive and negative 
pressures necessary to generate new approaches for reducing the impact of AEs associated with 
adjuvant therapy.  
Regulators  
Roles  
Broadly speaking, both the U.S. and European-based regulators interviewed for this study 
defined their primary role as evaluators of safety and efficacy data on novel therapeutics. They 
emphasized that their role in the oncology space is to balance the critical need for access to novel, 
 
72 
life-saving therapies with the reality that many of these therapies have expected and potential 
toxicities to the patient. A further discussion of current regulatory standards for oncologic therapy 
approvals and adjuvant approvals is included in the drug development sector discussion above. 
The roles of the specific interviewees engaged for this study included nonclinical safety 
evaluation, clinical efficacy and safety data evaluation, national and international regulatory 
standard setting, and regulatory program coordination.  
Roles Related to Adjuvant Therapy  
With regard to adjuvants, not unlike the interviewees in the drug development sector, the 
respondents observed that regulatory review of novel adjuvants occurs with less frequency than 
for primary therapies. Also, as described above, regulators most involved with nonclinical data 
noted that such data are not often directly incorporated into adjuvant therapy approval 
considerations. However, they did provide perspectives on the translational relevance of 
nonclinical data for adjuvant products.  
Current Challenges 
With respect to their role in informing adjuvant therapy development and use, the most 
commonly cited limitations were as follows.  
The regulatory approval process for adjuvant cancer therapy requires a difficult 
balance of weighing future risks against future benefits. All of the regulators interviewed 
noted that they must consistently strike a balance between evaluating the safety of the oncology 
products that they approve and ensuring that approvals are expeditiously delivered to patients.  
We don’t have the long-term data when we have to make decision on approval. 
And it’s often not reasonable to wait for that long to have very firm outcome data 




While this was not offered as a challenge to be “overcome,” the respondents observed that 
decision making in this context requires a fluid approach to evaluating trade-offs with often 
imperfect datasets. They noted that striking this balance for therapies to be used in an adjuvant 
setting requires yet another layer of calibration. In the case of an adjuvant, regulators must weigh 
risk:benefit where a patient is (putatively) cancer free and the trade-off becomes risk of potential 
toxicity versus risk of potential tumor recurrence.  
Often with the adjuvant therapies you’re exposing many people who will never 
get the disease [i.e., recurrence of the tumor]… even if they hadn’t had the 
therapy. You really have to look at the burden of treatment for the entire 
population versus benefit in perhaps the small group of people who will relapse 
with the disease. 
While no alternative approaches were offered, the respondents consistently noted that 
decisions in the adjuvant space require a complex and expert-judgement–driven process that 
weighs available data against uncertain potential outcomes. 
Data to inform decisions are variable in their relevance and availability. Per above, the 
respondents consistently noted that longer-term outcome studies on tumor recurrence and/or 
adverse effects following adjuvant therapy are sometimes limited in availability and utility. 
Specifically, the following limitations were cited by multiple respondents: 
• Rigor of PRO data. Several respondents noted that they are encouraged by the 
increasing incorporation of PRO measures in clinical trials, as they feel it is an 
important step toward better engaging patient perspectives. However, there was 
general concern about the interpretability or maturity of these data for informing 
regulatory decisions. Specific comments included the following: 
The quality of the data (PRO data) is much lower, usually it has been, 
which makes them less useful. 
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I think the use of a lot of the patient quality of life information is relatively 
primitive in cancer in my opinion, compared to other fields.  
Stated concerns around PRO data quality and data “maturity” primarily included 
uncertainties about how to rigorously and consistently incorporate PRO data into 
regulatory decisions, perceived variability in the consistency/accuracy of patient self-
reporting, and concerns about a lack of consensus methodology for collecting and 
interpreting PRO data. 
• Durability of patient registries. The value of patient registry data as a source of 
extended patient outcome on adjuvant therapy was viewed as questionable by some. 
The databases that are set up for surveillance are not adequate… 
the surveillance databases are good for about 2 to 3 years after 
product approval… they’re not directed at long-term effects.  
In this regard, respondents often cited difficulty in continuing to keep track of patients 
and/or their medical history and exposures over longer terms. 
• Uncertain causality of AEs. More than half of the respondents emphasized the 
challenges of distinguishing adjuvant treatment-related AEs from other background 
morbidity in patient populations. They noted that effects that can be defined as 
treatment-related AEs (e.g., pain, fatigue) are also commonly reported ailments in 
control groups and populations at large. A regulatory decision as to causality can thus 
be confounded. 
• Relevance of animal model data. Stakeholder feedback from the regulatory 
stakeholders interviewed varied on this point. Some seemed to feel that, for small 
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molecule therapies,10 the current nonclinical animal database is sufficient to broadly 
predict long-term AEs.  
Overall, for small molecules, they [nonclinical models] have been 
predictive of effects in humans, and long-term effects are being 
addressed through carcinogenicity studies… carcinogenicity studies 
can detect toxicities that we are not seeing in 1-month or 3-month 
studies… I don’t know what else we can do.  
Others highlighted challenges in using traditional animal or in vitro models to generate 
longer-term toxicity data, data relevant to patients with multiple comorbidities and 
polypharmacy, and data on QoL-type endpoints like pain and nausea. All agreed that translatable 
animal models for evaluating AEs from novel immunotherapy (in adjuvant or metastatic settings) 
is a growing challenge. 
Future Needs 
All of the stakeholders in this category cited future opportunities to improve the development 
and/or or use of AE information in the adjuvant context. The most common recommendations 
were as follows:  
Improve/develop better metrics for assessing “burden of treatment.” The majority of 
respondents noted a desire for improved tools, data, and approaches to consistently capture and 
integrate the overall burden of treatment. They noted that they work very hard to rigorously 
apply available information against current regulatory standards. However, their efforts would be 
facilitated with new methods for systematically and rigorously defining and integrating a broader 
range of information on a patient population’s anticipated experience (e.g., fatigue, pain, impact 
                                                 
10“Small molecules” refers to the therapeutic classes and structures of drugs traditionally developed and delivered 
for chemotherapy. This would not include new therapies such as immunotherapy. 
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on daily activities, long-term or delayed AEs associated with a therapy, etc.) into regulatory 
decisions/actions on adjuvants. One subject summed it cogently as follows:  
If you’re talking about adjuvant therapy where you may take it for a long time, 
and you may take it when you’re healthy and you’re not at [immediate] risk of the 
disease, then it’s more important to understand the actual burden of treatment to 
the patient, and their quality of life. And those instruments are, I think, not as 
readily available. 
Re-evaluate societal values regarding risk:benefit trade-offs in cancer therapy. As the 
societally appointed arbiters of risk:benefit information for adjuvant therapies, more than half of 
the regulatory-sector respondents called for renewed discussion around the appropriate set points 
for such decisions.  
There is a societal need to talk about the risk:benefit for short-term versus long-
term toxicity and efficacy.  
Respondents generally viewed this societal discussion a critical step in incentivizing and 
guiding the design of future data, guidelines, communication tools, and patient support. 
Respondents broadly indicated that shifts in survival rates and increasing societal value for 
patient QoL considerations are drivers for these discussions. However, neither specific forums 
nor conveners for these conversations were specified by the respondents.  
Enhance public access to clinical data. Although some aspects of trial reporting are already 
legislatively mandated, several of the respondents called for further enhanced public data sharing 
of clinical trial data. They offered that more rapid and complete access to all trials could better 
inform clinicians, healthcare agencies, academicians, and patients about anticipated outcomes 
and effects and could be mined for research. 
Improve communication to patients. Several of the respondents noted that the regulatory 
arena could better serve patients if information around “quality of life” and AEs associated with 
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a therapy was conveyed in a more systematic, readily understandable, and patient-relevant 
format. One respondent noted,  
We’ve always hoped that information (on the label) could be translated by others 
or made into more accessible forms for others.  
The accountability for achieving this goal was not clearly defined by the respondents but did 
not seem to be viewed as a regulatory role.  
Summary of Roles and Accountability  
Respondents highlighted their role as one of reviewing and evaluating information on 
adjuvant therapy to evaluate risk:benefit trade-offs. Limitations in long-term outcome data—and 
longer-term AE and QoL information—were acknowledged. However, the necessity of 
progressing approvals to support patient access to adjuvant therapy in the face of imperfect 
information was stressed. The potential to recalibrate societal expectations as to what is 
“acceptable” with respect to a burden of treatment for adjuvant therapy was posed as a critical 
future discussion point. These stakeholders offered few details as to who should be accountable 
for furthering such discussions, but they predicted that such discussions could translate into 
changes in regulatory practice at some future time. 
Clinicians 
Roles  
Two subcategories of MD-level clinicians were interviewed for this research: oncologists and 
other specialists (cardiologists and rheumatologists) who support AEs that can be associated with 
some adjuvant therapies. For all respondents, their general role was characterized as providing 
advice and clinical therapy to patients to help promote their long-term survival and meet 
contemporary health challenges. Many of the clinicians interviewed discussed their role in 
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working with patients to understand their long-term treatment goals and to describe how 
available therapeutic options could impact those goals.  
Roles Related to Adjuvant Therapy 
All of those interviewed noted particular challenges in advising patients who are initiating or 
on adjuvant therapy. They observed that adjuvants can be viewed as “preventative therapy” and 
may follow a long and difficult course of curative therapy. Thus, the burden of novel treatment 
efforts and potential AEs at a time when the tumor burden is absent or negligible can be 
particularly stark for these patients.  
It is a more complicated decision process for them (patients considering adjuvant 
therapy) than those who are not getting it in an adjuvant setting. I think they can 
be more frustrated when they have adverse events in adjuvant settings rather than 
primary treatment settings.  
The oncologists involved in this study emphasized that a key component of their role in 
counseling patients on the use of adjuvant therapy is helping them determine when and whether 
to initiate treatment. According to one respondent,  
Adjuvant therapy is insurance, more than anything else. But it does come with 
risks. And so, every single discussion should really be around weighing the risks 
and the benefits around this treatment. 
The rheumatologists and cardiologists who were interviewed were very explicit in their 
defining themselves in a supportive role relative to cancer patients—and not the lead resource for 
the overall treatment strategy or decision making. They often used phrases such as “I facilitate 
the patient’s ability to continue on cancer therapy” or “My role is mostly supportive.” Roles for 
these physicians were primarily limited to helping to manage and/or monitor for possible 
treatment-related side effects to facilitate the patient’s ability to stay on the therapy, increase the 
patient’s symptom management, and to maintain overall health during and following the course 
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of adjuvant therapy. They noted that decisions about which adjuvant cancer therapy should be 
pursued are “deferred to the patient and their oncologist.” 
Current Challenges  
With respect to their role in supporting patients on adjuvant therapy, the most commonly 
cited limitations across the clinicians interviewed for this study are those described below. The 
text below specifies whether these perspectives were shared or differed between oncologists and 
the specialists interviewed for this study. 
Insufficient information on some adjuvant-related AEs. All of those interviewed cited 
concerns about the insufficiency of data for some adjuvant-related AEs. These limitations fell 
into three general categories: insufficient numbers of clinical studies on adjuvants, insufficient 
reporting of adjuvant-related AE data within published studies or in drug labels, and insufficient 
mechanistic understanding of the biological pathways underlying treatment-related AEs. As one 
respondent neatly summarized, “For prevention [i.e., adjuvant therapy], there are fewer trials.” 
Participants also commented extensively on the disparities between published trials and their 
professional experience with respect to some AEs. They observed that, in some instances, the 
breadth and impact of AEs experienced by their patients receiving adjuvant therapy was not well 
reflected in published reports and labels. One went as far as to say, “For me, drug labels are 
pretty much useless for what I’m doing specifically.” It is important to clarify that the clinicians 
interviewed here did not appear to feel that therapy delivery was unsafe but rather that 
documentation was not adequately nuanced. 
The limitations referenced in these comments extended to both extensively used adjuvants as 
well as more recently approved adjuvants. For the oncologists interviewed, their most prominent 
concerns related to perceived deficiencies in the data around nonlife-threatening AEs. To 
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compensate for systematic deficiencies in the available data on adjuvant therapy-related AEs, 
most of the oncologists interviewed emphasized that they had to rely on their own professional 
experience as a resource.  
 What is less obvious or clear from the evidence base, but that emerges with time 
is what patients are telling us about their experiences on these treatments… those 
things like gastrointestinal symptoms, muscle cramps, etc.… there is some level 
of signal of symptomatic adverse event that’s needed to really bring that issue to 
attention, and otherwise, it largely comes from experience to understand what 
people are going through.  
This sentiment was extended further by those respondents, typically specialists, addressing 
AEs associated with more recently adopted adjuvant therapeutic approaches. The following 
comment is emblematic of the challenges described by these respondents:  
 We have a little network of people who ask each other questions (“Have you had 
this sort of situation?”), and try to pool our knowledge to give the patient the best 
information. But I think that’s what you have to do in the early days of something 
when there’s not a robust literature of prospective studies.  
A third area of concern around data availability focused on a lack of understanding of the 
pathogenesis of particular adverse effects. Some of the respondents noted that the lack of clear 
understanding of the pharmacological mechanism of action driving these adverse effects is an 
impediment to providing treatment to reduce or eliminate their impact on patient health. 
Difficult to maintain currency with available information. All of the respondents 
emphasized challenges in maintaining currency with evolving data and practice 
recommendations, particularly on more recently released therapies (e.g., immunotherapy). For 
the respondents in this study, all connected to major academic or research hospitals, logistical 
access to information via their own institutional library systems and personal attendance at 
scientific conferences was not in itself viewed as a hurdle. However, they observed that 
managing the volume of information and determining its quality and relevance for their 
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individual practices was a significant challenge. Respondents identified a lack of time to 
routinely review and compare/contrast new studies as a major limitation. 
Integrating information is complex. Some of the most pervasive and prolific commentary 
from this stakeholder group focused on the challenges of effectively integrating information 
across clinical studies, published guidelines, and patient preferences into rigorous treatment 
recommendations. Existing “risk calculator” tools were acknowledged as a sometimes-helpful 
starting point, but none of the interviewees who addressed these tools felt that they were fully 
sufficient for facilitating treatment decision making.  
 Ultimately, it’s garbage in, garbage out… When I use things like [risk 
calculators], I do so understanding that it might not be completely updated. It 
might not have all the studies included in it that I might have hoped, and it is 
really more about getting a general sense of a where a patient may fall. 
Comments about existing tools ranged from overall dismissal to general caution against 
asking more of the existing tools and data than they can provide.  
Changing medical practice requires tackling a daunting breadth of issues. All of the 
clinicians interviewed envisioned a future in which an improved understanding of and support 
for adjuvant treatment-related AEs would result in improved patient experience and outcome. 
However, many were uncertain how to realize this future state given the number of stakeholders 
and systemic components (regulatory, technology, work flow, logistics, data availability, 
heterogenous patient populations) that could impede change. One clinician commented that it is a 
“pretty daunting task that would require sustained effort to generate something that would be 
reliable and useful.” Several questioned what group or groups would have the accountability to 




The following recommendations and future opportunities were identified by this stakeholder 
group. 
Build evidence-based guidelines for managing AEs. The specialists interviewed for this 
study were most adamant about the need for more consistent, evidence-driven guidelines to help 
them treat patients on adjuvant therapy in a way that alleviates symptoms but does not hinder the 
efficacy of the adjuvant therapy itself. While some clinicians felt that informal, peer-to-peer 
information exchange was both a necessity and valid, others expressed concern that such 
approaches lack consistency and would fail to systematically inform future treatment approaches. 
The most eloquent summation of this concept was as follows: 
There are dangers in creating practice without data, but there’s nothing more 
dangerous than having no agreements and then everybody does whatever they 
want… 
Physicians who echoed this sentiment called for efforts to better promote discussion around 
best practices and to actively share contemporary experiences to inform treatment.  
Enhance coordination between oncologists and other medical fields via raised 
awareness of shared issues. Several respondents called more fluidity of care and interaction 
between oncologists and those treating therapy-related symptoms. They acknowledged that this 
occurs, in part, because “everybody has their checkboxes and neither of us is on each other’s 
checkbox.” Recommendations included development of clinical pathways that are more 
multidisciplinary and other less formal means of raising “awareness” of multidisciplinary 
treatment approaches. Highly specific means for improving cross-disciplinary coordination was 




Leverage standard-of-care settings to generate meaningful information on PROs and 
outcomes. Many of those interviewed expressed frustration that more was not being done to 
collect and analyze patient experience in standard-of-care settings, and many felt that more 
progress should be made in this regard.  
We end up generalizing the decision for the patient based on what has been 
collected in clinical trials that might have been conducted 10 years ago on a 
different continent. But we treat patients every single day, but that data is not 
being put to good use for the patient that I have in the clinic.  
Everybody does a little bit on what they feel, but we are not collecting these data. 
It was recognized, however, that the way data are currently collected and stored in EHRs is 
not fully conducive to research and decision making. Some noted that current data collection in 
EHRs in standard practice is designed for payment and insurance systems. They offered that 
future progress will require not only a commitment to collecting and interrogating these data, but 
possibly a restructuring of the data formats and content at the outset. 
Expedite access to data from clinical trials. Several of the respondents were frustrated that 
access to clinical trial data can be very slow and challenging. They called for more rapid and 
complete data accessibility, but specific mechanisms were not described. 
Reduce the cost of care. Some of the respondents noted that reducing the overall cost of 
care would benefit their patients who are receiving adjuvant therapy by decreasing financial 
barriers to the initiation or maintenance of treatment (or supportive services). A small subset of 
those interviewed were actively engaged in policy discussions around healthcare costs, but 
discussions around specific policy approaches were not explored in this study. 
Create robust tools to allow clinicians and their patients to better understand 
risk:benefit trade-offs. One of the most common recommendations across the clinical 
 
84 
stakeholders interviewed was a call for understandable, visual, and reliable tools that would aid 
in shared doctor-patient decision making.  
We’ve often talked about how it’d be very helpful to have better evidence and 
probably graphical representations of patient experience factors related to 
symptoms, function, and quality of life or otherwise… those types of data and 
representations just really don’t exist in ways that can be easily relied upon as 
reference materials. 
A key subcomponent of this recommendation was the call for enhanced data of relevance for 
predicting the nature and frequency of treatment-related AEs for adjuvants.  
Summary of Roles and Accountability  
These stakeholders focused on their role in providing decisional and medical support to 
patients considering or pursuing adjuvant therapy. Challenges associated with tracking, 
integrating, and communicating complex data sources (sometimes containing too much 
information, sometimes not enough) were stressed. Disparities between clinician experience of 
AEs during adjuvant therapy and the published literature/drug labels were noted. Opportunities 
to engage data and experience from standard-of-care settings were promoted, although the 
resources, incentives, and logistics for achieving this objective were elusive. This stakeholder 
group directly addressed the need for systemic change in the collection, use, and dissemination 
of AE information for adjuvant care. However, discussions around accountability for change 
resulted in lists of many stakeholder groups as well as concern around how such groups might be 





The patient advocates interviewed for this study primarily described their roles as supporters 
of cancer patients and cancer survivors, in almost any nonmedical capacity they need. One 
advocate summed up the role as “enfranchising and articulating, midwifing, patient voice at the 
micro, meso, and macro level.” Roles included serving as a resource for accessible information 
about treatments, sharing experiences with therapy, learning about economic and employment 
issues, mental health issues, and insurance coverage, and so forth. Advocates also described their 
role in “validating” patient experience by providing a central point for patients to share their 
experiences free of judgement and among their peers. They noted that more than 80% of cancer 
patients are treated at community hospitals and thus their support role is particularly acute in 
those settings.  
Role in Adjuvant Therapy 
Interestingly, some of the interviewees noted that their support roles can be even more 
pronounced in the adjuvant setting because the initial “warrior mode” associated with battling 
metastatic disease has passed for many patients, leaving fatigue and desire to focus on things 
other than treatment. According to several of the respondents, patients at this stage sometimes 
need even more significant support to manage diagnosis, treatment options, and self-care. The 
advocates interviewed frequently noted that their organizations serve as a resource for coalescing 
and sharing information generated by other sources. They cited a heavy reliance on published 
sources of information such as the NCCN, ASCO, NCI, PubMed, Cochrane Reviews, and so 
forth. Sometimes information from these sources was compiled into content delivered via 
websites, patient navigators (often with some scientific or medical training), or novel formats 
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that are language and culturally appropriate. Many referenced the role that patients play in 
sharing self-identified methods to manage both the effects of cancer and the effects of treatment-
related AEs via chat rooms and other online or live patient forums. For example, one advocate 
described the development of Spanish-language content in a short pictorial story format that 
would be familiar and accessible to its intended audience.  
In the patient advocacy arena (perhaps more than any of the other four stakeholder groups 
interviewed for this study), the discussion of limitations and future needs was almost inextricably 
intertwined.  
Current Challenges 
The following limitations and challenges were most commonly cited by the patient advocacy 
stakeholders interviewed for this study. 
Focus on treating symptoms and not the patient. Many of the advocates described a 
consistent lack of clinical acknowledgment of the personal impact of nonlethal treatment-related 
side effects (e.g., pain, balance issues, weight gain, etc.) on patients. There was a clear sense of 
frustration that some clinicians do not appreciate the burden that these effects bring to their 
patient’s ability to achieve daily tasks, engage with family, manage friendships and work, and so 
forth. They were careful not to implicate all clinicians but were also adamant about the scope of 
the problem. Advocates expressed frustration that a “there’s a pill for that” attitude can result in 
additional layers of pharmaceutical burden without adequately focusing on solutions that both 
lessen adjuvant treatment-related AEs and accommodate other daily living requirements and 
limitations. There was no clear consensus from these stakeholders as to how clinicians should 
specifically support and address these symptoms.  
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Insufficient therapeutic options. This feedback was most prevalent from those advocates 
who worked frequently with patients with less treatable cancers but was echoed by all in one 
form or another. The advocates cited limitations of available therapeutic options for both primary 
and adjuvant treatment.  
Patients’ unwillingness to take ownership of their own care. Several of the advocates 
expressed frustration that patients do not often enough demand more information, service, 
options, and consideration from their clinicians and health providers. They noted that patients 
must recognize that “they are essentially the decision makers,” and that they have a right and 
obligation to make their own treatment choices, to the extent feasible. 
Lack of accessible and understandable sources of information. A concern about access to 
information included reference to both written content and verbal communications. One advocate 
described efforts to bridge this gap by development of materials about treatment, side effects, 
financing and insurance, and so forth in a variety of languages and formats to support patients 
who are not native to the United States. Others described the complexity and inaccessibility of 
many elements of the administrative elements of the treatment process, particularly the legalistic 
language within consent forms for clinical trials. The role of “patient navigators” in synthesizing 
information or facilitating access to information resources was cited repeatedly as a critical role, 
but one that was often under-resourced and underpopulated. The provision of information on 
“access to quality care” (i.e., types of services offered from specific providers; available medical, 
social, and economic support options and the logistics, financing, and eligibility associated with 
access to these services; the treatment options available and their implications for the patient, 




The following future needs were identified. 
Patients and clinicians should more openly confront issues around mortality. Although 
this point was not noted by all the patient advocates that were interviewed, for those who raised 
it, it was clearly a point of significant passion: “We have to get as comfortable as can be with the 
prospect of our own death and dying.” It was noted that until there is more open 
acknowledgment that no therapy is ultimately truly preservative (e.g., all patients and their 
doctors will die), it will be impossible to candidly and honestly discuss trade-offs between 
quality and quantity of life.  
Clinician-patient relationships should be partnerships that reflect greater mutual 
understanding of options and preferences. Many of the advocates called for greater balance in 
doctor-patient decisions around treatments. Interestingly, these discussions called almost equally 
on both doctors and patients to invest more of their time, judgement, and emotion in better 
meeting this challenge.  
The healthcare system in the United States should be more efficient and less expensive. 
When asked about future needs, opportunities to improve the U.S. healthcare system were 
frequently cited. Advocates observed significant disparities between the amount of money 
flowing through the U.S. healthcare system and their sense of the overall quality of care 
delivered to patients. They expressed frustration that treatment decisions were overly 
administrative and insufficiently responsive to patient concerns.  
More research on long-term effects of treatment is needed. The need for additional 
research on the long-term health impacts of adjuvant therapy was cited as an unmet opportunity. 
As one respondent noted,  
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Too few people are studying what it means long term to live with the after-effects 
of treatment… that’s the poor stepchild of survivorship. They don’t care about 
that. You are lucky to be alive. 
Per the above, some of the advocates reflected frustration that patient feedback on AEs or 
other QoL endpoints was at times undervalued and/or dismissed. Some advocates specifically 
called on drug developers to further develop information relating to AEs and/or to develop 
therapies with fewer AEs, whereas others failed to specify who might take on this role. 
More tailored information is needed in order to know what is relevant for specific 
patients. Several respondents called for access to more tailored information such that individual 
patients could make decisions that are right for their disease, personal situation, finances, and so 
forth. To this end, all called for clinicians to engage more comprehensively with their patients to 
facilitate the application of tailored medical treatment. For example, one recommended the 
development of information “passports” that would accompany a patient and include details 
around their genetic profile, disease status, prior treatments, and so forth to ease these 
conversations and reduce the information retention burden on patients.  
Summary of Roles and Accountability  
The patient advocates engaged in this study emphasized their role in providing informational, 
emotional, and logistical support to patients on or considering adjuvant therapy. They cited more 
extended, frank, and collaborative discussions and decision making between clinicians (and other 
caregivers) and their patients as a key need. The challenge of supporting patients deciding to 
embark on “preventative” therapy (and balance the subsequent burdens against uncertain 
outcomes) were cited as an essential but demanding role. A need for increased focus on patient 
QoL and desire to address, and not just medicate, treatment-related morbidities was also stressed, 
although consensus around specific approaches was lacking. With respect to accountability, 
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some elements of desired change were assigned to groups such as patients, drug companies, 
clinicians, or patient navigators. However, resources or incentives to systematically support these 
future changes were typically described as highly limited.  
Payers 
Roles 
The payers interviewed for this study included those from both governmental and private 
insurance programs (see Chapter 3 for a more complete description). The roles described by 
these subjects fell primarily into three categories: 1) providing financial support to cover services 
and therapies required by those utilizing their insurance coverage, 2) providing case management 
and navigation services to those same individuals, and 3) developing and evaluating new models 
of care coverage. In the first category (payment), all of the subjects were adamant that they 
“don’t tell a physician how to practice medicine” and provide coverage for that which is 
“reasonable and necessary.” A further discussion of limitations in this role follows below.  
With regard to providing case management and information-sharing services, most of the 
stakeholders described their role (or their organization’s role) in providing support to patients on 
an assigned or on-demand basis. They noted that this information is often also available from 
clinicians, but “case managers are also another layer of support for them once they get home and 
are experiencing those side effects.” Information provided via these individuals included 
“psychosocial” support, information about treatment side effects, information on therapeutic 
options, and so forth. One participant noted that this support role is particularly important in the 
adjuvant and postadjuvant setting because “a lot of time[s] a health plan will focus really on the 
patient as they’re undergoing active treatment. And when they switch to nonactive treatment 
[adjuvant or maintenance therapy] …you’re actually spending less time with them… we’ve 
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rolled out patient education programs that don’t stop when treatment stops.” Specific resources 
cited as a basis for both education and/or treatment approvals include published clinical trials, 
educational resources, and data/treatment synthesis reviews prepared by professional scientific 
societies such as ASCO, the American Cancer Society, community oncologist associations, and 
so forth. Some also noted that information was reviewed and evaluated by an internal physician 
advisory board that reviews evidence-based guidelines and best practices. These advisory boards 
serve as a resource to the case managers and inform treatment approval decisions by the payer. 
Role in Adjuvant Therapy 
In characterizing their roles in providing support to patients on adjuvant therapy specifically, 
many respondents chose to focus on recent payment models that they felt had the potential to 
improve quality of care for patients on adjuvant therapy. Specific analysis of these payment 
models and their strengths and weaknesses is beyond the scope of this study. However, a brief 
discussion of the roles that these systems may play in supporting patients on adjuvant therapy, as 
described by the study respondents, follows below. On the public side, subjects described the 
Medicare Oncology Care Model (OCM) as a novel opportunity to improve care delivery and 
enhance cost efficiency for cancer patients. The OCM was described by the subjects as an 
exploratory model that “doesn’t have silos so you can look outside of classic care [model], so 
you can do the right thing.” Respondents focused on the OCM’s goal of incentivizing clinicians 
to look at the “total cost of care” and make choices that reduce overall costs to the system. As 
described by the participants, in this model, “wraparound services” such as transportation to 
routine doctor visits to address side effects from adjuvant therapy may be eligible for coverage if 
such expenditures are anticipated to reduce the likelihood and expense of a subsequent 
emergency room visit. With respect to evolving payment models on the private payer side, some 
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participants described the Patient-Centered Medical Home (PCMH) model. The PCMH is a 
payment model focused on providing comprehensive, quality care as coordinated at the primary 
care level. The respondents commented that the PCMH’s focus on “quality of care” and access to 
patient navigation services makes it a robust model for supporting cancer patients on adjuvant 
therapy. Although the participants characterized the inclusion of navigation and wraparound 
services in the fee structure of these models as a positive for patients on adjuvant therapy, they 
acknowledged that these models are relatively new and evolving. The overall cost:benefit to the 
payers and impact on patient service utilization (and cost to patients) is yet to be fully 
determined. 
Most participants observed that payers have no role or only a very limited role in generating 
public or systemically accessible learnings from their database of adjuvant therapy 
delivery/support approaches and patient outcomes. Some of the limitations in this regard are 
discussed below.  
Current Challenges  
The major themes with respect to challenges and limitations as cited by the payers 
interviewed for this study are described below.  
Healthcare plans are limited in their ability to be nimble and personalized. While most 
of those interviewed stated a personal recognition of the value of offering a broad range of 
wraparound patient support services (e.g., transportation, massage therapy, counseling, etc.), they 
confirmed that the ability to offer such services in a customized and nimble manner is 
necessarily delimited. As one of the private payers noted,  
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Health plans are under very strict monitoring for individual considerations… any 
types of one-offs that we approve without clear written criteria… and so there is a 
lot of hesitance in the payer space to provide wraparound service[s] because not 
everybody needs them… it’s difficult to write a medical policy when not 
everybody needs something but it’s something that maybe a couple of people 
might need based on their goals or based on their specific circumstances. 
In addition to challenges in offering services that meet the needs of only selected participants 
in the plan, some payers also noted that coverage of a novel supportive service (at least in 
traditional payment models) is dependent upon a robust evidence base on its efficacy. However, 
as one respondent noted, “The evidence base is really lacking for these kinds of wraparound 
therapies.” Specific opportunities to enhance this evidence base were not defined by the 
participants.  
The use of datasets held by payers to improve future care has significant limitations. 
Many of the respondents noted significant limitations on the use of information collected by payers 
(e.g., treatment type, cost of care, patient characteristics and prior conditions, patient outcome, 
clinician location and characteristics, etc.). Many commented that, while entirely appropriate, data 
privacy limitations make it difficult/impossible to comprehensively evaluate and share information 
that might benefit the broader clinical community. Some also noted that payers’ ability to 
efficiently collect, synthesize, and share information (even within their own network) can be 
problematic. As such, the ability to identify and adopt time-sensitive calibrations in payment 
coverage or recommendations regarding treatment can be stymied. The third limitation related to 
challenges in collecting and evaluating data in a statistically robust manner. It was noted that data 
about treatment outcomes and care delivery could be “lumped” to create a larger base for analysis 
and detection of trends. However, in those scenarios, the diversity of variables associated with care 
delivery, patient types, and so forth was often so significant that extraction of only very broad 
trends was possible. When data were “split” into smaller and more homogenous subunits to 
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promote more ready interpretation, the total “n” for analysis also decreased substantially and thus 
interpretation was challenged by inadequate sample sizes.  
Cost of drugs negatively impacts the patient’s quality of care and adherence. Both 
public and private payers commented on the impact of high drug prices on patient outcome. They 
cited cost of both adjuvant and nonadjuvant therapies (even with insurance coverage) as a hurdle 
to accessing the best possible therapies and/or to sticking to treatment schedules. Many 
respondents observed that the costs of cancer therapies are, in general, increasing and felt that 
this trend is becoming increasingly problematic. 
Patient awareness of the impact of nonadherence is inadequate. A subset of the 
respondents noted that one of their challenges in realizing optimum outcomes for patients in their 
plan is a lack of compliance with proscribed treatment schedules.  
A lot of it breaks down to patient education and patients understanding that the 
schedules need to be followed very well in order to … have the most impactful 
treatment.  
Providing additional education and outreach to patients was recommended as a remedy. 
Patients on adjuvant therapy are a distinct subcategory of cancer patients with unique 
and challenging needs. A subset of the respondents observed that their programs provide less 
focused service delivery and decision support for patients in the adjuvant treatment phase 
relative to other treatment phases. One respondent noted, with some frustration, that “The 
majority of plans are really looking at a population of people who are at the end of life and not 
people who are going to enter into a maintenance phase.” This same respondent also noted that 
the information support needs of patients considering adjuvant therapy present unique challenges 
relative to patients in the metastatic or palliative care phase: “There’s a very open trade-off 
between quality of life and length of life… that makes this phase pretty difficult to sort through.” 
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Data relating to treatment options and care pathways are complex and rapidly 
changing. All the participants confirmed that internal clinical advisory boards rely on available 
scientific/clinical data to inform plan coverage and provide information to participants. A range 
of views were expressed as to whether these teams are able to effectively review and integrate 
this information in a timely and robust manner. Challenges related to having the time to perform 
routine systematic reviews of novel studies and identifying data of relevance to a specific patient 
or patient population.  
Future Needs 
The following specific recommendations and future opportunities were offered by a majority 
of the stakeholders interviewed in the payer category. 
Improve support for chronic AEs associated with therapy. Many respondents observed a 
trend in the payer sector toward greater recognition of patient QoL as a metric of quality care. 
They also anticipated increasing attention on the role that chronic toxicities/AEs play in QoL.  
There is an increased awareness in the long-term toxicities of therapies, both 
physical and emotional and socio-economic in terms of holding to a job and all 
those things… There’s also an increased awareness that we aren’t doing as well as 
we could … there’s still work to be done. 
Very specific recommendations for making improvements in this arena were not offered, but 
in response to questions in this regard, there were suggestions that new models such as the OCM 
and the PCMH model might help to address this in the future. In this vein, many also called for 
increased support for access to a diverse range of services that support QoL during and following 
adjuvant therapy. Although suggestions for the specific types of supportive services and plan 
coverage mechanics varied across the participants, there was general recognition that optimizing 
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outcomes and reducing side effects for patients receiving adjuvant therapy requires consideration 
of more than just traditional medical intervention. 
Adopt new payment models (such as the OCM and the PCMH model) as new 
standards. The majority of the payers that were interviewed for this study promoted the further 
adoption and codification of novel payment models as a means to enhance care provision and 
reduce costs for patients on adjuvant therapy. It should be noted that the majority of those 
interviewed also hold professional roles in the development and evaluation of novel models such 
as the OCM and the PCMH model. However, even those not involved with these models 
specifically observed that current insurance models will require some type of innovation to better 
serve the needs of cancer patients on adjuvant therapy. 
Reduce the cost of drugs. The majority of the respondents called for a decrease in oncology 
drug prices as a means to enhancing access to and coverage for quality oncologic care. However, 
most anticipated a continued rise in pricing. 
Enhance data sharing across plan participants and with insight from the clinical 
community. The opportunity to use data sharing from within payers’ databases and experience 
to improve outcomes for patients and enhance system performance was a commonly stated 
future goal.  
If there [were] more robust data sharing [and] more robust collaboration from an 
education standpoint, I would see that as a huge win for our patients and 
members… I think we all have a common goal but we’re just not as integrated or 
as connected as we need to be.  
However, as noted in the limitations section, many respondents cited the numerous and 
substantial barriers to this type of data sharing and use. Specific means to reducing these barriers 
and thus realizing this opportunity were not identified by the respondents.  
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Enhance the systematic capture of patients’ experience of QoL when evaluating quality 
measures associated with insurance coverage. The majority of the payers interviewed called 
for more systematic means to capture and integrate QoL measures in payment plan evaluation 
efforts. They acknowledge a growing awareness of the importance of patient perception of QoL 
and its direct relevance in the adjuvant space. However, they noted the need for development of 
tools and methods that would allow for its routine integration into plan evaluation in the future.  
Provide more frequent access to clinical information (24/7) so that minor problems do 
not become major ones. A subset of the stakeholders interviewed called for enhanced patient 
access to clinical advice. They postulated that by creating almost unlimited access for response 
to questions and concerns, they could significantly reduce more costly visits to emergency rooms 
and specialty care centers.  
Summary of Roles and Accountability  
 These stakeholders described their roles in providing healthcare reimbursement/coverage as 
well as in developing and innovating healthcare payment models in general. They stressed the 
need to engage with patients on adjuvant therapy in an ongoing and interactive way (to benefit 
the patient and to avoid preventable costs due to deferral of care). Some stakeholders described 
challenges in aligning the provision of consistent, evidence-based coverage with variable patient 
needs. Opportunities to support an LHS were commended and pursued by some, but logistical, 
privacy, and technological hurdles were also identified. This stakeholder group largely viewed 
themselves as implementers of information generated by others (e.g., study data, pricing data, 
healthcare usage data, etc.) but as leaders in the development of new payment models. These 
stakeholders generally viewed their remit as internally focused—that is, largely delimited to the 
use of their own data and published data to promote modifications to their internal systems.  
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Further Exploration of Intra-Stakeholder Differences as Revealed via Code Application 
Because all stakeholder groups were interviewed with the same core survey questions, an 
analysis of variations in code application provides insight into areas of differential focus and 
priority. Trends in code frequency were evaluated qualitatively and in relation to the pooled 
interview data for each stakeholder category. Plots of the frequency of use of a given code for 
each stakeholder group were generated using Dedoose’s online analysis tools. (Note: The default 
setting for these plots includes a reporting of percentages. However, quantitative assessment is 
not appropriate for this dataset and statistical/quantitative variance assessment was not 
conducted.) The investigator used these plots to look for gross visual trends in code application. 
Figure 11 provides an example of a plot representing a “major trend” and a plot where no major 
trends are observable with respect to code use (plots contain actual data). 
FIGURE 11: An illustrative example of an approach to visual trend analysis of codes  
 
The top chart (as generated with the Dedoose software) illustrates a clear variance in use of the 
code “Motivators to Generating or Using Data” by the payer sector relative to others. The bottom 
chart is representative of datasets where no visual trends in code application are observable. 
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Of the 10 codes utilized in this study, the frequency of application of the codes was 
consistent11 for all but the following three codes: “Roles in Data Generation,” “Motivators to 
Generating or Using Data,” and “Specific Data Resources.” A discussion of this variance and its 
implications for understanding differences in stakeholder roles follows below. 
The code “Roles in Data Generation” was applied with far greater frequency in relation to 
feedback from respondents from the drug development sector as compared to others. This 
differential likely reflects this sector’s self-professed role in developing primary data associated 
with adjuvant therapy design and use and their significant focus on fulfilling regulatory data 
generation requirements (see above). Although all stakeholder groups involved in this study 
provided some examples of their roles in data generation, most groups focused proportionally 
more on their roles in information use and/or dissemination.  
The code “Motivators to Generating or Using Data” was used significantly more to 
characterize feedback from payers as compared to other stakeholders. In this context, payers 
often focused on novel payment bundling models that, according to the respondents, create 
economic incentives to use or collect information that would result in a more efficient system 
and/or better active care for the patient. The absence of focus on motivators is a theme that will 
be further addressed in the conclusion of Chapter 5.  
The code “Specific Data Resources” (used to denote respondent discussion of named data 
sources or reference materials) was applied most often to feedback from clinicians and patient 
advocates as compared to other respondent categories. This frequency likely reflects the 
                                                 
11It is important to note that the frequency of application does not equate to consistency of themes or topics. As 
reported here, codes such as roles, barriers, and future needs were used consistency and frequently across all 
stakeholder groups. However, per the detailed reports in this chapter, specific focus and priorities identified within 
these topical areas varied considerably from stakeholder to stakeholder. 
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significant role that these stakeholders play in integrating and/or sharing specific information and 
resources that are developed by others (see detailed discussions above). Although many 
respondents described the general categories of information that they utilize, the patient advocate 
and clinician groups were far more likely to discuss specific named resources. Many times, these 
named resources were compilations of existing studies (treatment guidelines, ASCO or NCCN 
reports or summaries, etc.). 
In addition to evaluation of individual code frequency, an analysis of code co-occurrences 
provides further insight into the structure and thematic focus of the respondent commentaries. Co-
occurrence is defined as follows. Each substantive section of text in the interview is assigned one or 
more codes (see Chapter 3). With the aid of the Dedoose analytical tool, it is possible to review the 
collective texts to determine which codes were most often assigned concurrently to sections of text. 
When codes commonly co-occur, it indicates that respondents addressed the themes embedded in 
those codes in an integrated or linked manner. The text below explores the co-occurrences observed 
in this study and their implications for understanding cross-stakeholder perspectives. 
The codes “Barriers to Generating or Using Data” and “Future Needs for System” were the 
two codes most commonly applied to common sections of text. This co-occurrence is not entirely 
unexpected given the focus of the conversation (e.g., participants describing how they see 
barriers being overcome in the future). However, it is interesting to observe that the future needs 
discussion frequently did not link to discussion of motivators. This may suggest that respondents 
were more focused on or aware of hurdles rather than incentives in their feedback. The 
infrequent reference to incentives/motivators is consistent with the stakeholders’ reported 
uncertainties around their accountability for undertaking novel data generation, facilitating novel 
conversations, building new tools, and so forth.  
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The next most common code co-occurrence was between “Barriers to Generating and Using 
Data” and either “Roles in Information Sharing” or “Roles in Information Use.” This linkage is 
likely explained by respondent focus on describing specific challenges associated with the 
effective and efficient use and sharing of available information on AEs as they relate to adjuvant 
therapy. The fact that the code “Roles in Information Generation” was not equally prevalent in 
co-occurrence with “Barriers” is likely a result of the fact that very few stakeholders in this study 
described themselves as information generators (drug developers were most likely to 
characterize their role as data generators). It is interesting to note that within the drug 
development sector responses, there were numerous comments around barriers to generating 
novel data of relevance for characterizing AEs in adjuvant therapy. Yet the barriers cited by drug 
developers in this context were not routinely cited (if at all) by any of the other stakeholder 
groups in this study. Given the number of stakeholders that utilize the data generated by the drug 
development sector, this disparity could be symptomatic of a systemic gap in awareness around 
inherent challenges in generating new data and could signal the need for greater communication 
of these challenges across the stakeholder community. 
Summary and Application of Results 
This chapter provides novel insights into differential roles, perceived challenges, and 
proposed future action across the five stakeholder groups engaged in this study. As described 
above, each of these stakeholders holds a unique role in the ecosystem of effort associated with 
supporting patients on adjuvant therapy. Many of the future needs and challenges are aligned 
(e.g., need for greater engagement of patient preference in care decisions), whereas others were 
noted by only one or two sectors (e.g., need for novel nonclinical models to develop safety 
biomarkers for AEs). The perspectives reported in this chapter are anticipated to serve as an 
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important resource for those seeking to understand broad role differentials across the landscape 
and/or those seeking to build alliances on areas of mutual interest. A comprehensive discussion 
of cross-stakeholder challenges and opportunities, as well as priority areas for future action, is 




CHAPTER 5: CROSS-STAKEHOLDER RESULTS AND DISCUSSION—USE OF 
THEMATIC ANALYSIS TO IDENTIFY OPPORTUNITIES FOR CHANGE 
Overview 
This chapter evaluates cross-stakeholder alignment in recommendations and challenges 
regarding the use of AE information to improve cancer patient care (study sub-aims 3 and 4). 
The analysis complements the intra-stakeholder summaries in Chapter 4 with a comparative 
assessment of stakeholder views on systems-level trends, needs, accountabilities, and 
opportunities. A cross-stakeholder evaluation approach was chosen in support of the study’s 
objective of identifying systemic opportunities for improvement.  
The respondent perspectives synthesized in Chapter 4, and an inductive approach, were used 
to build cross-sectional themes relating to systemic challenges in the adjuvant therapy setting. In 
the discussion below, each of these themes is summarized with respect to those key messages 
that span across the stakeholders. To achieve the study goal of defining novel opportunities to 
realize systemic change, these syntheses are also compared with ongoing and proposed 
initiatives as described in Chapters 1 and 2 of this study. The resultant analysis reveals a 
previously unrecognized systemic gap. This novel finding is incorporated into a new conceptual 
model for the effective integration of AE information to improve cancer patient care and serves 
as the basis for the Plan for Change included here as Chapter 6.  
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Aligning Stakeholder Responses Against Common Themes 
After thorough and inclusive review of the stakeholder-specific perspectives on roles, current 
challenges, and future needs (Chapter 4), four inductive themes were developed. The application 
of inductive logic in qualitative research is characterized by the development of organizing 
themes and categories based upon a researcher’s review of open-ended responses from interview 
participants (Creswell, 2014). Inductive logic approaches also recognize the use of these themes 
to build novel theories and models.  
The following themes comprehensively represent the feedback captured in Chapter 4: 
• Information Resources. Stakeholder discussion of perceived data/knowledge needs and 
opportunities relating to the development or use of adjuvant therapy. 
• Integration and Implementation. Stakeholder discussion of perceived gaps and 
opportunities for improved use or synthesis of available information to guide the design, 
evaluation, or delivery of adjuvant therapy. 
• Value Systems and Culture. Stakeholder discussion of desired changes in cultural and 
financial value models that would beneficially impact adjuvant therapy development and 
delivery. 
• Alignment and Ownership. Stakeholder perspectives on the incentives, drivers, and 
coordination necessary for supporting proposed changes in the design or use of adjuvant 
therapy that would benefit cancer patient outcomes.  
Table 11 illustrates the thematic alignment of all of the current challenges (C) and future 
opportunities/needs (O) identified in bold text in Chapter 4, along with syntheses of the 
accountability/ownership discussions.  
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TABLE 11: Summary results: synthesis of stakeholder perspectives on alignment, 
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AE, adverse event; C, challenge; O, opportunity; PCMH, Patient-Centered Medical Home; PRO, 
patient-reported outcome; QoL, quality of life. 
The discussion that follows here provides a broad synthesis of the scope of recommendations 
within each of the four thematic areas and a high-level comparison of these recommendations 
with the findings in Chapters 1 and 2. 
Theme 1: Information Resources  
Challenges associated with the development of and access to patient and adjuvant treatment-
relevant data sets were among the most pervasive themes across all stakeholders. Most 
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stakeholders responded by citing data-related challenges or opportunities most relevant to their 
specific roles (see Chapter 4), although areas of overlap were not uncommon. Perhaps most 
predominant was a call to develop data that reflect “real-world” patient scenarios in the adjuvant 
setting, including considerations of long-term effects of treatment and the impact of patient 
comorbidities and polypharmacy. The prevalence of this recommendation stands in stark contrast 
to the far less common acknowledgment of technological and logistical challenges associated 
with collecting such information.12 The need for more consistent, rigorous, and accessible data 
reflecting PRO measures and calls for more rapid and extensive access to clinical trial data of 
relevance to adjuvants were also broadly recommended.  
Although Chapters 1 and 2 are not limited to the adjuvant treatment arena specifically, the 
future needs identified in these chapters directly mirror the above KII-derived perspectives with 
respect to information resources. For example, Chapter 2 concludes that “Future initiatives 
seeking to provide integrated information to patients and clinicians relating to therapeutic choice 
in cancer settings would benefit from incorporation of AE data of greater relevance to the ‘real-
world’ patient experience (i.e., ‘more patient-relevant information’).” It is important to note that, 
as described in Chapters 1 and 2, numerous ongoing efforts are seeking to address these gaps via 
investment of time, funding, and strategy. While the breadth and depth of feedback from the 
respondents suggests that current efforts are in some way (or many ways) failing to hit their 
mark, there can be no doubt that this thematic area is under active development and evaluation.  
                                                 
12Per Chapter 4, the drug development sector develops a significant majority of information on treatment-related 
AEs for adjuvants. However, those in the drug development sector also focused heavily on the scientific and 
logistical challenges associated with collecting data of relevance for some of the additional endpoints/scenarios 
recommended by many of the stakeholder groups. The drug development sector was also far more likely to discuss 
challenges associated with data generation than any other sector. 
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Theme 2: Integration and Implementation  
This thematic area captures multi-stakeholder struggles in combining complex, rapidly 
changing, and sometimes disparately constructed data sources to inform decision making or 
support information sharing. Integration and implementation are captured as a single thematic 
area, as discussions around a stakeholder’s ability to implement action were inextricably linked 
with discussions around processes for integrating information, resources, and preferences. 
To this end, many stakeholders specifically cited the need for improved tools and/or 
methodologies that would coalesce data on treatment efficacy, toxicity, cost, and impact on 
patient QoL in a way that would inform action. Although the context of use for such approaches 
varied depending on the stakeholder’s role (e.g., regulatory, payer, clinician, patient), the call for 
innovation was consistent. It is notable that not all stakeholders called for literal “tools.” 
However, each of the stakeholder groups in this study identified needs for more interdisciplinary 
approaches to informing care-related decisions and therapy development for adjuvants. A need 
for these types of integrative tools and approaches was also highlighted in Chapter 1 of this 
study. Chapter 1 includes a detailed discussion of the strengths and limitations of contemporary 
value frameworks that seek to address exactly these needs (Table 1).  
Other commonly cited challenges included technical challenges (how to get information into 
comparable formats, templates, and algorithms), bandwidth challenges (how to find the time to 
maintain currency with evolving data and best practices), and privacy/intellectual property 
challenges (limitations on sharing of data across groups because of potential to violate privacy or 
intellectual property rights). These challenges were observed to inhibit stakeholders’ ability to 
make optimal decisions, compare and contrast information sources, and/or innovate care 
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delivery. The majority of these challenges and limitations were also reported in Chapters 1 and 2 
of this study and are, to varying degrees, the subject of ongoing initiatives. 
Also of note was a call to more actively elicit patient preferences in making decisions around 
treatment or supportive care in the adjuvant therapy setting. Detailed recommendations as to how 
to calibrate treatment against a specific set of patient preferences were not offered. Interestingly, 
many of the stakeholder groups specifically cited challenges associated with having the time, 
resources, or expertise to facilitate the collection and integration of such preferences. As 
discussed in Chapter 1, the effective consideration of patient preference is a standing tenet of the 
“patient-centered care” philosophy. The stakeholder perspectives offered here not only provide 
support for the importance of these considerations, but they also demonstrate evidence of the 
need for continued effort to effectively realize this goal in practice.  
Theme 3: Value Systems and Culture 
This thematic area addresses the stakeholder calls for changes in cultural and financial value 
models that could beneficially impact adjuvant therapy development and delivery. The topics of 
cultural values and finance are grouped together because recommendations in this arena shared a 
focus on modulating societal conversations and expectations.13 Specifically, these discussions 
relate to proposed shifts in cultural expectations, social and financial structures, and/or personal 
versus societal “willingness to pay” for modified risk:benefit trade-offs. 
Many of the stakeholder groups identified a need to actively reconsider what they perceive to 
be the current societal “set-point” for an acceptable balance of risks versus benefits in the 
adjuvant therapy setting. The impact of a modified set-point was envisioned differently by 
                                                 
13Specific drug pricing issues, options, and alternatives were generally considered to be beyond the scope of this 
study. However, they are addressed here as they relate to overall access to care and reimbursement via payers. 
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different stakeholders. For example, regulators envisioned that such discussion could lead to 
altered future regulatory standards with novel mandates to lower toxicities associated with 
adjuvants relative to their potential preventative benefits. Some drug developers envisioned that 
a cultural shift in risk:benefit expectations could lead to novel financial demand or societal 
pressures driving the private sector to produce/support adjuvants with diminished toxicity 
profiles. Other stakeholders envisioned cultural shifts leading to more frequent and candid 
doctor-patient, clinician-payer, and patient-payer conversations around quality and quantity of 
life trade-offs (including the financial implications of such). Across all stakeholders, there was 
significant uncertainty as to how and where such culturally impactful conversations might be 
mediated.  
The cost of care, and payment models for supporting it, was also broadly cited as an issue to 
be tackled at a macro level. Some stakeholders asserted that the cost of treatment (particularly 
drug costs) is a barrier to treatment access and/or adherence for some patients. Stakeholders also 
commonly observed that traditional insurance and reimbursement models may be misaligned 
with the extended support needs of patients receiving or completing adjuvant therapy. As 
described in Chapter 4, several novel payment bundling models (e.g., OCM) are being explored, 
but cross-stakeholder calls for continued and expanded innovation in this arena were consistent 
in this study.  
As described in Chapter 1, the recent initiation of regulatory programs like the Patient-
Centered Drug Design effort at FDA, the launch of the federally mandated Patient-Centered 
Outcomes Research Institute (PCORI), private and clinical sector funding and focus on creation 
of shared decision-making models, the increasing prevalence of PRO data collection, and the 
innovation of payer models all suggest a broadening cross-sector discussion on the issues at the 
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heart of this thematic area. However, much like the prior three thematic areas, stakeholder 
feedback suggests that progress is both insufficient and fragmented.  
Theme 4: Alignment and Ownership 
This thematic area conveys perspectives on the incentives, alignments, and accountabilities 
necessary to meet the challenges noted in Themes 1–3.  
As described above, the cross-stakeholder feedback synthesized in these first three themes is 
largely valuable for its nuancing and reinforcement of previously established systemic 
challenges.14 In contrast, a synthesis of stakeholder views with respect to this theme reveals a 
critical and previously unrecognized aspect: The challenge of using AE information to more 
effectively inform cancer patient care is a challenge that lacks clear ownership. In various ways, 
all stakeholders questioned the assignment of responsibility and resourcing for both the 
collective and individual challenges described in this study. Per Chapter 4, many did discuss 
their sector-specific accountabilities. Yet they also acknowledged that successful realization of 
their broader objectives would require a currently nonexistent level of interactivity across 
stakeholder groups and focal areas. With respect to their proposed future actions, stakeholders 
alluded to the need for literal or figurative connectivity of content and effort across currently 
distinct silos. Consistently, they observed the absence of a clear framework to link these siloed 
efforts and philosophies. Many noted that these discontinuities and unclear accountabilities 
directly impacted resourcing. They pointed to the absence of either incentives or mandates to 
justify novel resource allocation for many of the cross-sector challenges identified in Themes 1–
                                                 
14Although many of themes in Chapter 5 were previously reported, it is notable that the intra-stakeholder analysis 
conducted in Chapter 4 revealed important and novel details around sector-specific roles, limitations, and objectives. 
The intra-stakeholder roles and drivers identified will provide useful guideposts for focusing future action and 




3 above. This theme was also observable in the code co-occurrence and code-differential analysis 
summary reported in Chapter 4, in which very few stakeholders commented on motivators to 
generating or using information and instead focused on the barriers.  
A New Conceptual Model and Next Steps 
The analysis above confirms three previously reported areas of strategic challenge (Themes 
1–3) and highlights a previously unrecognized challenge associated with the modified use of AE 
information to improve cancer patient care (Theme 4). A novel conceptual model (Figure 12) 
was developed to illustrate the current and potential future linkages between these four thematic 
areas and the defined systemic goal.  
As illustrated in Field A, and evidenced by the stakeholder-derived feedback, the 
development of novel information resources and implementation and integration approaches are 
often proximate, but rarely directly connected. Furthermore, discussions around value systems 
and culture appear to operate in a space that is even further disconnected from the latter two 
fields. As described by the stakeholders in this study, all three areas illustrated in green in Figure 
12 lack a defined linkage to each other and the broader goals of improving the use of AEs to 
inform cancer patient care. Field B illustrates how future incorporation of the stakeholder-
reported gap in defined alignment and ownership could promote enhanced progress toward the 
stated systemic goals for cancer care. Simply stated, to turn the crank in this system, a novel 
focus on alignment and ownership must be pursued.  
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FIGURE 12: Original conceptual model demonstrating the integral role of defined 
alignment and ownership in facilitating improved use of AEs to inform cancer patient care  
  
As illustrated in Field A, initiatives relating to information resources, integration/ 
implementation approaches, and value systems/culture considerations currently operate in a 
siloed manner without connectivity to other components aligned with achieving a broad goal of 
improved use of AEs. As illustrated in Field B, the inclusion of defined alignment and ownership 
provides the connectivity necessary to achieve the desired system goals. 
To the investigator’s knowledge, most prior publications on this topic have focused on the 
green components illustrated in Figure 12 with respect to proposed future action. As such, a 
future initiative to address issues around alignment and ownership is anticipated to provide a 
novel opportunity for systemic progress. A specific Plan for Change to address this opportunity 




CHAPTER 6: PLAN FOR CHANGE 
The practical challenge for a wicked problem is the tendency for the effort to 
become fragmented and fail.  
—Conklin, Basadur, & VanPatter (2007)  
Overview 
In this study, stakeholder groups (patient advocates, clinicians, regulators, drug developers, 
and payers) identified a number of specific inter and intra-stakeholder opportunities to improve 
the patient and societal benefit of the generation, dissemination, or use of adjuvant treatment-
related AE information (Table 11). These opportunities fell into the following major areas: 
Information Resources (e.g., approaches to generate or capture adjuvant-related AE information), 
Integration and Implementation Approaches (e.g., tools for or practices in which AE information 
is incorporated into decisions on drug design, regulatory approval, clinical care, supportive care, 
insurance coverage, patient-level treatment choices, etc.), and Value Systems and Culture (e.g., 
considerations of societal standards, willingness to pay, and risk:benefit tolerance associated 
with the delivery of adjuvant therapy and the support for patients who are/have received it). As 
illustrated in Figure 13, this study also revealed an additional systemic deficit. Ongoing efforts to 
address Information Resources, Integration and Implementation Approaches, and Value Systems 
and Culture lack the connectivity (e.g., alignment and ownership) necessary for them to 
synergistically achieve their collective objectives of improving patient QoL and health outcomes 
via eliminating or reducing adjuvant therapy-related AEs. To this end, the stakeholders 
uniformly highlighted the deficit of a lack of ownership for the cross-sector and cross-
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disciplinary issues associated with defining, managing, and/or reducing the impacts of adjuvant 
treatment-related AEs.  
FIGURE 13: Conceptual model driving the Plan for Change 
 
This chapter proposes an actionable plan to address this systemic limitation via construction 
of a new epicenter of “Alignment and Ownership.” The proposal is based upon published 
approaches for similar multicomponent public health challenges, published strategies for 
affecting broad systemic change, and the investigator’s 20 years of experience in coordinating 
and leading multisector collaborative initiatives. The stakeholders anticipated to engage in or be 
impacted by the proposed Plan for Change include those involved with drug design, regulatory 
standards, clinical care, healthcare insurance coverage, treatment decision making, supportive 
care services, and of course, patients and their families; however, other stakeholder groups may 
also find value in involvement. 
A Difficult Problem, But Not a Novel Construct 
Before building specific action plans to address this challenge, it is first useful to consider the 
broader literature on the strategic limitation of unclear alignment and ownership of a societal 
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problem. Diffuse and/or overlapping accountabilities are common hurdles to the resolution of 
those societal challenges sometimes referred to as “wicked problems.” Wicked problems, such as 
those identified in Chapter 5 of this study, are characterized by “multiple, overlapping, 
interconnected subsets of problems that cut across multiple policy domains… across hierarchy 
and authority structures within and between organizations” (Weber & Khademian, 2014). As 
such, the literature on wicked problems and their resolution is used here as a launching point for 
the development of an approach for forward action.  
The term “wicked problem” was introduced into the urban planning literature in 1973 as a 
means of describing societal challenges that defy linear planning and problem resolution 
approaches. According to the seminal article on this topic, such issues are characterized by the 
complexity of “locating problems (finding where in the complex causal networks the trouble 
really lies)… [and] identifying the actions that might effectively narrow the gap between what-is 
and what-ought-to-be” (Rittel & Webber, 1973). Wicked problems touch a diverse and often 
divergent set of stakeholders and vested interests. In wicked problems, such as the one that is the 
focus of this study, stakeholders internalize different views of the overall problem(s) and often 
struggle to define coordinated interventions and resourcing toward resolution (Crowley & Head, 
2017; Head & Alford, 2015; Innes & Booher, 2016; Weber & Khademian, 2014). In sum, the 
alignment between the types of challenges that surfaced in this study and the classical definition 
of “wicked problems” is very strong.  
The theoretical and applied literature on approaches for addressing the hurdle of unclear 
“accountability and alignment” in the context of wicked problems is extensive. This literature 
describes a diversity of policy, management, economic, sociobehavioral, and governance 
approaches and considerations. An unstructured survey of the literature was conducted to 
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identify the most prominent considerations of relevance to this study. These findings and their 
relevance to the construct of an actionable plan to improve the use of AEs in informing cancer 
patient care follow below.  
Cross-Sector/Cross-Disciplinary Initiatives Are Essential for Addressing Wicked Problems But 
Are Also Inherently Challenging 
A call for cross-sector and cross-disciplinary networks or collaboratives to build alignment in 
addressing wicked problems resounds across the literature (Head & Alford, 2015; Hearld, Bleser, 
Alexander, & Wolf, 2016; Norris, O’Rourke, Mayer, & Halvorsen, 2016; Van Tulder & Keen, 
2018; Waddock, Meszoely, Waddell, & Dentoni, 2015). Such networks are, not surprisingly, 
identified as critical opportunities to better define cross-stakeholder problems, build agreement 
on potential solutions, and promote shared resourcing and implementation.  
As one researcher noted, “Collaboratives will be more attractive relative to independent 
organizations or markets when the degree of ambiguity regarding the intervention(s)/solution(s) 
is high (e.g., multiple technologies or disparate industry inputs required, complex sequence of 
actions needed)” (Hearld et al., 2016). Because the issues at the heart of this study are inherently 
ambiguous, cross-sectoral, and cross-disciplinary, the creation of a novel networking opportunity 
that links all stakeholders initially appears as a ripe opportunity. At present, there is no 
consolidated forum or nexus for interaction for stakeholders to address the breadth of issues 
identified in Table 11.  
However, the investigator’s experience in designing and managing cross-sector consortia—
and the published literature—provides reason for caution. An effort to coalesce all of the 
stakeholders and ongoing efforts into a unified and hierarchically managed collaborative would 
surely be infeasible, unwieldy, impractical, and as likely to slow progress as expedite it. As one 
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practitioner warned, “Don’t collaborate unless you have to!” (Huxham & Vangen, 2006). The 
specific recommendations to follow here will thus focus on the promotion of novel alignment 
and interaction across the stakeholders in ways that do not involve top-down command and 
control or forced interactions across stakeholders. 
Defined Facilitation and Collaborative Capacity Building Roles Are Essential 
Many publications identified the critical importance of skilled and vested staff to facilitate 
interactions across stakeholders that are (or should be) engaged in tackling wicked problems 
(Bryson, Ackermann, & Eden, 2016; Head & Alford, 2015; Weber & Khademian, 2014). 
Typically, these individuals were envisioned as neutral conveners (not top-down directors) and 
“collaborative capacity builders” with expertise in problem formulation, team building, 
facilitation, communications, and administration. Adaptive leadership skills (e.g., building on the 
efforts, interests, and skills of subsidiary teams to inform the overall leadership/management 
strategy) were cited as key attributes in this setting (Northouse, 2016). Opportunities to leverage 
effective capacity builders for both top-down and more loosely interconnected cross-stakeholder 
efforts were noted.  
To address the unmet needs around alignment and accountability identified in this study, the 
initiation of some type of collaborative capacity building staff (or facilitator) role will likely also 
be important. The investigator’s 20 years of experience in consortia management/coordination 
also supports the essentiality of these roles. The specific Plan for Change below clearly defines 
the scope and accountability for facilitation/capacity building roles at multiple stages of the 
proposed project process.  
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There Is No Perfect Approach for Translating Collaborative Interactions Into Systemic 
Change  
Although a systematic review is beyond the scope of this study, a preliminary review of the 
literature suggests that there is no consensus on ideal approaches for translating multi-
stakeholder interactions into actionable initiatives to address wicked problems. Among the many 
concepts proposed were recommendations to convene advisory team meetings to define and 
coalesce around efforts with shared goals, to identify incentives and reward structures to promote 
continued collaborative engagement from across diverse stakeholders, to create platforms for 
pooling budgets, and to establish opportunities for iterative problem formulation efforts that 
reflect the fluidity of issues, resources, and information associated with wicked problems 
(Bryson et al., 2016; Innes & Booher, 2016; Norris et al., 2016). Some offered suggestions for 
specific methodologies to facilitate these objectives. For example, one group proposed that 
Theory of Change15 models could be developed as a resource to promote “dialogue about how 
and why proposed actions will generate desired outcomes… and greater confidence in attributing 
subsequent changes to previous specified actions” (Van Tulder & Keen, 2018). These authors 
noted both the potential and challenges in applying this relatively linear approach (a + b =c) to 
highly complex systems like those inherent in cross-stakeholder wicked problems. Others 
described the use of stakeholder mapping (“collaborative goal mapping”) to create visual maps 
to illustrate how stakeholders view their perceived roles, audiences for their efforts, and their 
linkages with both other stakeholders and the broader systemic objectives (Bryson et al., 2016). 
The lack of consensus around best practices could convey a failure to conduct data-driven 
                                                 
15Theory of Change models are used to build collective understanding of the way in which different interventions 
and initiatives are predicted to impact the overall systemic objective (Funnell & Rogers, 2011). 
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evaluations of the effectiveness of different approaches, insufficient collective experience in 
exploring different methodologies, and/or a practical reality that approach selection is inherently 
situational (and perhaps there is no “best” practice).  
Collectively, this literature, as well as the experience of the investigator, provides support for 
construction of a plan for change that can be nimble with respect to the promotion of interactions 
across stakeholders. The specific plan below will describe a phased approach that incorporates 
the potential for modulating objectives and opportunities.  
Resources to House Collaboratives, Hire Capacity Builders, and Execute Cross-Stakeholder 
Efforts Are Critical But Elusive 
Ironically, and unfortunately, the same literature that identifies resource allocation 
uncertainties as a critical challenge in addressing wicked problems broadly fails to adequately 
identify or acknowledge gaps in resources for executing the types of remedial approaches 
described above. The need to procure resources to fund a capacity builder or facilitate a 
“stakeholder mapping” meeting is woefully under-recognized in these papers. Similarly, these 
publications tend to omit discussion of practical approaches for building resourcing for future 
efforts.  
To improve alignment and accountability with respect to the use of AEs in cancer patient 
care, it will be essential to not only propose novel interactive forums but also to identify 
sustainable resourcing for their execution. The proposal that follows below offers a strategic 
approach to address this critical component. 
The following Plan for Change will build on the specific recommendations in Chapter 5 and 
incorporate the following elements: 
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• Creation of novel opportunities to enhance ownership of the systematic challenges 
and promote cross-stakeholder alignment, interaction and synergy; 
• Identification of individuals or organizations with resources and expertise to build 
collaborative capacity across stakeholders; 
• A flexible, fluid, and evolutionary approach to selecting and executing cross-
stakeholder activities and areas of strategic focus for inter- and intra-stakeholder 
tactical efforts; and  
• A defined resourcing and incentives strategy to support the three components above. 
Initiating Focused Change 
The following plan for action seeks to address this wicked problem based on lessons learned 
from the wicked problem literature (see above), the investigator’s 20 years of experience in 
designing and facilitating collaborative programs, accepted practices for program design and 
evaluation, other collaborative models applied in the cancer space such as the White House 
Cancer Moonshot initiative, and a published framework designed to help create environmental 
conditions that are favorable for systemic change (Foster-Fishman & Watson, 2012; White 
House, 2016; Wholey, Hatry, & Newcomer, 2010).  
The specific change framework chosen to help guide this plan for action is the ABLe Change 
Framework (Foster-Fishman & Watson, 2012). The ABLe Change Framework is a model 
developed to inform the design and implementation of system or community change efforts. 
While it is not specific to wicked problems, the model was selected for its specific focus on 
facilitating the environment for change (referred to as “below the line” focal points by the 
model’s authors), not just the resourcing of specific tasks. The ABLe Change Framework 
describes four areas that should be addressed when readying an environment for change: 
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readiness, capacity, diffusion, and sustainability. The Plan for Change that follows here 
incorporates each of these elements as summarized in Table 12 and further described in detail 
below.  
TABLE 12: Application of selected ABLe Change Framework elements to the  
proposed Plan for Change 
ABLe Change Framework 
factors for readying the 
environment for change  
Implementation in this Plan for Change 
Readiness: This factor 
emphasizes the importance of 
working with system actors to 
promote the belief that “change 
is necessary, feasible, and 
desirable.” 
In this plan, a leadership team will serve this role by 
conveying the overall mission and encouraging other 
stakeholders to believe in its potential to be realized 
successfully through collaborative effort. This group will 
communicate specific strategic objectives that may benefit 
from collective effort. (Steps 1 and 2) 
Capacity: This factor relates to 
improving our understanding 
of how and which problems 
“emerge from current system 
characteristics.”  
In this plan, a set of defined opportunities and challenge 
areas will be agreed upon and published for access by 
stakeholders, as will opportunities to better understand how 
these problems relate to the overall system of information, 
accountability, and resourcing. (Step 3)  
Diffusion: This factor relates 
to the “promoting broad scale 
awareness of change effort 
across system actors” and 
encouraging stakeholders to 
take new action. 
In this plan, a series of communication efforts and incentives 
will be defined to create new systems of stakeholders and 
incentivize novel action. (Steps 4 and 5)  
Sustainability: This factor 
relates to maintaining 
“policies, practices, and 
changes” wrought by an effort. 
This plan contains approaches to address sustainability and 
resourcing. The plan defines and encourages changes that 
are tactical and achievable as discrete programmatic 
initiatives and incorporates approaches to evaluating the 
programmatic effectiveness. (Steps 5 and 6)  
However, it also incorporates efforts to raise awareness of 
issues and opportunities that would otherwise fall between 
the cracks of accountability and resources via the actions of 
the leadership team. (Step 4)  
 
The investigator proposes to launch this strategic Plan for Change via her role as executive 
director of the Health and Environmental Sciences Institute (HESI). HESI is an international, 
nonprofit organization that serves as a neutral facilitator of scientific collaborations across 
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academe, government, clinical medicine, nongovernmental organizations, and industry and has 
decades of history in international initiatives to enhance the safety and efficacy of medicines. 
The organization has been growing its activities in the oncologic therapy safety arena under the 
investigator’s leadership and has the support of the organization’s Board of Trustees to continue 
to do so.  
Proposed Implementation Strategy 
The strategy below consists of six major steps as follows: 
• Step 1: Assign the Name and Mission. This step involves the creation of an overall 
organizational mission to guide the collaborative and creation of a name for the 
proposed program of work. 
• Step 2: Form the Leadership Team. This step involves identifying and engaging a 
leadership team that is motivated to contribute time and resources to the 
collaborative’s mission.  
• Step 3: Define Systemic Needs. This step requires the elucidation of both tactical 
and strategic challenge areas/needs that must be addressed to realize the mission.  
• Step 4: Initiate Leadership Team Outreach. This step will engage the leadership 
team in catalyzing the mission through their actions as individual entities and through 
combined efforts as a collective team.  
• Step 5: Involve Other Stakeholders. This step engages a broad base of stakeholders 
to contribute to addressing the challenges identified at Step 3 and to proactively align 
their roles with the overall mission. 
• Step 6: Evaluate the Program. This step, to be conducted as the program evolves, is 
intended to inform refinements to the design and implementation strategy. 
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The specific implementation of these steps follows below. 
Step 1: Assign the Name and Mission  
As a means of grounding the strategy and addressing the ABLe Change Framework 
“Readiness” factor, the initiative will be given a proposed name and mission statement: the 
Adjuvant Care Together (ACTogether) effort. ACTogether is envisioned as a new “community 
of commitment”16 that will focus awareness and resources on the challenging issues identified in 
this study:  
The mission of ACTogether is to improve quality of life for patients who are 
receiving or have received adjuvant therapy by enhancing our ability to 
understand, address, support, and convey benefits and risks of alternative 
approaches.  
The mission statement is anticipated to play a critical role in this strategy as it will serve as a 
common currency to bridge otherwise disconnected teams and initiatives. (Note: As the mission 
statement is only “proposed” at Step 1, it is anticipated that once the leadership team is formed 
they will further discuss and potentially refine/modify the mission statement as noted in Step 3 
below. The development of a draft mission statement/name before convening a leadership team 
is proposed as a means to facilitate outreach to potential leadership team members.) 
Step 2: Form the Leadership Team  
As identified in the wicked framework literature and the ABLe Change Framework, a team 
of collaborative capacity builders must be formed in order to tackle otherwise “unowned issues” 
and bring readiness, resources, connectivity and catalytic energy to systemic change efforts 
                                                 
16The term “community of commitment” was initiated by Kofman and Senge in 1993 in reference to the need to 
build systems that foster learning and personal interaction across otherwise fragmented individuals and efforts 
(Kofman & Senge, 1993). 
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(Foster-Fishman & Watson, 2012; Weber & Khademian, 2014). This de novo leadership team 
will serve as the proactive facilitator, program evaluator, and leading voice for the ACTogether 
initiative. As noted above, the investigator and her organization, HESI, are expected to initiate 
formation of a leadership team. Populating the team with additional leaders (and maintaining 
HESI’s organizational support for the investigator’s efforts) will require a balance of strategy 
and pragmatism.  
The leadership team should reflect the core strengths of the program: robust technical and 
reputational credibility, strong programmatic and strategic skills, operational flexibility, 
representation of the ACTogether stakeholder landscape, and a commitment to the ACTogether 
mission. Based on the professional experience of the investigator and recommendations from 
other business and government sector sources, an initial steering team of four to six individuals is 
proposed (Ohio Office of Budget and Management, n.d.; Wharton School of Business, 2009). 
Although there is some literature suggesting that steering teams should consider including 
representatives from all of a program’s stakeholders, given the potentially huge stakeholder base 
and limited resources, it is proposed that the initial team be composed of leaders who in 
themselves span multiple stakeholder groups (HBR Staff, 2016).  
For the ACTogether program, there is neither a top-down directive to mandate leadership 
participation nor is there stimulatory funding. As such, leadership team members will need to see 
value for their in-kind and financial resource support for the effort. Potential leadership team 
members are expected to be motivated to join because they both believe in the program mission 
and expect to realize an immediate or future benefit by stepping forward in a leadership capacity 
(Northouse, 2016). For example, organizations seeking to broaden or reinforce their perception 
as a community thought-leader in the cancer or patient care arena may choose to contribute in 
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this role. The reputational benefits (e.g., public relations value) of stepping forward on an 
“unowned” wicked problem may be enticing for some. Reputational benefits can bring returns 
such as new partnerships, increased engagement in ongoing efforts, enhanced credibility, and so 
forth. These reputational and thought-leadership benefits are of significant value to the HESI 
organization and will be used to justify resource allocation as a leadership team member. It is 
also possible that the investment of time, funds, and/or staff into leadership on the ACTogether 
problem could result in direct financial returns to a participating organization. For example, 
visibility as an ACTogether leadership team member may make that organization a stronger 
candidate to receive funding in areas within the ACTogether mission.  
Additionally, organizations that have already invested in efforts related to the ACTogether 
mission may perceive value in the potential to better leverage these efforts by promoting a more 
connected and resourced system overall. For example, participation in ACTogether may allow 
stakeholders to demonstrate to funders that their investments are made more efficient by literal or 
topical connectivity with other efforts to drive improved systemwide outcomes.  
Based on these criteria and the investigator’s professional experience and contacts, the 
following organizations are anticipated to be potential candidates for leadership roles. (Note: 
This list is exemplary, not exhaustive. The organizations noted here have not made any defined 
commitments at this time.)  
• Health and Environmental Sciences Institute (HESI). This organization is a 
nonprofit with decades of experience in facilitating collaborative science across 
stakeholders and has a growing strategic focus on cancer therapy safety issues. HESI 
participation brings a strong engagement of scientists from the pharmaceutical, 
regulatory, clinical, and research sectors. As noted above, HESI will commit to 
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providing initial staffing and financial resources to convene and facilitate the 
leadership team, launch and maintain the ACTogether website, and lead the initial 
metrics and evaluation process for ACTogether (further details on this at the end of 
the chapter). 
• Biden Cancer Initiative (BCI). The BCI is a high-profile and recently founded 
nonprofit organization dedicated to serving a convening role on a broad range of 
cancer research and treatment issues in follow-on to the previous U.S. federal Cancer 
Moonshot program. HESI is a recognized partner of the BCI as of September 2018, 
and the investigator has strong points of contact within the BCI program staff and its 
advisory boards. A core component of the BCI mission is to serve as a high-visibility 
platform to elevate and catalyze the work of important, but less visible, initiatives. 
BCI’s stakeholder base is very broad and includes patients, patient advocacy groups, 
government agencies and funders, payers, researchers, clinicians, and private 
industry. 
• Ellison Institute for Transformative Medicine. The University of Southern 
California Lawrence J. Ellison Institute for Transformative Medicine is a leading 
research and clinical center that seeks to conduct research on cancer therapies, 
develop best practices in therapeutic treatment, and promote systemic change in 
cancer care to benefit patients. Leaders of the institute are active as senior advisors to 
the BCI and HESI organizations. The Ellison Institute’s participation would bring 
active clinical and research expertise. 
• National Patient Advocate Foundation (NPAF). This patient-focused nonprofit 
seeks to build and implement innovative policies and programs that recognize and 
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elevate patient perspectives and challenges across a broad range of health issues. 
Leaders in the NPAF are engaged as advisors on HESI’s cancer therapy safety 
programs and in a variety of national cancer patient QoL initiatives.  
• Additional leadership team members from the pharmaceutical sector (possibly from 
the PhRMA Foundation), clinical sector (e.g., ASCO), regulatory sector (possibly 
from the Oncology Center of Excellence at FDA), and payer sector may also be 
useful additions to the team, and their additions could be the subject of initial 
discussions with the stakeholders above. However, the broad scope of the initial 
leadership team above provides for an initial capture of all of these arenas and is thus 
anticipated to be a viable and manageable starting point for this new effort. 
Step 3: Define Systemic Needs 
In order to focus efforts within the ACTogether framework and better understand how and 
which problems “emerge from current system characteristics,” a set of defined gaps and 
opportunities will serve as the focal point for a systemic call to action (Foster-Fishman & 
Watson, 2012). As a means of launching the ACTogether effort, and building upon the research 
conducted in this study, the stakeholder-derived challenges and opportunities identified in 
Chapters 4 and 5 (summarized in Table 11) will be used as a starting point (i.e., “ACTogether 
challenge areas”). As the HESI organization proposes to take the lead in launching this program, 
they are anticipated to commit financial resources for initial convening of the leadership team to 
discuss and build consensus on the challenge areas and draft mission (e.g., multiple web 
conferences and possibly one in-person meeting to facilitate reaching consensus).While 
agreement on the challenge areas will be important, the list is intended to be directional and not 
exhaustive. Refinements in the challenge areas are expected over time. 
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Step 4: Initiate Leadership Team Outreach  
A primary goal of the ACTogether leadership efforts is to promote the expansion, 
perpetuation, or initiation of activities that are responsive to the challenge areas. This step meets 
the ABLe Change Framework’s recommendation to promote “broad scale awareness of the 
change effort across system actors” (Foster-Fishman & Watson, 2012). Leadership team 
members will be expected to pool resources (financial, staff, websites, social media accounts, 
etc.) to support communication, strategy, and networking efforts toward this objective. The 
efforts of the leadership team are expected to contribute to both direct changes (e.g., enaction of 
new research or programmatic work) and to the creation of an environment that is more aware of 
and conducive to making progress toward the ACTogether goals. A diagrammatic representation 
of the actions and impacts of Steps 4 and 5 follows here in Figures 14 and 15. 





FIGURE 15: Changes in overall environment resulting from ACTogether  
  
Having agreed upon the challenge areas, the leadership team will initiate its external 
activities as follows: 
Launch of the ACTogether web page. This page/site will describe the mission, leadership 
team, and challenge areas and will be resourced and hosted by HESI.  
Publicize a “call to action” and recruit named supporters. The leadership team will 
collectively design and execute a “call to action” to encourage other stakeholders to align their 
efforts with ACTogether challenge areas. This public “call to action” will define the need for and 
mission of ACTogether and call upon stakeholders to voluntarily align their current or planned 
efforts with the ACTogether challenge areas. Stakeholders will be encouraged to bring visibility 
to their efforts—and the overall ACTogether mission—by signing a noncontractual program 
commitment letter for 2019–2021. A sample of this commitment letter is included as Appendix 
G. Although this letter does not elicit binding commitments, nor does it commend enforcement 
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by the ACTogether leadership team, this model is anticipated to promote progress toward the 
ACTogether mission. Similar voluntary and unenforced commitment models have been used to 
great success in other initiatives in which binding commitments and enforcement would be 
programmatically stifling and economically infeasible. For example, the White House (2016) 
Cancer Moonshot achieved unfunded outcomes by calling on groups to make voluntary 
commitments to enhancing the pace of cancer research. Further, the Center for Open Science 
(https://cos.io/our-services/top-guidelines/) changed the practices of hundreds of scientific 
journals and researchers by asking signatories to make voluntary commitments to sharing 
scientific information, protocols, and so forth in compliance with the center’s recommended 
guidelines. For more detailed discussion on why stakeholders might choose to participate in as 
signatories, see Step 5 below.  
Publicizing the call to action could be achieved through a variety of mechanisms and may 
benefit from a multipronged approach. For example, a published commentary in a high-profile 
journal of relevance to the cancer community (e.g., Journal of Clinical Oncology) would raise 
visibility and create a resource that can be cited by others. This call to action should also be 
communicated via the proposed ACTogether website/web page, along with the social media and 
other communication platforms used by the leadership team members. This multicomponent 
outreach strategy is expected to be beneficial given the diverse stakeholder base (e.g., patients, 
advocacy groups, regulators, payers, clinicians, drug developers, academic researchers, funders, 
legislators, etc.) targeted by this initiative. The leadership team should periodically review and 
refine the alignment between their intended audiences and the outreach approaches that are 
undertaken. A discussion of a proposed metrics and evaluation approach is addressed in Step 6. 
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Collectively execute strategies that promote progress in otherwise unowned issues (e.g., 
alignment and ownership issues identified in Table 11). The challenges described in the 
“Alignment and Ownership” column in Table 11 will serve as the basis for novel collective 
action by the leadership team. These actions will be critical to the success of this program 
because they bring resources and visibility to issues that would otherwise fall “between the 
cracks.” Per the ABLe Change Framework, providing support for such issues that would 
otherwise go unattended is critical to creating an environment in which change in sustainable 
(Foster-Fishman & Watson, 2012). Practically, the leadership team is not initially anticipated to 
have the funding or remit to actively resolve any of these issues. However, public discourse on 
these issues is so nascent that simply creating opportunities for stakeholders to provide 
perspectives and debate priorities is itself a meaningful forward step. For example, the leadership 
team may propose to convene stand-alone workshops or panel/symposium discussions at 
scientific conference (e.g., ASCO, American Association for Cancer Research, American 
Association for the Advancement of Science, etc) that focuses experts on issues such as the 
following:  
• “What is an acceptable ‘burden of treatment’ for potentially curative adjuvant 
oncology therapies?”  
• “Should regulatory systems ever re-evaluate societal risk versus benefit tolerances for 
adjuvant therapies and, if so, why and how?”  
• “What incentives or information would encourage drug developers/researchers to 
design second-generation adjuvant therapies and what hurdles would disincentive it?” 
• “Who is/should be/can be responsible for and proficient in collecting information on 
long-term patient outcomes following adjuvant therapy?”  
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• “Beyond data generation, who is responsible for data dissemination to different user 
groups and/or data conversion into formats that are understandable and/or useful for 
those groups?”  
Funding for this effort might be contributed by the leadership or could be solicited as a grant 
from organizations such as PCORI, which offers “convening” grants for workshops. Similarly, 
these discussions could be elevated to the public domain via a series of published commentaries 
written by the leadership team and/or by invitation of guest authors to respond to questions or 
themes posed by the leadership team.  
The goal of these efforts is to raise cross-stakeholder awareness of issues, structures, and 
needs that fall between traditional disciplinary, funding, and/or governance lines. The hope is 
that by promoting awareness, it may spur discussion of potential solutions and potentially 
encourage the commitment of new resources or launch of new collaborations. These efforts 
could also, over time, help change the landscape in which other efforts are undertaken, such that 
resource procurement for those efforts is less challenging (i.e., it may be easier to make the case 
for funding for any given program if the overall context of need is more clearly defined).  
Leadership team members will be expected to pool resources (financial, staff, websites, 
social media accounts, etc.) to support communication, strategy, and networking efforts toward 
this objective.  
Each leadership team member will independently initiate and/or resource at least one 
new activity in support of one of the challenge areas. A commitment to adopting one or more 
activities in support of the challenge areas will be defined as a prerequisite for membership on 
the leadership team. These tactical efforts will be essential to demonstrating leadership via action 
and will provide opportunities to realize near term (1-3 years) progress. The demonstration of 
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near term progress is an important component of maintaining collective interest in change efforts 
(Kotter, 2007) Examples of near-term ‘wins’ that might be pursued by the leadership team 
(and/or the broader stakeholder group to be engaged in Step 5) are described below. These are 
not exhaustive and are provided for illustrative purposes. 
In the area of ‘information resources’: A consortium could be launched to better define 
collaborative approaches for sharing adjuvant drug safety information generated by drug 
developers/other researchers and by aligning data collection with clear contexts for use of the 
information in safety decision-making. This effort could include collating data on AEs, models, 
or experimental approaches and in the near-term could be anticipated to generate novel shared 
learnings. (Note: it is anticipated that the investigator’s organization (HESI) may contribute 
(and elicit funding for) staff time and databases that will facilitate this effort.)  
Other achievable near-term actions could include the development of evidence-based case 
studies demonstrating similarities and differences in AE nature, scope, and frequency reports in 
clinical trials versus standard of care settings for specific adjuvant treatment scenarios, the 
engagement of pharmacies to collect data on prescription adjuvant use rates and adherence (as 
measured by prescription fulfillment), or the compilation of a public data repository to centralize 
published studies on benefits (or lack thereof) of ‘wraparound’ services in mitigating the impact 
of treatment-related AEs. 
In the area of ‘integration and implementation’: Near-term achievable approaches could 
include the initiation of a patient advocacy/pharma joint advisory group to develop actionable 
recommendations for integrating the ‘patient perspective’ in drug development. Patient-advocate 
and clinician led stakeholder teams might develop and implement a novel outreach and 
educational seminar series targeted at a broad range of audiences (e.g., research, regulatory, 
 
136 
clinical) to raise awareness of and elicit input on the assessment of ‘burden of treatment’ in the 
adjuvant setting. 
In the area of ‘value systems and culture’: Near-term actionable approaches could include 
development of a proposal to initiate an ‘Adjuvant Safety and Efficacy’ workstream within the 
existing FDA Oncology Center of Excellence. If such a proposal were adopted into the existing 
Oncology Center of Excellence, it could serve as a platform for facilitating novel regulatory 
conversations around risk:benefit and cultural values. The proposed AACR workshop series 
described above could also facilitate this objective in the near term. Other possibilities include 
the engagement of stakeholders not directly included in this study such as health 
economists/healthcare think tanks to develop case studies and build recommendations to better 
define the ‘value’ of AEs to patients, providers, payers, etc. in a way that promotes access to 
improved information and care.  
Of course, there are endless additional tactical and strategic opportunities that might be pursued 
in both the short and longer terms. These examples are offered as possibilities that could help achieve 
some of ACTogether’s objectives and realize observable impacts in the relatively near term. 
Step 5: Involve Other Stakeholders  
As illustrated in Figure 14 and described above, the leadership team efforts seek to mobilize 
and synergize the effort of a broader stakeholder base toward realization of the ACTogether 
mission. These stakeholders include patients and patient advocates, clinicians, regulators, 
government research centers, academia, industry, foundations, professional societies, payers, and 
so forth. Just as the leadership team members can be expected to act with a combination of self-
interest and mission-interest, the same is true for ACTogether’s stakeholders. The following 
outcomes might be expected.  
 
137 
Extension, expansion, redirection, or initiation of ACTogether-relevant efforts by 
stakeholders who choose to align with the effort as signatories. The opportunity to gain 
public recognition and reputational benefits as a signatory may motivate some stakeholders to 
extend, expand, redirect, or initiate ACTogether-relevant efforts. In the proposed model, the 
signatories are not contractually bound to demonstrate results or meet any specific expectations. 
Although some stakeholders could seek to leverage reputation benefit as a signatory without 
expanding or committing resources, the downside risks to the ACTogether are low and 
outweighed by the potential benefits. If program resources were expanded at a later date, the 
implementation of a curated signatory program could be pursued.  
Extension, expansion, redirection, or initiation of ACTogether-relevant efforts by 
stakeholders who do not align with the effort as signatories. It is expected that not all 
stakeholders who are influenced by ACTogether outreach will chose to become a signatory. 
Stakeholders who opt not to sign on as supporters may feel that the nonbinding commitment 
lacks rigor or utility, may lack the organizational authority to sign such statements, may find the 
statement too limiting or burdensome, may not wish to formally associate with other 
ACTogether stakeholders, or may just not want to bother. However, it is plausible that those 
entities might choose to take action in support of ACTogether even without becoming a 
signatory. The publication of the “call to action” and challenge areas may be valued as a frame of 
reference for stakeholders who are already resourced to work in the adjuvant arena or are 
pursuing resources in these areas. These stakeholders may value ACTogether’s specification of 
key needs (and their role in facilitating systemic change) as a citable resource to inform 
stakeholder project design, funding prioritization, grant applications, and so forth.  
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Diffusion of the ACTogether mission and culture. The development of a list of signatories 
committed to ACTogether may aid in communicating the mission, as it is reasonable to expect 
that those signatories will do some of their own “advertising” of their role in the initiative. This 
novel community could also serve as a network to spur new opportunities for collaboration, to 
recommend new challenge areas, and to achieve the goal of changing the overall environmental 
awareness. 
Step 6: Evaluate the Program  
As part of the program launch, the leadership team will be responsible for designing and 
overseeing a manageable metrics and evaluation process for ACTogether, with staffing support 
from HESI. Because resources for this effort will be limited, the evaluation is envisioned as a 
relatively high-level exercise to be conducted during the course of the first 2 years of the 
program. The proposed goal for this effort is to generate sufficient information to inform 
leadership discussions on necessary refinements to the strategy, with a goal of enhancing 
ACTogether’s reach and impact. This effort also addresses the goal of maintaining effective 
policies and practices as commended by the ABLe Change Framework (Foster-Fishman & 
Watson, 2012). The Centers for Disease Control and Prevention (CDC) evaluation framework 
(Figure 16) is proposed as a guide for this evaluation (CDC Evaluation Working Group, n.d.).  
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FIGURE 16: Overview of the Centers for Disease Control and Prevention  
Framework for Program Evaluation 
 
Per the CDC framework, it is proposed that the leadership team members act as the 
“stakeholders” for the initial program evaluation. Much of the content in this project plan can 
serve to “describe the program.” The largest challenge will be to focus the evaluation design and 
decide upon the evidence to be collected.  
A sample outputs, impacts, and metrics table is offered below to illustrate what might be 
collected and evaluated in the first 2 years of the program that meets the CDC’s call to collect 
metrics that have utility, feasibility, propriety, and accuracy (Table 13). It is notable that, with 
the current level of resourcing, tracking the launch and impact of specific new efforts in relation 
to the challenge areas is beyond the scope of this inaugural ACTogether effort (e.g., not feasible 
and likely not accurate). However, by collecting and reviewing the metrics described below, the 
leadership team should be positioned to understand how the program is progressing in achieving 
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the impacts described below, and to use these learnings to inform future strategy/design of the 
program. Iteration of this evaluation approach on an annual or bi-annual approach is 
recommended. If expanded resources for the program administration and leadership become 
available, an expanded evaluation and metric collection approach may be both feasible and 
appropriate.  
TABLE 13: Anticipated program activities, impacts, and metrics that could be collected  
in an initial metrics and evaluation effort for ACTogether 
Program activity Potential impacts Metrics 
Publication of “Call to 
Action” 
Visibility for program and mission 
Incentives to act 
Creation of a reference 
Reference for the publication 
Citations of the publications by others 
(published or otherwise) 
ACTogether website 
launched  
Visibility for program and mission 
Incentives to act 
Creation of a reference 
Creation of a focused community 
of practice 
Date of website launch 




media, websites, e-mail 
communication, etc.) 
Visibility for program and mission 
Incentives to act 
Types of approaches used for outreach 
Intended/anticipated audiences (who 
they are and if possible, how many) 
ACTogether workshop 
or panel discussions on 
“unowned” issues 
around adjuvants 
Visibility for program and mission 
Novel public discussion on 
unaddressed issues 
Changes in stakeholder perception 
of needs 
Incentives to act or provide 
resources 
Progress toward the ACTogether 
mission 
Dates, locations, and audiences for 
workshops 
Anecdotal feedback following the 
workshops 
Survey to workshop participants to 
elicit feedback 
Types of organizations who attend (to 




Signatories commit to 
ACTogether mission 
Visibility for program and mission 
Progress toward the ACTogether 
mission 
Creation of a community of 
concern 
Number of signatures 
Signatory reports on the projects they 
will undertake (per the commitment 
letter)  
Types of signatories (which sectors, 
which topical areas, etc.) 
Rate of signatory additions 
Examples of signatories who 
reference the ACTogether program in 
other public forums/documents 
Anecdotal feedback from signatories. 
Stakeholders launch or 
expand efforts aligned 
with the challenge areas 
Progress toward the ACTogether 
mission 
Novel resourcing or prioritization 
of ACTogether issues 
 
Funding provided to ACTogether 
leadership or novel ACTogether 
efforts 
Anecdotal reports by stakeholders 
Signatory reports on the projects they 
will undertake (per the commitment 
letter)  
Publications or communications that 
reference ACTogether as a driver for 
efforts 
Launch of new work that cites 
ACTogether as driver 
 
Conclusion 
The Plan for Change described in this chapter proposes a strategic approach for driving 
progress in the improved the use adjuvant-related AE information to improve cancer patient care. 
Opportunities to actively implement this plan are currently under exploration by the investigator, 




 APPENDIX A: OUTREACH SCRIPTS FOR KEY INFORMANT INTERVIEW 
PARTICIPATION 
E-Mail Outreach Script for Key Informant Interview Participation 
This e-mail template was used as a guide for initial outreach to proposed interviewees, 




My name is Syril Pettit and I am a doctoral candidate at the University of North Carolina’s 
Gillings School of Global Public Health. For my dissertation, I am conducting a research study 
(Institutional Review Board [IRB] study no. IRB-17-2590) that includes a series of interviews 
with stakeholders engaged in the development or use of information on cancer therapy side 
effects to improve cancer patient care. 
For your reference, I have attached a brief project description to this e-mail (Appendix E). 
I would genuinely appreciate the opportunity to speak with you, as I believe your 
perspectives could offer great insights for this study. If you are willing to participate, I will 
schedule a discussion via phone at a time that is convenient for your schedule in the next couple 
of weeks. The interview will last no more 45 minutes. 
Please note that your participation in this project is voluntary and, furthermore, should you 
agree to participate, you have the option to decline to answer any question. Additionally, I will 













Telephone Outreach Script for Key Informant Interview Participation 
The following scripts provide guidelines for scheduling interviews with participants based on whether 
the potential interviewee picks up the telephone. Calls will be placed as a follow-up to an initial 
outreach e-mail if the proposed participant does not respond within a few days. 
If Leaving a Voicemail 
Hello, Mr./Ms./Dr.________. I am following-up on an e-mail I sent you on ________ 
regarding a study I am conducting on whether improved information about unintended adverse 
effects of cancer therapy can be used to improve cancer patient care. This research includes the 
conduct of interviews with stakeholders engaged in the development or use of information on 
cancer therapy’s unintended side effects. 
Your participation is voluntary, and the interview would take place via phone, lasting no 
more than one hour. I would like to schedule the interview to take place in the next ____weeks at 
a time that is convenient for your schedule. Additionally, I will not attribute any statements to 
you by name when reporting results. 
You can reach me at (703) 887-4046 or by e-mail at tjp3sd5@live.unc.edu. I look forward to 
hearing from you and hope you are willing to participate. 
If Speaking With a Contact 
Hello, Mr./Ms./Dr.________. I am following-up on an e-mail I sent you on ________ 
regarding a study I am conducting for my doctoral dissertation on whether information about 
unintended adverse effects of cancer therapy can be used to improve cancer patient care. Do you 
have a couple minutes to talk? 
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Part of my research includes a series of interviews with stakeholders engaged in the 
development or use of information on cancer therapy’s unintended side effects and I believe your 
perspectives could offer great insights for this study. Your participation is voluntary, and the 
interview would take place via phone, lasting no more than one hour. I would like to schedule a 
discussion with you in the next ____weeks at a time convenient to your schedule. 
Would you be willing to participate in this study? 
 
Individual agrees: Excellent. As I mentioned, I would like to schedule a discussion in the 
next ______ weeks. Offer two to three time slots in the interviewee’s desired date range. Are you 
available during any of these times? Schedule the interview. 
 
If individual asks to think about it: Thank you for considering my request. I attached a brief 
project description to the e-mail I sent on ________, which I will resend following our call. 
If I don’t hear back from you in a few days, I will follow up again. Do you prefer that I contact 
you via e-mail or phone? 
Thank you. I look forward to hearing from you. 
 




APPENDIX B: INFORMED CONSENT FORM 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants 
 
Consent Form Version Date: October 1, 2017 
IRB Study # 17-2590 
Title of Study: How can adverse events information be used to more effectively inform cancer 
patient care? 
Principal Investigator: Syril Pettit 
Principal Investigator Department: Health Policy and Management 
Principal Investigator Phone number: (703) 887-4046 
Principal Investigator E-mail Address: tjp3sd5@live.unc.edu  
Faculty Advisor: Ethan Basch 
Faculty Advisor Contact Information: (919) 966-6759 
_________________________________________________________________ 
What are some general things you should know about research studies? 
You are being asked to take part in a research study. To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for 
any reason, without penalty. 
Research studies are designed to obtain new knowledge. This new information may help 
people in the future. You may not receive any direct benefit from being in the research study. 
There also may be risks to being in research studies.  
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Details about this study are discussed below and I have provided you with written 
information electronically in advance. It is important that you understand this information so that 
you can make an informed choice about being in this research study.  
You should ask the researchers named above, or staff members who may assist them, any 
questions you have about this study at any time. 
What is the purpose of this study? 
The purpose of this interview is to learn how your organization develops and/or uses 
information that helps inform patients and other stakeholders about potential unintended impacts 
of cancer therapy on their health and quality of life. I’m interested in your organization’s role in 
developing, distributing, and/or using information of importance for making informed decisions 
about a potential therapy’s impact of a patient’s short- and long-term quality of life and overall 
health. This type of information can take many formats, including risk:benefit evaluation, AEs 
reporting, PROs, safety profiles, quality of life metrics, etc. for a specific therapy or therapeutic 
class. You may have other thoughts on the types of information important to cancer treatment 
decision making for you and your organization/sector. 
You are being asked to be in the study because you have knowledge and expertise in your 
sector. 
Are there any reasons you should not be in this study? 
You should not be in this study if you feel you do not have adequate experience with the 
topic area or comfort level in discussing this topic.  
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How many people will take part in this study? 
Between 20 and 25 individuals will be recruited to take part in the study and there will be 3–
5 people from each stakeholder group (patient advocacy, regulatory science, drug development, 
clinical care) taking part in the study. 
How long will your part in this study last? 
This interview should take about 45 minutes. There is a chance that I will need to contact you 
for some follow-up information but that would be brief and can be completed by telephone or e-
mail. 
What will happen if you take part in the study? 
 If you agree to participate in the study, I will ask you some questions about your 
sector/organization’s role in contributing information that supports decision making about cancer 
treatment selection. For my study, I will be interviewing a broad range of stakeholders involved 
in developing, approving, administering, or financing cancer therapy and those who are 
advocating for cancer patients. My research seeks to understand whether we can improve long-
term patient quality of life by enhancing the way we generate or use information about 
unintended negative health effects associated with cancer therapy. I am specifically interested in 
understanding your current role(s) with regard to either generating or utilizing information 
around cancer therapy’s impact on quality of life/toxicity (AE) and subsequent treatment 
decisions. This interview will focus on therapies administered for long-term cancer control (e.g., 
adjuvant therapy). I will ask you questions about the types of information you generate, 
audiences for the recommendations/information that you generate, and/or the types of 
information you do or would like to use to inform cancer treatment/therapy evaluation decisions. 
It will be completely confidential and any information that you provide will be released as a 
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summary or combined into general themes. Your name will not be connected to your answers in 
any way. Furthermore, this worksite will remain blinded and will not be listed by name but only 
with reference to your general sector (e.g., patient advocacy, regulatory, clinical medicine, drug 
development, etc.). With your permission, I would like to record our interview. Digital audio 
files and transcripts will be confidentially destroyed at the end of the research study. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. You will not benefit 
personally from being in this research study. 
What are the possible risks or discomforts involved from being in this study? 
Although no risks are anticipated, there may be uncommon or previously unknown risks. 
You should report any problems to the researcher. 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.  
How will information about you be protected? 
 I am taking multiple steps to ensure that your privacy and confidentiality will be protected. 
• Your name will only appear on the consent form. All records will be kept in a locked 
location and electronic files will require a password. 
• I am the only person who will have access to individually identifiable information. ID 
numbers will be used to identify the stakeholder and the file that links them will 
require a password to access them. 
Participants will not be identified in any report or publication about this study. Direct quotes 
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will be used but not attributed to any person specifically. Although every effort will be made to 
keep research records private, there may be times when federal or state law requires the 
disclosure of such records, including personal information. This is very unlikely, but if disclosure 
is ever required, UNC-Chapel Hill will take steps allowable by law to protect the privacy of 
personal information. In some cases, your information in this research study could be reviewed 
by representatives of the University, research sponsors, or government agencies (for example, 
the FDA) for purposes such as quality control or safety. 
As soon as the audio recordings are transcribed and checked for accuracy, the audio files will 
be destroyed. Transcripts will be kept in a folder requiring a password for one year after the 
study conclusion and the dissertation is accepted. After one year, the transcripts will be 
destroyed. 
Check the line that best matches your choice: 
_____ OK to record me during the study 
_____ Not OK to record me during the study 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty. The investigator also has the 
right to stop your participation at any time. This could be because the entire study has been 
stopped. 
Will you receive anything for being in this study? 
You will not receive anything for taking part in this study. 
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Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions about the study (including payments), complaints, concerns, or if 
a research-related injury occurs, you should contact the researchers listed on the first page of this 
form. 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare. If you have questions or concerns about your rights as a research subject, or if 
you would like to obtain information or offer input, you may contact the Institutional Review 




APPENDIX C: KEY INFORMANT INTERVIEW GUIDE 













To be completed 
at interview time 
To be completed 
at interview time 
To be completed 
at interview time 
To be completed 
at interview time 
To be completed 
at interview time 
*Links between codes and interviewee names to be kept on a separate form and stored with 
password protection. Interviewee name and identifiable information not to be included with 
response data. 
Introduction 
Hello, I am a UNC Gillings School of Global Public Health doctoral candidate and this 
outreach is part a study to understand stakeholders’ roles in supporting cancer patient quality of 
life. As you know, there are more than 20 million cancer survivors in the United States currently 
and the number is growing. As many as 50% of these survivors, however, will experience some 
type of adverse health effect associated with their cancer therapy. This can include everything 
from minor ailments associated with a therapy—for example, minor fatigue, minor nausea—to 
more serious health impacts such as debilitating nerve pain or heart damage. These effects can 
impact overall health status as well as a patient’s ability to earn an income, enjoy family, or 
achieve daily tasks. For my study, I will be interviewing a broad range of stakeholders involved 
in developing, approving, administering, or financing cancer therapy and those who are 
advocating for cancer patients. My research seeks to understand whether we can improve long-
term patient quality of life by enhancing the way we generate or use information about 
unintended negative health effects associated with cancer therapy.  
With this interview, I hope to learn more about your organization’s role with regard to 
adjuvant cancer therapies. Adjuvant therapies are those that are administered after primary 
treatment to lower the risk that a cancer will come back, such as certain chemotherapy, hormone 
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therapy, targeted therapy, or biological therapy. One example of an adjuvant therapy that 
produced unanticipated adverse effects is the use of certain aromatase inhibitors to treat breast 
cancer patients. These drugs are effective in reducing the recurrence of breast cancer after initial 
therapy. However, an unanticipated outcome of their use is chronic pain (arthralgia) in many 
patients. In some cases, this pain can be debilitating to the patient and inhibit their quality of life, 
overall health, ability to work, and their ultimate adherence to the therapy. This means that some 
patients are unable to realize the full benefit of their treatment and that patients and payers may 
bear additional financial burdens. This scenario raises questions about who is responsible for 
generating information about benefits and risks; how this information is shared across 
researchers, regulators, clinicians, patients, and payers; and whether there are opportunities to 
more effectively support cancer patient care or treatment options in the future. While I don’t 
want to focus on this case scenario specifically, I offer it as an example of the situations and 
roles I’m interested in exploring in our conversation.  
 I recognize that you are not an official spokesperson for (your organization, your sector, 
others like you) and I appreciate that you are offering your personal perspective based on your 
professional knowledge and experience. 
This interview should take about 45 minutes. Again, it will be completely confidential and 
any information that you provide will be released as a summary or combined into general 
themes. Your name will not be connected to your answers in any way.  
With your permission, I would like to record our interview. Digital audio files and transcripts 




• Do you have any questions about the research study or the interview before we begin? 
• Do you consent to be interviewed? 
• Do I have your permission to record the interview?  
• Once the recording starts, ask the same two questions again—Just for the record, do you 
consent to participate? Do you consent to be recorded? 
INTRODUCTORY QUESTION 
1. “Please tell me about your organization and its mission with regard to cancer therapy and cancer care. 
What is your role in this organization?” 
ROLE 
2. “Please describe your role in balancing the beneficial and negative effects associated with the provision 
of adjuvant therapy to cancer patients.” 
Probe: 
Does this role help to inform the way adjuvant therapy is developed or used? If so, how? If not, why not? 
Is your organization unique in this role or are there others doing similar or synergistic work? Please 
describe. 
RESOURCES 
3A. “In the context of the roles you have described, can you tell me about the resources you rely 
upon to support these roles (e.g. data, experts, studies, funding, medical records, invoices, etc.)? 
Probe:  
Where do you get this information?  
Do you or your organization generate information used? If so, what type? 
Do you or your organization use information others generate for cancer therapy and cancer care? If so, 
how? 
Is it easy or challenging to access? 
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3B. “Do these resources meet your needs? Why or why not?” 
Probe:  
How timely is the information? 
How would you describe the quality of the information you use? 
FUTURE NEEDS: SELF 
4. “Are there other types or sources of information or resources that you wish your organization had to 
help with respect to helping patients balance the beneficial and negative effects of adjuvant therapy?”  
Probe:  
If so, what are they? 
Tell me a little more about why you think that’s needed. 
FUTURE NEEDS: SYSTEM  
5. “Moving forward, is there anything you would you like to see change (either in your own organization 
or others) to improve our overall approach to balancing treatment-related risks and benefits related to 
adjuvant therapy?”  
Probe (not all questions will be appropriate to all respondents): 
Do you think that the information generated is the right type of information? If not, what needs to 
change? 
Do you think that the information is readily accessible and usable by those who need it? If not, what 
needs to change? 
Is information provided in a timely way to the organizations who need it? If not, what needs to change? 
Does your organization use the available information to inform decision making? If not, why not? 
Do you provide feedback to those who generate information about the type of information you need?  
OPPORTUNITY FOR OPEN-ENDED INPUT 




APPENDIX D: CODE BOOK 
INTERVIEW QUESTIONS CODE NAME DESCRIPTION 
Introduction Questions 
Please tell me about your place of 
employment and its mission/scope 
of service with regard to cancer 
therapy and/or cancer patient 
support.  
Please describe your role in terms 
of support cancer patient quality of 
life and health. 
Participant Job and 
Personal 
Background 
Use this code when participants 
discuss their job title, personal 
background and role in general.  
Also use this code when 
participants mention their current 
place of employment and its 
mission as it pertains to providing 
therapies and/or support to 
patients with cancer.  
Roles 
Can you describe your role more 
specifically in terms of adjuvant 
therapy?  
For regulators: What is your role 
with regard to the review or 
evaluation of adjuvant therapies? 
Please explain.  
In this role, have you had situations 
where you had to address/support 
the balance of beneficial and 
negative effects associated with the 
provision of adjuvant therapy to 




Use this code when participants 
discuss their roles within the 
organizations they serve and the 
scope of their work as it relates to 
making risk:benefit-based 
decisions about adjuvant therapy 
in contrast to other cancer therapy 
types. 
Also use this code when 
participants talk about like-roles 
from other people or 
organizations that they have relied 
upon as it related to making 
risk:benefit-based decisions about 
adjuvant therapy in contrast to 
other cancer therapy types. 
Do you feel that your role in 
(treating patients, supporting 
patients, funding treatment, 
conducting regulatory review, or 
designing research) is inherently 
different for longer-term adjuvant 
therapies versus primary treatment? 
Please describe. 
Has your view of your role in 
supporting patients on adjuvant 
therapy changed in the last 5 years? 
If so, please describe. 
Job Role Changes 
Over Time 
Use this code when participants 
discuss how they perceive their 
roles to change, if at all, with 
longer-term adjuvant therapies 
versus primary treatment. 
Include mention of how they have 
seen their role in supporting 
patients’ change, if at all, over the 
past 5 years.  
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If you/your organization generates 
the information needed, can you 
describe what type of information?  
Where do the resources come from 
to support this data generation? 
Roles in Data or 
Information 
Generation 
Use this code when participants 
describe current practices of data 
generation (what kind of data and 
generated for whom). 
Information should relate to 
generating information needed to 
inform patient quality of life and 
safety in the adjuvant treatment 
setting.  
If you/your organization uses 
information others generate for 
cancer therapy and cancer care, can 
you describe how?  
Do you or others in your 
organization use the available 
information to inform decision 
making? If not, why not? 
Are there other organizations or 
roles that you relied upon to 
help/partner with you in these 
settings? Are there others playing 
parallel or similar roles? Please 
describe. 
Roles in Data or 
Information Use 
 
Use this code when participants 
describe the process for selecting 
the information available and the 
ways they have used the 
information to inform or support 
decisions for patients who 
are/were/may be on adjuvant 
cancer therapy. Decision making 
relates to the integration of 
information from different 
sources to make a judgement call 
(about treatment, regulation, drug 
development, payment, etc.). 
Also use this code when 
participants describe how and to 
what degree they use information 
other organizations have 
generated.  
Do you proactively share your 
experience in any format? If so, 
how? If not, why not?  
Do you provide feedback to those 
who generate information about the 
type of information you need?  
Do you feel that your 
experience/role with regard to 
supporting quality of life for 
patients receiving adjuvant therapy 
informs others? 
Does this role help to inform the 
way adjuvant therapy is developed 
or used? If so, how? If not, why 
not? 
Roles in Data or 
Information 
Sharing 
Use this code any time 
participants discuss improvements 
or suggestions they have offered 
or would like to offer for the way 
information is being shared.  
Use this code any time participant 
discusses the way in which their 
actions or efforts affect other 
stakeholder’s ability to inform 







Have the sources of information 
you use to support this role changed 
over time? Please describe. 
How timely is the information? 
Is information provided in a timely 
way to the organizations who need 
it? If not, what needs to change? 
Do you think that relevant 
information is readily accessible 
and usable by those who need it? If 
not, what needs to change? 
How would you describe the quality 
of the information you use? 
Do you think that the information 
generated is the right type of 
information? If not, what needs to 
change? 
Do these resources meet your 
needs? Why or why not? 
Barriers to 
Generating or Using 
Data 
Use this code when participants 
describe barriers or obstacles for 
generating or using adjuvant 
cancer therapy data or knowledge.  
Include mention of when 
participants talk about the 
timeliness, quality, relevance, 
utility, and/or accuracy of the 
information that is generated and 
what changes should be made to 
the information, if any, to make 
the data better with regard to any 
of these criteria.  
Use this code when participants 
discuss changes they have 
experienced in the timeliness, 
value, quality, relevance, etc. of 
data over the years regarding 
information used for risk:benefit 
evaluation of adjuvant cancer 
therapy.  
 
Does this role help to inform the 
way adjuvant therapy is developed 
or used? If so, how? If not, why 
not? 
What is its greatest strength? 
Motivators to 
Generating or Using 
Data 
Use this code when participants 
describe requirements, incentives, 
or motivations that drive 
stakeholders to develop or utilize 
information of relevance for 
evaluating risk:benefit and AE for 
patients receiving adjuvant 
therapy.  
Resources 
In the context of the roles you have 
described, can you tell me about the 
resources you rely upon to support 
these roles? (e.g. data, experts, 
studies, funding, medical records, 
invoices, etc.)  
Where do you get this information?  
Specific Data 
Resources 
Use this code when participants 
describe specific data or 
information resources they use to 
inform risk:benefit considerations 





Are there other types or sources of 
information or resources that you wish 
you had to help with respect to 
helping patients balance the beneficial 
and negative effects of adjuvant 
therapy?  
If so, what are they? 
Tell me a little more about why you 
think that’s needed? 
Why isn’t this information available 
now? 
Moving forward, is there anything you 
would you like to see changed (either 
in your own organization or others) to 
improve our overall approach to 
balancing treatment-related risks and 
benefits related to adjuvant therapy?  
Future Needs for 
System 
Use this code when participants 
discuss missed opportunities or 
unmet data generation or data 
usage needs. This includes 
descriptions of what participants 
wish was available but is 
currently not available and why 
they think the information or 
approaches are not available now. 
Use this code when participants 
describe any suggestions for how 
to improve balancing treatment 
for patients to related risks and 
benefits of adjuvant therapy at a 
systemic level, or by groups other 
than their own.  
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APPENDIX E: ONE-PAGE RESEARCH PROPOSAL SUMMARY  
How Can Adverse Event Information Be Used to More Effectively  
Inform Cancer Patient Care? 
Life with cancer and its treatment—whether as a patient, survivor, or supporter—is an almost 
universal experience. Per the U.S. National Cancer Institute (NCI), 40% of the population will be 
diagnosed with cancer in their lifetime. Fortunately, the last decade has seen tremendous 
advances in cancer therapy design and delivery and thus an increase in survival rates for many 
cancer types (Edwards et al., 2014). This increasing efficacy means that patients are living longer 
while on therapy or following their primary course of therapy. Unfortunately, therapy-related 
adverse events (AEs) are an unintended, but not infrequent, outcome of these life-saving 
therapies (Cleeland et al., 2012). AEs can impact both the ability adhere to therapy and a 
patient’s immediate and long-term physical, emotional, and financial health and quality of life. 
Given the potential impact of AEs on patient outcome and experience, the relevance of AE 
data to inform decision making by drug developers, government regulators, patients, and 
clinicians seems evident. However, the cancer care community has only recently begun to 
robustly tackle this complex aspiration. A review of the current literature reveals an insufficient 
understanding of the processes and rationales that drive AE data generation, adaptation, 
dissemination, and use for cancer treatment-related decisions. This deficiency appears to extend 
to both individual stakeholder groups and across the network of stakeholders engaged as in 
treatment design, use, and supportive care decisions. 
This study will utilize key informant interviews to assess stakeholder perspectives on their 
perceived roles as developers and/or users of treatment-related AE information for cancer care 
decision making (as well as their perceptions of the roles of others). In this context, the cancer 
treatment stakeholder network is defined as patient advocacy, clinical care, regulatory science, 
cancer therapy research and development, and healthcare plans. The qualitative stakeholder 
data, in combination with the published literature, will be used to evaluate the systemwide 
alignment (or misalignment) of perceived roles across the stakeholders. The study will seek to 
identify any systemic gaps where there are failures in effective AE information generation, 
dissemination, or use. Although this study is expected to generate findings with relevance across 
a range of cancer therapy classes and scenarios, the interviews will focus on “adjuvant therapy” 
(i.e., therapies provided to prevent/limit cancer recurrence following initial treatment) because of 
their generally longer-term treatment duration and higher patient survival rates. 
The results of this research will be used to inform a plan for change that includes the 
development of multidisciplinary and multisector collaborative efforts to improve future cancer 




APPENDIX F: DEFINITIONS 
Adjuvant therapy. Additional cancer treatment given after the primary treatment to lower 
the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation 
therapy, hormone therapy, targeted therapy, or biological therapy. 
Disease-free survival (DFS). The length of time after primary treatment for a cancer ends 
that the patient survives without any signs or symptoms of that cancer. In a clinical trial, 
measuring the disease-free survival is one way to see how well a new treatment works. 
Progression-free survival (PFS). The length of time during and after the treatment of a 




APPENDIX G: DRAFT LETTER OF SUPPORT  
DRAFT 
Letter of Support for ACTogether 
2019–2021 Challenge Period 
 
 With this letter, we commit our support for ACTogether’s mission of improving quality of 
life for patients who are or have received adjuvant therapy by enhancing our ability to 
understand, address, and convey the benefits and risks of these approaches. We acknowledge that 
an improved future for patients will require consistent, creative, and collaborative efforts across a 
broad base of stakeholders and disciplines.  
As a named collaborator in the ACTogether effort, (Name of Organization or Individual) will 
actively work toward the fulfillment of the mission by addressing one or more of the named 
challenge areas during the 2019–2021 challenge period.  
Named collaborators will be acknowledged on the ACTogether website and in promotional 
materials at the discretion of the program organizers. Collaborators are asked to provide a brief, 
nontechnical description of their efforts below and align this with one or more challenge areas. 
 
Description (150 words or less):  
Related challenge area(s):  
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